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Abstract
The syndrome of chronic heart failure resulting from left ventricular dysfunction , either 
systolic or diastolic, is a public health problem for the Western world.
The study presented in this thesis looked at 1009 individuals aged between 55 and 74 
years of age randomly selected from the population of north Glasgow - response rate 
59.8%. Within the study cohort there was a significant prevalence of both hypertension 
(44.1%) and ischaemic heart disease (43.9%). Left ventricular (L.V.) systolic function 
was measured by calculating an echocardiographic left ventricular ejection fraction 
(L.V.E.F.) in 75% of participants. The median L.V.E.F. was 50.7% and significant left 
ventricular systolic dysfunction (L.V.D.) was shown to be represented by an L.V.E.F. of 
< 35%; being present in 6.7% of the cohort with a measured L.V.E.F. The prevalence 
of L.V.D. rose with age and was higher in men than in women (9.4% v 4.0% P=0.004). 
The proportion which was considered symptomatic was 45.0% with no age or gender 
effect. The principle aetiological associate of L.V.D. was ischaemic heart disease with 
it accompanying 78% of all cases. Isolated hypertension was no more prevalent in 
individuals with L.V.D. than in the whole population. The L.V.D. was undertreated 
with only 16% of cases currently receiving treatment with an angiotensin converting 
enzyme inliibitor.
The presence of L.V.D., even when apparently asymptomatic, was associated with a 
reduced effort capacity on treadmill testing. Similarly it was associated with impaired 
quality of life scores in affected individuals, being true for both symptomatic and for 
treated L.V.D. (using loop diuretics), and there was possibly a small effect seen in 
asymptomatic L.V.D.
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Transmitral Doppler indices were used to examine L.V. diastolic filling in participants 
and showed diastolic filling to be affected by several biological variables including 
gender, age, body mass index, blood pressure and relative L.V. wall thickness. Disease 
states such as hypertension, ischaemic heart disease and L.V.D. were all shown to be 
associated with abnormal L.V. diastolic filling. Looking at a group of individuals who 
reported breathlessness in the absence of either airways disease or L.V.D. showed that 
they had a higher prevalence of ischaemic heart disease but without any evidence of 
abnormal diastolic filling. Removing the individuals with ischaemic heart disease from 
this group revealed some abnormalities of diastolic filling but also removed any 
objective impairment of effort capacity.
Circulating plasma concentrations of the natriuretic peptides N-terminal atrial 
natriuretic (N-ANP) and brain natriuretic (BNP) peptides were shown to be elevated in 
the presence of L.V.D.. Individuals with increased measurements of L.V. mass also 
had higher levels of both peptides; as did individuals with evidence, by transmitral 
Doppler indices, of elevated L.V. operating pressures. Examining their potential as 
screening blood tests for the presence of L.V.D. in the population showed that BNP 
fared better than N-ANP with a sensitivity of 82.0% and a specificity of 57.6% at a 
concentration of 15.20 pg./ml. BNP also performed better in a high risk group with 
ischaemic heart disease (sensitivity - 97.4%, specificity - 20.5%, concentration - 8,30 
pg./ml) and had an excellent negative predictive value of 98.2% in this group. It also 
had a high negative predictive value in a group of breathless individuals for the 
presence of L.V. systolic dysfunction (97.1%). Natriuretic peptides were shown to lack 
some discriminatory power with reduced specificities and positive predictive values
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owing to the presence of confounding factors in the population. Their future role may 
therefore be to exclude the presence of L.V.D. in individuals. BNP concentrations 
measured in unextracted plasma using the relatively simpler, and recently commercially 
available, Shionoria immunoradiometric assay kit also performed well as screening 
blood tests but not as well those obtained using a standard radioimmunoassay from 
extracted plasma.
1. Introduction
1.1 Chronic Heart Failure -  Definition
Normal left ventricular (L.V.) function has been defined as the ability of the left 
ventricle to pump blood forcefully in systole and to fill adequately at low pressure in 
diastole (Vasan et al. 1996). Abnormalities of one, or indeed both, of these functions 
may cause the clinical syndrome of chronic heart failure (C.H.F.) with its own 
characteristic symptoms - breathlessness, either at rest or on exertion, fatigue and ankle 
swelling (The Task Force on Heart Failure of the European Society of Cardiology, 
1995). Increasingly C.H.F. is being viewed as a multisystem disorder and Poole- 
Wilson defined it as "a clinical syndrome caused by an abnormality of the heart and 
recognised by a chai’acteristic pattern of haemodynamics, renal, neural and hormonal 
responses" (Poole-Wilson, 1985),
1.2 Chronic Heart Failure -  A Public Health Problem
Heart failure has become a major public health problem in Europe and North America
(Dai'gie and McMurray J.V., 1994; O'Connell and Bristow, 1994) with increasing levels 
of morbidity, mortality and health budget expenditure attributable to it.
1.2.1 The Increasing Mortality from Heart Failure
Heart failure resulting from left ventricular systolic dysfunction (L.V.D.) carries with it 
a terrible prognosis. Untreated New York Heart Association (N.Y.H.A.) Class IV heart 
failure has an average survival of just under 18 months (Swedberg et al. 1999). 
Medical and surgical advances which have improved survival in coronary heart disease 
have brought with them an "ironic failure of success" (Beamish, 1994) as the number of 
people who survive to develop C.H.F. has increased (Zannad et al. 1999). Both of 
these facts are reflected in the substantial, and possibly rising, mortality rates 
attributable to C.H.F. in both the U.K. and North America.
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Examination of death certification data for Scotland shows that C.H.F. is a significant 
contributor to both total and premature mortality (Murdoch et al. 1998). It accounted 
directly for 1.5% of all deaths between 1979 and 1992 and was a contributory factor in 
15.6% of all deaths, including 8.3% of deaths amongst those aged below 65 years. 
Figures from the United States for the same period show that deaths due to heart failure 
rose to almost 50,000 per annum by 1995 (Centers for Disease Control and Prevention, 
1998).
1.2.2 The Increasing Morbidity from Heart Failure
Clnonic heart failure is associated with a substantial number of hospital admissions 
each year and this has increased over recent years. During the 1980's in Scotland there 
was a 60% increase in admissions primarily for heart failure (McMurray et al. 1993). 
In the United States the number of admissions related to C.H.F. has also increased since 
1985 and C.H.F. now directly accounts for 871,000 admissions and is a contributory 
factor in at least 2.6 million admissions annually (Haldeman et al. 1999).
The burden of care extends also into the community with almost a quarter of people 
over the age of 65 years discharged from hospitals in the U.S. with heart failure 
requiring long term care in the community (Croft et al. 1997). In addition to this, 
annually in the United States there are reckoned to be nearly three million outpatient 
and primary care consultations because of heart failure (National Heart Lung and Blood 
Institute, 1996).
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1.2.3 The Ageing Population Bear the Burden
The majority, 78%, of hospitalisations for heart failure occur in the over 65 years age 
group (McMuiTay et al. 1993) and heart failure is now the leading diagnosis for 
hospitalisations for individuals in this age group in the United States (Graves and 
Bilium, 1996). Again the majority of deaths due to heart failure occur in the over 65 
years age group with an annual age adjusted mortality rate of 32.2 per 1000 in the 
United States (Centers for Disease Control and Prevention, 1998).
1.3 The Benefits of Treatment in Left Ventricular Systolic Dysfunction
1.3.1 Treatment Improves Survival
It is now Imown from the results of 32 clinical trials, enrolling 7105 patients, that in 
individuals with C.H.F. resulting from L.V.D. treatment with angiotensin-converting 
enzyme (A.C.E.) inliibitors improves survival (Garg and Yusuf, 1995). It brings about 
an average 23% reduction in mortality with the greatest benefit being seen in those with 
the most severe grades of heart failure. Survival in N.Y.H.A. class IV heart failure may 
be increased to an average of 26 months (Swedberg et al. 1999). Mortality benefits 
have also been suggested from trials of treatment with angiotensin II receptor 
antagonists (Pitt et al. 1997).
More recently treatment with beta-adrenoreceptor blockers in addition to A.C.E. 
inliibitor therapy has been shown to bring about further survival benefits (Packer et al. 
1996b; CIBIS-II Investigators & Committees, 1999) with treatment with bisoprolol 
reducing mortality by 34% (CIBIS-II Investigators & Committees, 1999).
1.3.2 Treatment Reduces Morbidity
A.C.E. inliibitor therapy in individuals with L.V.D., whether symptomatic or not, results
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in fewer hospitalisations for heart failure (The SOLVD Investigators, 1991; The 
SOLVD Investigators, 1992) and in asymptomatic individuals treatment with enalapril 
reduces the progression to the overt clinical syndrome of C.H.F. (The SOLVD 
Investigators, 1992). Treatment with beta-hlockers also appears to reduce the 
frequency of worsening heart failure and the need for hospital admission: by 27% in 
one study (Packer et ai. 1996b) - even in mild classes of heart failure. Treated patients 
had fewer symptoms and treatment in the longer term appeared to improve L.V. systolic 
fmiction (Olsen et al. 1995) and thus to be actually influencing the course of the 
disease.
With these available effective therapies the assessment of L.V. systolic function in 
patients with suspected heart failure has therefore become critical (Senni et al. 1999).
1.4 Diagnosing Left Ventricular Systolic Dysfunction
1.4.1 The Problems with Clinical Diagnosis
There is no one accepted set of criteria for making a clinical diagnosis of C.H.F. 
(Denolin et al. 1983) and such a clinical diagnosis lacks the ability to accurately 
distinguish between individuals with impaired systolic function and individuals with 
preseiwed systolic function (Cowie et al. 1997b; Remes et al. 1991). Such false 
positives for the diagnosis of systolic dysfunction are more common amongst women 
(Hlatky et al. 1986) and the elderly (Wong et al. 1989). Factors such as obesity, 
pulmonary disease and unrecognised myocardial ischaemia increase their occurrence 
(Remes et al. 1991). Even two of the best known research criteria - the Framingham 
and the Boston Criteria - have been shovm to be relatively insensitive and non-specific 
for detecting the presence of L.V.D. (Marantz et al. 1988).
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Accurate clinical diagnosis is further hampered by the fact that chronic heart failure is 
characterised by the activation of a number of compensatory mechanisms which 
remove some of the classical clinical signs and symptoms (Stevenson and Perloff, 
1989). Fmlhermore L.V.D. may exist in an asymptomatic state which camiot be 
detected by clinical examination (The Task Force on Heart Failure of the European 
Society of Cai'diology, 1995).
1.4.2 The Case for Echocardiography
In view of the above, the guidelines published by the European Society of Cardiology 
(The Task Force on Heart Failure of the Euiopean Society of Cardiology, 1995), the 
American College of Cardiology and American Heart Association jointly (American 
College of Cai'diology/American Heart Association Task Force on Practice Guidelines, 
1995), and the Agency for Health Care Policy and Research (Agency for Health Care 
Policy & Research, 1998) all recommend that echocardiography be performed in 
individuals with suspected C.H.F. since in patients with the syndrome of C.H.F. but 
with preserved systolic function it may provide clues to the aetiology of their cardiac 
dysflmction by assessing valvular function, L.V. mass, regional wall motion 
abnormalities and diastolic filling (Senni et al. 1999) and so may guide further 
investigation and treatment.
1.4.3 Measuring L.V. Systolic Function by M-mode Echocardiography
This echocardiographic modality has been extensively used since the 1970's for follow-
up in the Fraiuinghaiu Heart Study (Savage et al. 1987). The investigators found there 
to be a significant learning curve for this measurement with an increase in the number
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of acceptable echocardiograms from 28% during the first part of the study to between 
74 and 81% after two years. Male sex, increasing age, and a reduced forced vital 
capacity decreased the likelihood of having an acceptable echocardiogram. This was 
partly explained by the greater prevalence of emphysematous changes in the fifth 
tlu’ough seventh decades of life which reduces the availability of the parasternal echo 
window.
There are a number of drawbacks to using M-mode echocardiography to derive a 
measure for global L.V. frinction (Weyman, 1998). The measurement is made from a 
single pair of points at the base of the heart which means that the measure of L.V. 
function will be influenced heavily by abnormal basal and septal wall motion as may 
occur in localised infarction and also in circumstances not necessarily associated with 
impaired L.V. function such as left bundle branch block, right ventricular pressure 
overload, right ventricular pacing and post cardiac surgery effects. Equally it will not 
take into account the effects of apical wall motion abnormalities. It has also been 
shown that geometric assumptions based on M-mode echocardiography do not apply if 
the L.V. is remodelled and dilated (Weyman, 1998) .
1.4.4 Measurement of Ejection Fraction by Echocardiography
A more precise method of measuring L.V. systolic function is allowed by calculating 
L.V. volumes, and hence a left ventricular ejection fraction, using a biplane algoritlim 
("method of discs summation", Simpson's rule) (Schiller et al. 1979). Measuring 
cardiac volumes accurately by echocai'diography is generally limited by the ability to 
identify and measure the entire endocardial left ventricular contour (Rumberger et al.
1997). This process also has a pronounced learning phase attached to it (Rumberger et 
al. 1997) and interobserver variation for the technique has been quoted as high as
15
26.1 % (Gopal et al. 1995).
In one study of patients following a myocardial infarction 67% of patients had suitable 
echocardiographic images to allow calculation of an ejection fraction by a biplane 
Simpson's method (Breekland et al. 1997). The correlation between this echo ejection 
fraction and an ejection fraction obtained by radionuclide ventriculography was good 
with a correlation coefficient of 0.88 (Breekland et a l 1997). In that study biplane 
Simpson's ejection fraction measurements were found to be accurate, sensitive and 
specific for identifying ejection fractions at differing levels as determined by 
radionuclide ventriculography. Both single plane ejection fractions and a wall motion 
score index fared less well at the lower range of ejection fractions. Other studies 
comparing the Simpson's method with radionuclide ventriculography have shown the 
results from both techniques to be within 19 to 21% of each other 95% of the time 
(Gopal et al. 1995).
Althought the differences between the two methods of measuring L.V.E.F. may appear 
relatively small, a major problem occurs when absolute values of L.V.E.F. ai'e used to 
classify patients as either normal or abnormal. Such cut-off values are often quoted in 
reports of clinical trials, and easily become adopted into clinical practice without 
necessaiily making adjustment for the method of measuring L.V.E.F. used locally, and 
the normal distribution of L.V.E.F. by this method. A common example of this is the 
use of guidelines for phaimacological intervention in L.V.D. e.g. in the post myocardial 
infarction setting. There is no guarantee that the absolute value of L.V.E.F. quoted in a 
paper as the cut-off for diagnosing L.V.D. corresponds to anything similar when using 
the local method of measuring L.V.E.F.; whether it be echocardiography or
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radionuclide ventriculography. This can lead to the misclassification of a substantial 
number of patients. This degree of misclassification increases with the variability of the 
measurement, and since the variability is greater with echocardiography, so the degree 
of misclassification may be greater by echocardiography. One study carried out in 
Glasgow amongst post myocardial infarction patients (Ray et al. 1995) showed that the 
proportion of patients assigned to A.C.E. inhibitor therapy for L.V.D. varied widely 
between different hospitals, and between methods of measuring the L.V.E.F.. The 
greatest variation was seen between echo cardiography and radionuclide 
ventriculography. Therefore, when absolute values of L.V.E.F. are quoted it is 
important to laiow by which method they were obtained, and how they correlate with 
the results which would be obtained locally, using possibly a different method of 
measurement.
1.5 The Epidemiology of Heart Failure -  What the Studies Teii Us
1.5.1 Prevalence
Prevalence estimates for both C.H.F. and L.V.D. vary considerably reflecting 
differences in methodology, timing and populations studied (Cowie et al. 1997a). 
Epidemiological studies have either studied the prevalence of the clinical syndrome of 
heart failure (including inevitably both individuals with impaired and individuals with 
intact L.V. systolic function) diagnosed according to various clinical and radiological 
criteria, or else have looked specifically at the prevalence of left ventricular systolic 
dysfunction by echocardiography. Studies are therefore not necessarily stating the 
prevalence of the same condition.
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(a) Prevalence Studies Using Clinical Criteria
(i) Within the United Kingdom
Two large retrospective general practice casenote studies have been undertaken. The 
first carried out in London in 1988 (Parameshwar et al. 1992b) examined the records of 
30,204 patients. They were only able therefore to identify symptomatic individuals 
who had sought medical attention and found the prevalence to be 0.4% in the whole 
population and 2.8% in those aged 65 years and older. The second study carried out in 
1994 in Liverpool (Mair et al. 1996) searched 17,400 casenotes and found the overall 
prevalence to be 1.53%. In both studies less than one third of individuals with heart 
failure had had an echocardiogram performed.
(ii) Outside the United Kingdom
The best Imovm of all cardiovascular epidemiology studies is the Framingham Heart 
Study (McKee et al. 1971) wliich has studied a large, unselected, geographical 
population since 1948 using a combination of clinical and chest radiograph findings to 
diagnose heart failure. Data from the 1980’s (Ho et al. 1993b) showed that the 
prevalence of clinical heart failure was 0.7% with roughly equal proportions men and 
women. The prevalence rose with age from 0.8% in the sixth decade to 7.9% in the 
ninth decade.
Another large study in the U.S. used the same diagnostic criteria as the Framingham 
Heart Study to look at 14,407 individuals aged 25 to 74 years during the 1970s and 
reported the prevalence to be 2% (Schocken et al. 1992). Males tended to have a 
higher prevalence than females and the prevalence again increased with age.
"The Men Born in 1913" study based in Gothenburg, Sweden looked at men from age
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50 years onwards and last reported findings at age 67 years (Eriksson et al. 1989). 
Again this was a clinical diagnosis of "manifest heart failure". The prevalence 
increased steadily up to the age of 60 years and then rose at a much greater rate. By age 
67 years 13% were found to have manifest heart failure.
(b) Prevalence Studies Using Echocardiography
(i) Within the United Kingdom
Two recent studies have used echocardiography to look for the presence of L.V.D.. In a 
random sample of the population of North Glasgow aged between 25 and 74 years 
(McDonagh et al. 1997) the overall prevalence of significant L.V.D. was found to be 
2.9% of which 48% was considered asymptomatic. The prevalence increased markedly 
from the fifth decade onwards for men and from the seventh in women mirroring the 
age related increase in ischaemic heart disease in that population (Tunstall-Pedoe et al.
1994). Overall there was a 2:1 ratio of men to women affected.
A more recent study from Poole, England (Morgan et al. 1999) examined an older 
group of patients from general practice aged between 70 and 84 yeai's and found the 
overall prevalence of L.V.D. to be 7.5%. The prevalence was again higher in men than 
in women - more than four times higher.
(ii) Outside the United Kingdom
The Rotterdam Study (Mosterd et al. 1997) looked at 1980 individuals aged 55 years 
and older by means of M-mode echocardiography and found a prevalence of reduced 
left ventriculai' systolic function of 3.0%.
The Cardiovascular Health Study (Gardin et al. 1995), a large echocaidiographic study
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of 5201 women and men from various communities in the U.S. aged 65 years and over, 
reported the overall prevalence of L.V.D. to be 6.3% in men and 1.8% in women. The 
prevalence increased steadily with age and was higher in men.
1.5.2 Aetiology - A Changing Picture
Classification of aetiology is dependent upon the criteria used. By clinical criteria alone 
and without using coronary angiography and echocardiography the aetiology of heart 
failure is subject to misclassification.
Coronary heart disease and hypertension (either singly or together) account for the vast 
majority of cases of heart failure within the developed world (Cowie et al. 1997a). The 
relative importance of these two factors appears to have changed over the past 50 years. 
The Framingham Heart Study showed that hypertension carried the greatest population- 
attributable risk for the development of heart failure between 1960 and 1990 (Kannel et 
al. 1972) (Levy et al. 1996) but only because the definition of hypertension was 
changed during the thirty year period with a resultant increase in its prevalence. Over 
the same period however the relative importance of coronary artery disease showed a 
true increase (Ho et al. 1993a). Conversely valvular heart became a less frequent 
cause of heart failure. Myocardial infarction, despite its low prevalence in this 
particular population, carried a high population-attributable risk and amongst 
hypertensive individuals myocardial infarction increased the risk further.
The Men born in 1913 study concluded that in 1980 the most important risk factors for 
developing clinical heart failure were hypertension, smoking and obesity (Eriksson et 
al. 1989). However 35.8% of those who developed heart failure had suffered a
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myocai'dial infai'ction and 26.1% suffered from angina compared with only 19.1% and 
7.7% respectively for the total population.
The relative importance of coronary artery disease over that of hypertension was 
confirmed recently on both sides of the Atlantic in the North Glasgow study 
(McDonagh et al, 1997) and the Cardiovascular Health Study (Gardin et al. 1995). 
The latter study showed the prevalence of L.V.D. to be 10.5% in people with coronary 
artery disease (with or without hypertension) and only 1.7% in people with isolated 
hypertension. McDonagh found that in Glasgow the aetiological factor conferring the 
greatest relative risk for L.V.D. was a clinical or electro cardiographie diagnosis of 
ischaemic heart disease especially in combination with hypertension.
Diabetes has been shown to be an important precursor to C.H.F.. In the Glasgow study 
the prevalence of L.V.D. was high amongst diabetics - 17% - but all had co-existing 
coronary artery disease and 75% had co-existing hypertension.
1.5.3 Aetiology - Reasons for the Changes
Preventative medicine may be playing a role in the changing aetiology of C.H.F.. 
Improved treatment and detection of hypertension may have reduced the population- 
attributable risk associated with it (Yusuf et al. 1989). Trials have shown that by 
treating hypertension - systolic at least - the incidence of clinical C.H.F. can be reduced 
(Kostis et al. 1997). The reduction appears to be higher in individuals with a history of 
previous myocardial infarction underscoring the apparent synergism between 
hypertension and coronaiy heart disease for the development of C.H.F. The only note 
of caution to be sounded is the lack of differentiation in studies between systolic and 
diastolic L.V. impairment. Therefore at least some of the reduction reported in the
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prevalence of C.H.F may be through a reduction in diastolic L.V. impairment (Kostis et 
al. 1997).
Over the past five years a case has been made for the use of cholesterol lowering 
therapy in individuals with established coronary artery disease. This has be shown to 
reduce the incidence of myocardial infarction (Scandinavian Simvastatin Survival Study 
Group, 1994) and with it hoth the risk of C.H.F. and C.H.F.-related mortality (Kjekshus 
et al. 1997). This adds further weight to the evidence that ischaemic damage to the left 
ventricle from coronary artery disease is a major factor in the development of L.V.D. at 
least within the population of North Europe (Coats, 1998).
1.5.4 Survival in Chronic Heart Failure
Median survival in Framingham between 1948 and 1988 after the onset of heait failure 
was 1.7 years in men and 3.2 years in women being worse in elderly subjects (Ho et al. 
1993a). Over the period of the study there was no appreciable change in overall 
survival. The Olmsted County incident study of heart failure in 1991 (Senni et al.
1998) confirmed the prognosis to be poor with only 35% of patients alive at 5 yeai's. 
Even when early mortality was taken out the 5 year survival was still only 41%.
1.6 The Syndrome of Heart Failure with Normal Left Ventricular 
Systolic Function
1.6.1 The Diagnosis of Primary Diastolic Heart Failure
When studies began to look objectively at L.V. function in people with the clinical
syndrome of C.H.F. they found that some individuals, although they had signs and 
symptoms of raised L.V. filling pressures - pulmonary and systemic congestion, they
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had normal L.V. systolic function (Vasan et al. 1995). This led to the recognition that 
abnormalities of L.V. diastolic filling could lead to the clinical syndrome of C.H.F. in 
the absence of systolic dysfunction (Wheeldon et al. 1994) - so-called primary diastolic 
heart failure (Goldsmith and Dick, 1993; Shiels and MacDonald, 1998; Brutsaert et al. 
1993).
Tlii'ee obligatory conditions need to be simultaneously satisfied to diagnose primary 
diastolic heart failure (European Study Group on Diastolic Heart Failure, 1998). 1. The 
presence of signs or symptoms of C.H.F. attributable to raised left atrial pressure: 
exertional dyspnoea being frequently the earliest symptom. 2. The presence of normal 
or near normal L.V. systolic function. 3. Evidence of abnormal L.V. diastolic filling.
1.6.2 Prevalence of Diastolic Heart Failure
The prevalence of diastolic heart failure in the community is largely unknown (Vasan et 
al. 1995). In studies looking objectively at L.V. systolic function in individuals with a 
clinical diagnosis of C.H.F. the proportion found to have normal systolic function varies 
widely from 13% to 74% with an average prevalence of at’ound 40% (Vasan et al. 
1995). This prevalence is much higher amongst the older population (Wong et al. 
1989; Takarada et al. 1992). In studies looking at these individuals with normal 
systolic function between 20% (Soufer et al. 1985) and 62% (Aguirre et al. 1989) will 
have echocardiographic evidence of abnormal diastolic function.
1.6.3 Aetiology of Diastolic Heart Failure
Similar to systolic dysfunction, the main diseases implicated in the aetiology of 
diastolic dysfunction are hypertension - in between 11% (Madsen et al. 1994) and 83% 
(Brogan et al. 1992) - and coronary artery disease in between 5% (Echeverria et al.
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1983) aiid 67% (Judge et al. 1991).
1.6.4 Prognosis of Diastolic Heart Failure
The reported annual mortality rate in heart failure with intact systolic function varies 
widely from 1.3% (Brogan et al. 1992) to 17.5% (Kinney and Wright, 1989). One of 
the best studies to look at this was the V-HeFT study (Cohn et al. 1986; Colm et al. 
1991) where the annual mortality of patients with C.H.F. and a normal ejection fraction 
was 8% which is substantially lower than the 15 to 20% mortality rate that was seen in 
those with a depressed L.V. ejection fraction (Chon and Johnson, 1990). A more 
recent community based study from the U.S. showed, after adjustment for the presence 
of coronary artery disease, similar survival rates for individuals with C.H.F. whether 
their L.V. systolic function was preserved or impaired (Senni et al. 1998).
The different estimates for prognosis most likely relate to differences in the prevalence 
and severity of coronary artery disease (Gheorghiade and Bonow, 1998). The 
Coronary Artery Surgery Study registry showed that for people with heart failure 
symptoms but normal L.V. systolic function the 6-year survival rate was 92% with no 
coronary arteiy disease, 83% with one or two-vessel coronary disease, and 68% in 
patients with three-vessel coronary disease (Judge et al. 1991).
1.6.5 The Pathophysiology of Diastolic Dysfunction
Abnormalities of diastolic filling may occur because of two main pathophysiological 
processes: impaired relaxation of the myocardium and/or reduced ventricular 
compliance (Devereux, 1989; Wheeldon et al. 1994; Lenihan et al. 1995; Grossman, 
1991).
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(a) Impaired relaxation of the myocardium
Relaxation of the myocardium during diastole is a an active energy-dependent process 
involving pumping of free cytosolic calcium into the sarcoplasmic reticulum (Pouleur, 
1990; Grossman, 1991); abnormalities of which will lead to impaired myocardial 
relaxation and to a slower decay in the atrioventricular pressure gradient in early 
diastole. This reduces the early phase of L.V. filling and proportionately greater filling 
from atrial contraction occurs as a compensatory mechanism (Taylor and Waggoner, 
1992; Grossman, 1991). It also takes an increased length of time for the left atrial and 
L.V. pressures to equalise and so the deceleration time is prolonged.
(b) Reduced ventricular compliance.
A reduction in the compliance of the L.V. will cause a rapid increase in the left 
ventricular pressure after its nadir so causing a rapid deceleration of the blood flow 
during early filling (Nishimura and Tajik, 1997). During atrial systole there will be 
reduced filling of the left ventricle because of the higher L.V. pressure.
1.6.6 Echocardiographic Assessment of Diastolic Function
All ventriculai' filling indices by echocardiography are indirect measures of diastolic
ftinction (Vasan et al. 1996). They have largely been based on transmitral flow 
velocity curves measured by Doppler echocardiography (Appleton et al. 1988). At any 
point in time these measure the relative driving pressure across the mitral valve from the 
left atrium to the left ventricle (Nishimura and Tajik, 1997; Appleton, 1993).
(a) Normal Transmitral Doppler Flow
In sinus rhytlun two distinct waves can be seen - Figure 1-1 - (Nishimura and Tajik, 
1997; Wheeldon et al. 1994) - the early or E wave - corresponding to the period of
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Figure 1-1 Patterns of Doppler Transmitral Flow Velocity Curves In Health 
and In Diastolic Dysfunction.
E A
DT DT DT DT
Normal Filling Abnormal Relaxation Pseudonormal Pattern Restrictive Filling
Abnormal Filling
Top - Patterns of transmitral flow with various degrees of ventricular diastolic 
dysfunction.
Bottom - Electrocardiographic tracings corresponding to diagrams.
In healthy subjects, the transmitral flow is biphasic, consisting of an initial tall E wave 
followed by a shorter A wave. The deceleration time (DT) is the interval between the 
peak early diastolic flow velocity and the onset of diastasis; this parameter measures 
how rapidly left atrial and left ventricular pressures equalize in early diastole and is 
related inversely to ventricular compliance.
From: Vasan,R.S.: Arch Intern Med, Volume 156(2).January 22, 1996.146-157
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passive early L.V. filling, and the atrial or A wave corresponding to atrial systole. 
Each has a peak velocity followed by an deceleration slope. The deceleration slope of 
the E wave is dependent mainly on the compliance of the left ventricle (Little et al. 
1995; Ohno et al. 1994). In normal individuals the E wave peak velocity exceeds the 
A wave peak velocity indicating the relative contributions of the early and atrial phases 
of filling to total L.V. filling. The ratio of these two peak velocities - the E:A ratio - is 
therefore normally greater than one.
(b) Abnormal Patterns of Transmitral Doppler
Tliree main abnormal patterns of tiansmitral Doppler have been described (Appleton et 
al. 1988; Ohno et al. 1994; Nishimura and Tajik, 1997) - Figuie 1-1.
1 . Impaired / abnormal relaxation pattern. - Abnormal relaxation without compensatory 
elevation of filling pressures causes a reduction in the peak velocity of the E wave; 
prolongation of the deceleration time of the E wave, and an increase in the proportion 
of filling due to atrial contraction - leading to an increase in the pealc velocity of the A 
wave.
2. Restrictive pattern - Abnormal compliance of the left ventricle leads to limitation of 
the extent of L.V. filling during atrial systole. Increases are seen in the peak velocities 
of both the E and A waves but with the E wave velocity increased proportionately more 
such that the E;A ratio increases. Because of the rapid rise in L.V. filling pressure 
during the early phase of filling there is a shortened deceleration time.
3. Pseudonormalisation - Experimental models of diastolic heart failure have shown that 
with abnoimal relaxation pattern may be a compensatory rise in left atrial pressure and
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preload causing the E:A ratio and deceleration time to appeal* normal - so called
pseudonormalisation (Iga et al. 1990; Wheeldon et al. 1994).
1.6.7 Pathological Conditions and Diastolic Dysfunction
(a) Left ventricular hypertrophy and hypertension
Left ventricular hypertrophy is a common cause of diastolic heart failure (Lenihan et al.
1995). Hypertensive individuals even in the absence of left ventricular hypertrophy 
have been shown to exhibit impairment of early diastolic relaxation, with a 
compensatoiy increase in atrial filling (Gardin et al. 1998; Inouye et al. 1984).
(b) Coronary Artery Disease
Some impairment of diastolic function may be present in the majority of individuals 
with coronary artery disease with or without previous infarction (Reduto et al. 1981; 
Bonow et al. 1982; Wheeldon et al. 1994). Such patients account for more than half of 
all the cases of heart failure with normal systolic function in studies (Vasan et al.
1995). It may be that ischaemia impairs calcium handling in the excitation- 
contraction-relaxation process (Pouleur, 1990).
(c) Systolic Dysfunction
Individuals with systolic dysfunction have been shown to frequently exhibit 
abnormalities of diastole; with echocardiography showing a restrictive pattern 
indicative of elevated left ventriculai' filling pressures (Rihal et al. 1994). This diastolic 
dysfunction appears to contribute to both symptoms and exercise intolerance (Packer, 
1990; Xie et al. 1996; Rihal et al. 1994). In a multivariate analysis (Xie et al. 1996) 
the presenee of a restrictive pattern of transmitral Dopplers correlated with worsening 
functional class and reduced exercise capacity, independent of the L.V. ejection 
fraction. Indices of diastolic filling may also be related to prognosis with patients who
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have short deceleration times having a poorer prognosis (Rihal et al. 1994).
(d) Diabetes Mellitus
Studies have suggested that there are small changes in diastolic filling in diabetic 
individuals manifest as an increase in the deceleration time of the E wave (Chen et al.
1996). Additionally, when challenged with acute preload reduction evidence of 
diastolic dysfunction can be unmasked suggesting that diabetics may have a preload 
dependence in diastolic filling (Gotzsche et al. 1993).
1.6.8 Factors Affecting Indices of Diastolic Filling in Normal Individuals
(a) Age
Ageing is associated with impaired L.V. relaxation and reduced compliance (Templeton 
et al. 1979). This leads to the finding of an abnormal relaxation pattern of transmitral 
Dopplers (Gardin et al. 1998; Benjamin et al. 1992; Kitzman et al. 1991). This effect 
has been shown across all age ranges and occurs in both sexes (Xie et al. 1995). In the 
Framingham Heart Study, looking at normal individuals, age was found to be the 
strongest factor determining Doppler indices (Benjamin et al. 1992).
(b) Gender
Women appear to have higher peak velocities of both the E and A waves after adjusting 
for other factors (Gardin et al. 1998; Xie et al. 1995). The E:A ratio does not however 
differ between men and women.
(c) Blood Pressure
Blood pressure appears to have effects on indices of diastolic filling but not in a 
consistent mamier in all studies. The Cardiovascular Health Study showed that the peak 
velocities of both the E and A waves were positively correlated with the systolic blood
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pressure and negatively correlated with the diastolic (Gardin et al. 1998). It may be 
therefore that there is a relationship between pulse pressure and diastolic filling 
velocities. Another study however showed that only systolic blood pressure exerted an 
independent effect and this was to increase the velocity of the A wave, so decreasing the 
E;A ratio (Xie et al, 1995).
(d) Left Ventricular Mass and Relative Left Ventricuiar Wall Thickness
In one study increased L.V. mass was shown to decrease the peak E wave velocity and 
so the E:A ratio (Gardin et al. 1998). However the Framingham Heart Study could not 
find any effect of L.V. mass on diastolic indices after correcting for other factors 
(Benjamin et al. 1992). A third study showed that the relative L.V. wall thickness 
correlated in women with an increased A wave velocity and a decreased E:A ratio (Xie 
et al. 1995).
(e) Mitral Incompetence
The presence of mitral incompetence increases the peak velocity of the E wave by 
increasing preload and so left atrial pressure (Gardin et al. 1998; Rokey et al. 1985).
(f) Body mass
Increased body weight appears to have a small effect, increasing the peak A wave 
velocity and decreasing the E:A ratio (Xie et al. 1995).
(g) Site of Doppler sampling
Sampling of the Doppler flow velocity at the mitral valve amiulus rather than at the tips 
of the mitral valve leaflets will result in lower peak E velocities and reduced E:A ratios 
(Gardin et al. 1986; Xie et al. 1996).
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(h) Loading conditions
Any variable describing diastolic function may change dramatically with different 
loading conditions on the heart (Nishimura et al. 1989; Choong et al. 1987). The peak 
E wave velocity is positively correlated to the degree of preload and thus left atrial 
pressure (Taylor and Waggoner, 1992). The deceleration time is negatively eorrelated 
to the preload probably because more rapid left ventricular filing occurs such that the 
atrial and ventricular pressures equalise more quickly during early filling (Taylor and 
Waggoner, 1992).
Increases in afterload will primarily prolong the rate of L.V. relaxation so reducing the 
peak E wave velocity and prolonging the deceleration time (Nishimura and Tajik,
1997).
1.6.9 Problems of Assessing Diastolic Filling by Transmitral Doppler 
Flow Velocities
Over the past years it has become apparent that simple Doppler indices cannot fully 
describe such a complex phenomenon as diastole with its interrelated factors (Cheitlin 
et al. 1997). The main drawbacks are: (1) The dependence on loading conditions of the 
common Doppler indices, (2) A normal Doppler pattern does not rule out significant 
diastolic dysfunction - this is because there is a continuum from abnormal (impaired 
relaxation) through pseudonormal to abnormal (restrictive filling) (Taylor and 
Waggoner, 1992). (3) The method is only applicable in the main in sinus rhythm.
Nevertheless the A.C.C. and A.H.A. guidelines (Cheitlin et al. 1997) state that 
echocardiographic indices of diastolic function are useful in characterising large groups 
of subjects. In addition "when interpreted in the context of clinical variables,
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recognising all the Imown potential confounding factors, they may provide valuable 
information in individual subjects".
1.7 Natriuretic Peptide System
1.7.1 The Biology of the Natriuretic Peptide System
Over the past twenty years a group of natriuretic peptides has been identified which 
plays a part in the integrated control of renal and cardiovascular homeostasis. To date 
tlii'ee peptide hormones have been described.
Atrial natriuretic peptide (ANP) is synthesised and stored in granules in atrial myocytes 
(de Bold et al. 1981). It is stored as a 126 amino acid prohormone which is cleaved by 
a membrane bound protease into two fragments both of which enter the circulation: the 
28 amino acid carboxyl-terminal (C-terminal) peptide and the 98 amino acid N- 
terminal-ANP (Glembotski et al. 1988). Only the C-terminal peptide is biologically 
active with a half-life of 13.3 minutes being cleared by both binding to a clearance 
receptor (Maack et al. 1987) and by enzymatic degradation by neutral endopeptidase 
(Struthers, 1994). The N-terminal has a much longer plasma half-life of 54.8 minutes 
and is probably renally cleared (Thibault et al. 1988). Circulating levels of N-terminal 
ANP are about ten to twenty-fold higher than those of C-terminal ANP levels 
(Sundsfjord et al. 1988).
Brain natriuretic peptide (BNP) is a 32 amino acid peptide which despite its name is 
synthesised mainly by ventricular myocardium (Sudoh et al. 1988; Mukoyama et al. 
1991). It is not stored to the same degree as ANP and so increased levels of BNP must 
be preceded by increased mRNA concentrations (de Bold et al. 1981). It has a half-life
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in plasma of 20.7 minutes and is cleared by degradation by neutral endopeptidase 
(Mukoyama et al. 1991). Circulating BNP levels are normally about 20% of 
circulating C-terminal ANP (Mukoyama et al. 1991).
ANP and BNP have similar physiological actions. They cause natriuresis, arterial and 
venous vasodilatation, and antagonism of the renin-angiotensin-aldosterone system 
(Struthers, 1994). This has the effect of reducing the circulating volume and thus 
cardiac preload (Wei et al. 1993). The stimulus to their release is volume expansion 
and pressure overload of the heart (Wilkins et al. 1997). Experiments suggest that 
ANP responds to acute elevations in preload whereas BNP increases during more 
clironic elevations of cardiac pressures (Lang et al. 1992). BNP concentrations appear 
therefore to reflect long-term intravascular volume status rather than momentary 
volume expansion (Cheung and Kumana, 1998).
The third natriuretic peptide, C-type (Sudoh et al. 1990), differs in its biology from the 
other two in that it is synthesised in the vascular endothelium (Stingo et al. 1992) and 
has more of a paracrine effect. Despite its name it lacks any natriuretic activity (Stingo 
et al. 1992) and causes vasodilatation particularly on the venous side of the circulation 
(Struthers, 1994).
1.7.2 The Natriuretic Peptides and Chronic Heart Failure
Left ventricular systolic dysfunction, both symptomatic and asymptomatic (Francis et 
al. 1990; Lerman et al. 1993; McDonagh et al, 1998) has consistently been shown to 
be associated with increased circulating levels of both ANP (C- and N-terminal) and 
BNP. The increased levels of ANP are brought about both by increased synthesis and 
release, secondary to atrial stretch (Cody et al. 1986), and by decreased clearance by
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the liver and kidneys (Richards et al. 1986). The increase in BNP is due to increased 
cardiac myocyte production (Takahashi et al. 1992). The ratio of concentrations of 
BNP:C-terminal ANP increases in heart failure and may exceed one in the most severe 
cases (Mulcoyama et al. 1991; Lang et al. 1992).
Levels of both ANP and BNP correlate with the degree of central haemodynamic upset 
in systolic dysfunction (Dickstein et al. 1995; Maeda et al. 1998). N-terminal ANP 
levels have been found to correlate with the L.V. ejection fraction (Lerman et al. 1993; 
Dickstein et al. 1995) and N.Y.H.A. functional class (Lerman et al. 1993; Dickstein et 
al. 1995). Dickstein found that N-ANP levels actually correlated better with functional 
class than did the L.V. ejection fraction, L.V. dimensions or pulmonary arteiy pressure 
(Dickstein et al. 1995).
BNP concentrations have been found to correlate more closely than N-terminal ANP 
with the degree of L.V.D. as measured by the L.V. ejection fraction (Lerman et al. 
1993). BNP concentrations have been shown to be an independent predictor of the L.V. 
end diastolic pressure in patients with symptomatic L.V.D. (Maeda et al. 1998). This 
perhaps underscores that fact that BNP is of ventricular origin (Lerman et al. 1993) but 
it may also reflect the fact that ANP levels fluctuate more than BNP due to the fact that 
ANP is subject to both more rapid degradation (Ruskoaho, 1992) and more acute 
regulation (Nicholson et al. 1993).
1.7.3 Effects of Treatment on Natriuretic Peptides
A.C.E. inliibitor therapy in patients with L.V.D. produces a fall in both ANP and BNP 
(Maeda et al. 1998; Motwani et al. 1993) which paiallels the fall in the L.V. end 
diastolic pressure (Maeda et al. 1998). BNP has been shown to be superior in tracking
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this response to treatment (Maeda et al. 1998).
1.7.4 Diagnosing Systolic Dysfunction Using Peptides
A number of studies have studied natriuretic peptides as blood markers for the presence 
of L.V.D. (McDonagh et al. 1998; Lerman et al. 1993; Davis et al. 1994; Cowie et al. 
1997b; Davidson et al. 1996; Omland et al. 1996a; Yamamoto et al. 1996; Friedl et al. 
1996). All found to varying degrees that N-ANP and BNP were sensitive and 
moderately specific. In the studies that compared N-ANP with BNP, the latter was 
fomid to have a higher diagnostic value (Omland et al. 1996b; Yamamoto et al. 1996; 
Friedl et al. 1996; Davidson et al. 1996).
(a) Clinical Studies in Patients
In symptomatic patients suspected of having C.H.F. in primary care (Cowie et al. 
1997b) measurement of BNP levels was shown to be both highly sensitive and specific. 
Measurement of N-terminal ANP in addition did not improve the diagnostie yield. 
Within a group of patients admitted to hospital with acute dyspnoea of unknown 
aetiology BNP, again more so than ANP, has been shown to accurately detect the 
presence of L.V.D. (Davis et al. 1994).
Natriuretic peptides have been studied extensively in the post myocardial infarction 
(M.I.) population. Elevated BNP levels have been demonstrated in L.V.D. following 
anterior M.I., which persist for at least six months (Motwani et al. 1993). Treatment 
with an A.C.E. inliibitor results in a reduction in these BNP levels (Motwani et al. 
1993). Elevated levels of peptides in the subacute phase of an M.I. have been shown to 
be associated with both a higher risk of developing overt heart failure and mortality 
(Darbar et al. 1996; Omland et al. 1996a; Hall et al. 1994).
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Concentrations of natriuretic peptides have been shown to provide prognostic 
information in L.V.D. over and above routine measurements such as the L.V. ejection 
fraction (Hall et al. 1994; Rouleau et al. 1994; Darbar et al. 1996; Omland et al. 
1996a). In patients with symptomatic L.V.D. BNP was shown to be a significant, 
independent predictor of mortality: a better predictor than L.V. ejection fraction 
(Tsutamoto et al. 1997). ANP was inferior to BNP in this respect.
(b) Studies in Unselected Populations
In McDonagh's large epidemiological study in North Glasgow BNP was found to be 
superior to N-ANP in detecting L.V.D., whether symptomatic or not (McDonagh et al. 
1998). The predictive accuracy of BNP was higher in high risk groups such as the older 
population and individuals with a clinical diagnosis of coronary heart disease.
A smaller study based within general practice in Glasgow (McClure et al. 1998) , 
looking at people with a previous myocardial infarction, found that neither BNP nor N- 
terminal ANP were useful in discriminating between normal and milder degrees of 
L.V.D.. The authors conclude that the diagnostic accuracy was reduced because their 
population was older and may have had a higher prevalence of hypertension, left 
ventricular hypertrophy and diastolic dysfunction all of which are known to increase 
levels of natriuretic peptides in the absence of systolic dysfunction (McClure et al.
1998). In addition the authors used only a semi-quantitative method for assessing L.V. 
systolic function.
1.7.5 Peptides and Left Ventricular Hypertrophy
In hypertensive patients with left ventricular hypertrophy (L.V.H.) plasma BNP
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concentrations have been shown to be elevated (Kohno et al. 1992; Kohno et al. 1995). 
This appears to be related to the degree of L.V.H. rather than the level of blood 
pressure. BNP levels correlate with the L.V. mass index and relative wall thickness 
(Kolmo et al. 1995) and regression of L.V.H. is associated with a fall in BNP 
concentrations (Kolmo et al. 1995).
A meta-analysis (Hollister and Inagami, 1991) of 17 case-control studies concluded that 
no significant difference existed in plasma ANP levels between subjects with normal 
blood pressure and those with untreated hypertension in the absence of target organ 
damage. In non-obstructive hypertrophic cardiomyopathy (Yoshibayashi et al. 1993) 
and normal L.V. systolic function plasma BNP levels have been shown to be 50 times 
higher than in normals and about ten times higher than in people with L.V.H. secondary 
to pressure overload e.g. aortic stenosis. ANP was found to be three times higher than 
normals in non-obstructive hypertrophic cardiomyopathy
1.7.6 Peptides and Age
In a wide range of individuals from the population C-terminal ANP levels have been 
shown to increase with increasing age (Flickinger et al. 1995).
1.7.7 Peptides and Diastolic Dysfunction
In patients with the clinical syndrome of heart failure but normal L.V. systolic function 
there is a significant negative correlation between the E:A ratio and both ANP and BNP 
(Lang et al. 1994). The raised operating L.V. pressures which characterise diastolic 
dysfunction triggers both BNP release and elevates left atrial pressures so increasing left 
atrial stretch and hence ANP release (Lang et al. 1994). In one study (Yamamoto et al.
1996) an elevated BNP concentration was found to have a sensitivity of 0.85 and a
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specificity of 0.74 for the presence of primary left ventricular diastolic dysfunction.
In hypertensives without L.V.H. ANP levels were negatively correlated with the E:A 
ratio (Pontremoli et al. 1993). It is hypothesised that impaired diastolic relaxation and 
reduced ventricular compliance secondary to hypertension may increase the left atrial 
pressure and so act as a stimulus for ANP secretion (Pontremoli et al. 1993).
In patients with L.V.D. both ANP and BNP levels are significantly higher in individuals 
with a restrictive pattern on transmitral flow Dopplers than in those without (Yu et al.
1996).
1.7.8 Stability of Natriuretic Peptides
Both N-terminal ANP (Murdoch et al. 1997; Hall et al. 1995) and BNP (Murdoch et 
al. 1997) are stable in whole blood stored at room temperature for up to 72 horns with 
only minor changes in concentration. N-teiminal ANP has also been shown to be 
resistant to two repeated ffeezing-and-thawing cycles (Hall et al. 1994).
1.7.9 Screening for Asymptomatic Systolic Dysfunction
The results of the above studies suggest that screening for asymptomatic L.V. systolic 
dysfunction by measuring plasma concentrations of natriuretic peptides, especially 
BNP, potentially fulfils the criteria for a . screening test (McMurray et al. 1998). 
However, as a screening test, the finding of a moderate concentration of BNP in any 
one individual may lack specificity (McMurray et al. 1998) but a low BNP level has an 
excellent negative predictive value for the presence of systolic dysfunction (Cheung and 
Kumana, 1998). This may therefore remove the need for further investigations in 
certain individuals.
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1.8 Effort Capacity and Heart Faiiure
Exercise intolerance is a cardinal feature of C.H.F. (Franciosa et al. 1979) and is one of 
the most common problems experienced by patients prompting them to seek medical 
help (Atherton et al. 1997). Patients stop exercising because of either breathlessness or 
fatigue depending on the form of exercise being undertaken (Atherton et al. 1997). 
Diuing fast treadmill exercise this is most likely to be breathlessness, and fatigue 
during slower walking or cycle exercise (Atherton et al. 1997).
1.8.1 Measurement of Effort Tolerance
Effort tolerance can be measured either by duration of exercise on a treadmill or bicycle 
or by the distance walked in a defined time period. These two measures give different 
information, the latter providing information about submaximal exercise capacity 
(Atherton et al. 1997).
(a) Symptom-Limited Exercise Testing and Measurement of Oxygen 
Uptake
The measurement of gas exchange and thus peak oxygen consumption during maximal 
exercise testing has emerged as one of the most important prognostic variables in heart 
failure (Parameshwar et al. 1992a) and its reduction is a major criterion of selection for 
cardiac transplantation (Costanzo, 1996).
(b) Six Minute Walk Test
This form of submaximal exercise testing has the advantage of more effectively 
evaluating the impairment and functional status during daily activities (Brunner-La 
Rocca et al. 1999) and has been shown to be reproducible (Guyatt et al. 1984). The 
test appears to be able to predict prognosis better than both the L.V. ejection fraction
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and the N.Y.H.A. functional class of patients. In the SOLVD Registry distance walked 
was inversely related to subsequent mortality and rate of hospitalisation for heart failure 
(Bittner et al. 1993).
1.8.2 Relationship of Effort Capacity to Severity of L.V. Systolic 
Dysfunction
Standard measures of cardiac function such as L.V. ejection fraction, echocardiographic 
L.V. dimensions, and pulmonary capillary wedge pressure do not consistently predict 
effort tolerance in patients with heart failure (Webb-Peploe et al. 1998; Franciosa et al. 
1981; Higginbotham et al. 1983). Neither does the degree of patients' symptoms on 
maximal exercise testing correlate with these markers of underlying L.V. systolic 
dysfunction and haemodynamic abnormality (Wilson et al. 1995). In particular the 
level of perceived dyspnoea does not correlate with the L.V. filling pressures as 
measured by the pulmonary capillary wedge pressure (Wilson et al. 1995). Some 
research suggests that echocardiographic variables such as preserved right ventricular 
function and the absence of a restrictive pattern on transmitral Dopplers predict 
improved effort tolerance (Webb-Peploe et al. 1998),
Despite the increasing functional impairment implied by the N.Y.H.A. grading of heart 
failure symptoms, objective exercise testing shows little difference in effort tolerance 
between patients in different N.Y.H.A. classes (Franeiosa et al. 1979; Bittner et al. 
1993)..
1.8.3 Effort Capacity in Asymptomatic L.V. Systolic Dysfunction
The SOLVD trial showed that individuals with L.V.D. who are either asymptomatic or 
only mildly symptomatic (defined as not requiring diuretic therapy) have lower values 
of peak oxygen uptalce during maximal exercise than control individuals (Liang et al.
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1992; LeJemtel et al. 1994). They however have higher values than symptomatic 
subjects but this difference cannot be explained by differences in L.V. ejection fraction 
between the asymptomatic and symptomatic groups.
1.8.4 Mechanisms of Effort Intolerance
The evidence suggests that effort intolerance is not solely due to abnormalities of 
central haemodynamics and the inability of heart failure patients to augment their 
cardiac output diuing exercise (Wilson et al. 1995; Atherton et al. 1997). Equally 
important are peripheral factors in skeletal muscle and the lungs (Atherton et al. 1997). 
Muscle wasting occurs early in even mild heart failure (Mancini et al. 1992) and 
patients have weaker limbs and fatigue more easily than controls (Harrington et al.
1997). There is a reduction in muscle efficiency accompanied by both histological 
(Drexler et al. 1992) and physiological changes (Massie et al. 1987). This is brought 
about by a number of factors including deconditioning - disuse atrophy - malnutrition 
and the action of cytokines especially tumour necrosis factor (Atherton et al. 1997).
Changes in the lungs contribute to symptoms during exercise including increased 
airways resistance, decreased lung compliance and ventilation/perfusion mismatch 
(Atherton et al. 1997). In addition there is a subjective component to the symptom of 
breathlessness which can be reduced by the administration of opiates allowing 
improved effort capacity (Chua et al. 1997).
1.9 Chronic Heart Faiiure and Quality of Life
1.9.1 Measuring Quality of Life
Quality of life is inherently subjective and can be influenced by many factors including 
an individual's own expectations (Testa and Simonson, 1996). Questiomiaires
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measuring quality of life can be divided into those which are specific for a particular 
disease and those which are generic. The latter can be used to compare the effects of 
different disease states on the same or on different individuals using a common 
yardstick (Garratt et al. 1993; Stewart et al. 1989),
The Short Form 36 (SF36) questionnaire is a generic measure of quality of life. It is a 
shortened version of a battery of 149 health status questions developed and tested on a 
U.S. population of over 22 000 patients as part of the Medical Outcomes Study (Tarlov 
et al. 1989). It has subsequently undergone minor changes of wording by a team in 
Sheffield to malce it acceptable to the British population (Brazier et al. 1992). It has 
been shown to be acceptable, internally consistent and to meet accepted criteria for 
reliability and validity (Garratt et al. 1993). It is designed to either be self 
administered, taking five to ten minutes to complete, or answered during an interview 
(Wai'eetal. 1993).
1.9.2 Studies of Quality of Life in Chronic Heart Failure
(a) Symptomatic Heart Failure
Comparison of the impact of a number of chronic illnesses, including C.H.F., on 
quality of life has been made in a couple of lai'ge epidemiological surveys in the U.S 
(Stewart et al. 1989; Fryback et al. 1993). The Medical Outcomes study in 1986 
(Stewart et al. 1989) showed that C.H.F. had effects on each aspect of functioning - 
physical, role and social - and on health perceptions. Among the clironic conditions 
studied health perceptions were poorest for C.H.F..
The SF36 questiomiaire was used as a measure in 1990 during a random survey of 
adults - the Beaver Dam Health Outcomes Study (Fryback et al. 1993). On the general
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health domain C.H.F. had the lowest score of all chronic conditions examined ranking 
lower than clironic back pain and chronic asthma. A study in 1994, from Oxford 
(Jenkinson et al. 1997), looked at 6 8  elderly patients with symptomatic heart failure 
and found that all dimensions of quality of life were severely reduced.
(b) Asymptomatic Left Ventricular Dysfunction
The SOLVD investigators showed tliat even individuals with asymptomatic L.V.D. had 
impaired quality of life compared to normals (Rogers et al. 1994). The impairment of 
quality of life was however less than that seen in symptomatic heart failure.
1.9.3 Effect of Treatment on Quality of Life in C.H.F.
In contrast to their effects on morbidity and mortality a beneficial effect of treatment 
with A.C.E. inliibitors on quality of life in C.H.F has not been proven. The V-HeFT II 
trial, using a disease specific questionnaire - the Minnesota Living with Heait Failure 
questionnaire, was unable to show a sustained improvement in quality of life for 
patients receiving treatment with A.C.E. inhibitors or other vasodilators (Rector et al.
1993). There was in fact a gradual decline over two years paralleling the decline in 
L.V. ejection fraction and VO2 max. Smaller trials of A.C.E. inliibitors confirmed this 
showing either modest (Bulpitt et al. 1998) or no benefit (Jenkinson et al. 1997) in the 
short to medium term. The SOLVD investigators (Rogers et al. 1994) were able to 
show that treatment with enalapril did not improve quality of life in asymptomatic 
L.V.D. but there was improvement for those who were symptomatic, persisting for at 
least one year.
1.10 Aims of This Thesis
Given what has been said above about the importance and impact of C.H.F., whether 
the result of systolic or diastolic L.V. dysfunction, on both the individual and the nation
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the emphasis must now be on prevention. Prevention of L.V. dysfunction in the first 
place (primary prevention) and prevention of progression of the dysfunction once 
established (seeondary and tertiary prevention). To do this there is a need for 
epidemiological studies, such as this current one, to determine who the affected 
individuals in the community are, and to develop strategies for identifying them at an 
early stage when secondary and tertiary prevention may be of benefit. Studies also 
need to identify "at-risk" individuals in whom primary prevention may be beneficial.
The aims of this study were:
1. To recruit and characterise a random selection of people from a defined geographical 
population with a presumed high prevalence of risk factors for ischaemic heart disease 
and subsequent left ventricular systolic dysfunction (Chapter 3).
2. To use echocardiography to determine normal and abnormal left ventricular systolic 
function in this cohort and thus determine the prevalence and aetiology of left 
ventricular systolic dysfunction (Chapter 4).
3. To examine the effects of this left ventricular systolic dysfunction on both effort 
capacity, as determined by formal exercise testing, and on quality of life (Chapter 5).
4. To look at the determinants of left ventricular diastolic filling in an unselected 
population and to assess whether or not abnormal diastolic filling has a significant 
effect on individuals within the general population as opposed to patients (Chapter 6 ).
5. To examine the relationship between left ventricular ftinction - systolic and diastolic - 
and natriuretic peptides, and to explore their use as blood screening tests for the 
presence of left ventricular systolic dysfunction in the community. As part of this to 
also compare the use of a new, commercially available, immunoradiometric assay for 
brain natriuretie peptide against the conventional radioimmunoassay (Chapter 7).
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2. Methods
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2.7 The Study Population -  Sampling and invitation Process
The theoretical population studied was defined as all persons resident within the 
boundary of the city of Glasgow, north of the River Clyde, born between 31/3/20 and 
1/4/39 and registered with a general practitioner, serving the same geographical area. 
This is the same geographical population as was studied by the World Health 
Organisation's MONICA study (Tunstall-Pedoe et ah 1994).
The study was designed to study 1000 randomly selected individuals - 125 males and 
125 females in each five year age band between 55 and 74 years. This was achieved by 
a two stage random sampling process. First a random 1 in 7 sample of the 210 general 
practitioners with praetices serving the area was chosen and the agreement of all thirty 
general practitioners to participate in the study obtained. Next a random sample of all 
patients meeting the above criteria was chosen with each practice contributing a "quota" 
of patients within each five year sex and age band in proportion to the practice size 
relative to the geographical population. Where necessary oversampling took place. 
The G.P.s were asked to exclude any patients who they felt would not be able to 
participate on the grounds of severe physical or mental ill health.
The subjects chosen were invited by letter to attend the study: enclosed with the 
invitation was information about the study. This was followed up by a telephone 
reminder or a postcard reminder, if they did not have a telephone. Those who did not 
attend were sent a further appointment. If individuals failed to attend for a second 
appointment a researcher visited their address to malce personal contact and to establish 
the accuracy of the address list.
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2.2 Questionnaires and Interview
With the invitation each individual received copies of a Personal Health Record (PHR) 
Questionnaire and the SF-36 quality of life questionnaire (Brazier et al. 1992) -  
Appendix A. The PHR sought basic demographic details; family history of early heart 
disease; physician made diagnoses of angina, myocardial infarction, hypertension, 
cerebrovascular disease, and diabetes mellitus; current medication; smoking history, 
and alcohol consumption in the form of a diary. Within the PHR were questions 
composing the M.R.C. breathlessness questionnaire (Fletcher et al. 1959) wliieh was 
designed to distinguish between breathlessness attributable to chronic bronchitis - 
defined as breathlessness associated with a cough productive of sputum occurring on 
most days during at least tliree winter months each year - and other causes.
The SF-36 questionnaire issued was the Brazier/Sheffield version (Brazier et al. 1992). 
The questionnaire was checked for completeness of information during the study visit 
and, if need be, it was administered in part or in full by interview. It was 
subsequently scored according to the scoring manual from the Medical Outcomes Trust 
(Medical Outcomes Tmst, 1994). A scale score was calculated if the respondent had 
answered at least half of the items in a multi-item scale (or half plus one in the case of 
scales with an odd number of items).
The deprivation category for each attendee was assigned on the basis of the postcode 
sector in which they lived, grouped by health board. The category was obtained from 
a table supplied by the Public Health Research Unit of the University of Glasgow and 
was based on the 1991 Scottish Census (McLoone 2000). The categories range from 
Depcat 1 (the most affluent postcode sectors) to Depcat 7 (the most deprived). They are
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calculated from the Carstairs score (Carstairs and Morris 1991) for each postcode sector 
and are based on four variables measuring: 1 ) overcrowding, 2 ) percentage male 
unemployment, 3) percentage low social class, and 4) car ownership. The Depcat 
score is thus a measure of deprivation for a postcode sector rather than for a specific 
individual.
2.3 Body Mass index
Participants' heights and weights were measured after removal of their shoes and heavy 
outer garments. Weight was measured by SECA electronic scales - checked daily 
using a British Standard 5Kg weight - to the nearest 100 grams. Body mass index 
(kg/ra^) was calculated as the weight (kg) divided by the height (m) squared.
2.4 Biood Pressure Measurement
Blood pressure readings were obtained with the use of a random-zero 
sphygmomanometer (Hawksley and Sons, Ltd., West Essex, England). A cuff size 
appropriate for the subject's arm was chosen. Two blood pressure readings were taken 
at least two minutes apait after ten minutes of seated rest. The pressure at Korotkoff 
phase I sound was recorded as the systolic blood pressure and the diastolic blood 
pressure was determined at the occurrence of Korotkoff phase V sound in all 
participants. The average of the two readings was recorded and used in further analysis.
2.5 Spirometry
Standard spirometric measurements of forced vital capacity (FVC), vital capacity (VC) 
and the forced expired volume in one second (FEVi) were made using a Microlab 3330 
spirometer (Micro Medical, Kent, England). The final measurement was recorded as 
the highest value of tliree attempts. A standard demonstration of the teclmique was
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given initially to the attendee and each was allowed two practise attempts with 
appropriate correction of technique if required. Uniform encouragement was given 
during each attempt.
2.6 Echocardiography
2.6.1 Performance of the Echocardiogram
Standard two-dimensional, colour-flow and Doppler echocardiography was recorded on 
an Acuson 128 ultrasound machine (Acuson Inc., Mountain View, CA, USA) with the 
individual reclining on a couch at 45 degrees in the left lateral position. An E.C.G. 
chaimel was recorded throughout the examination. The whole study was recorded in 
real time on half inch super-VHS video tape for later review with the participants 
identified only by a study number.
At least three single-cycle loops of both the apical 4- and 2-chamber views were 
digitised and transferred onto optical discs, as were frames of the M-mode 
measurements (at least five cardiac cycles) and the Doppler flow curves (at least five 
cardiac cycles) using an off-line digital image processing and analysis system (Tomtec 
Imaging System Inc., Boulder, Colorado, USA). Cardiac cycles that were ectopic 
beats, or pre- or post-ectopic beats were not analysed. Similarly only if the heart rate 
was 1 0 0  beats per minute or less were the echocardiograms analysed further 
objectively. All measurements were made during quiet respiration.
2.6.2 Measurement of Left Ventricular Ejection Fraction
The left ventricular' ejection fraction was measured using a biplane algorithm "method 
of discs summation", Simpson's rule (Schiller et al. 1979) as an average of three cycles. 
To be suitable for analysis at least 80% of the endocardium had to be visible. End-
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diastole was defined as the frame with the largest L.V. cavity at the initial systolic 
coaptation of the mitral valve, and end-systole as the subsequent frame with the 
smallest cavity area (Badano et al. 1996).
Previous work from our echocardiographic lab has shown the intraobserver variation for 
the L.V.E.F. measured by a biplane Simpsons method, expressed as a median 
percentage, to be 7% (McDonagh et al. 1997). For this study we assessed the 
interobserver variation by having a second observer analyse a subset of 90 
echocardiograms, from the cohort, for determination of an L.V.E.F.. This second 
observer was blinded to the results obtained by the first observer. The median 
percentage difference in L.V.E.F. between the two sets of results was 5.6%. Using the 
method described by Bland and Altman (Bland and Altman, 1986) the limits of 
agreement between the two measurements of L.V.E.F. were found to be between -14.8 
and 6 . 2  percentage points.
2.6.3 M-Mode Measurements and Derived Values
All M-Mode measurements were made on three consecutive cycles horn the parasternal 
long axis view with the M-mode sector positioned using 2D echo cardiography such that 
it was perpendicular to the interventricular septum at the level of the tips of the mitral 
valve leaflets. Diastole was defined as the onset of the R wave on the E.C.G. signal and 
systole as the point of maximal anterior excursion of the posterior L.V. wall.
Measurements were made as an average of three cycles according to the conventions 
established by the American Society of Echocardiography using a leading-edge-to- 
leading-edge method (Sahn et al. 1978) and the criteria of Schieken et al (Schieken et 
al. 1979) were used to determine the acceptable technical quality for M-Modes. The
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measurements talcen were: 1. the left ventricular end-diastolic dimension (LVEDD); 2. 
the left ventricle end-systolic dimension (LVESD); 3. the thiclcness of the 
interventricular septum in diastole (IVSd), and 4. the LV posterior wall thickness 
during diastole (LVPWd). From these the left ventricular mass was calculated using 
the Pemi Cube formula (Devereux et al. 1986) as below:
LV Mass (g) = 1.04 [(IVSd+LVEDD+LVPWd)’ - LVEDD3] -13.6 g 
The LV mass index was calculated by divided the L.V. mass by the height in metres. 
Both the L.V. mass and L.V. mass index, where appropriate, were considered seperately 
for males and females.
The relative L.V. wall thiclaiess (R.Th.) was calculated in diastole as the ratio of half 
the sum of the interventricular septum in diastole and the LV posterior wall, to half the 
LV internal dimension
i.e. Relative LV Wall Thickness (R.Th.) = [(IVSd + LVPWd) 4-2 ] ^  [LVEDD -2].
2.6.4 Doppler Echocardiographic Measurements
Doppler interrogation of the mitral valve inflow was obtained from the apical four- 
chamber view using pulsed wave Doppler with a 4mm sample volume placed in the 
mitral valve orifice close to the tips of the mitral valve leaflets. The measurements were 
regarded as acceptable if the angle between the Doppler beam and the mitral inflow did 
not exceed thirty degrees. The trans-aortic valve velocity profile was measured from 
the apical five-chamber view using continuous wave Doppler.
Measurements were taken as the average of five cycles and velocity curves were traced
at the outer edge of the spectral envelope. Wliere the deceleration slope of the early
transmitral velocity wave (E wave) could not be distinguished from the late transmitral
velocity wave (A wave) measurements were not made. The deceleration time of the E
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wave was measured from the peak of the E wave to a point on the baseline where the E 
wave by extrapolation of the slope would have intersected it.
2.6.5 Subjective Assessment of Left Ventricular Function
One observer with experience of reporting echocardiograms reviewed all the
anonymised video tapes to assess global left ventricular function using all the available 
views - parasternal long and short axis views and the apical four- and two- chamber 
views. Global function was graded as either impaired or normal. The definition of 
impairment was defined as being of clinical significance and ideally equating to an L.V. 
ejection fraction of 35% or less.
2.6.6 Valvular Dysfunction
The severity of any mitral incompetence seen on colour flow Doppler was graded by 
mapping the extent of the jet into the left atrium using pulsed wave Doppler; dividing 
the length of the left atrium behind the mitral valve into thirds. Mitral incompetence 
was considered mild if it extended less than one third, moderate if it extended between 
one- and two-thirds, and severe if it extended more than two-thirds of the length of the 
left atrium. Significant mitral incompetence was regarded as a severity greater than 
mild. Mitral stenosis was defined as the presence of thickened mitral valve leaflets 
and a pressure half-time of the transmitral E wave of greater than 100 msecs.
Aortic stenosis was regarded as a trans-aortic velocity of greater than 2.2 ms'^ (i.e. 
gradient > ~ 20mmHg). Aortic incompetence was graded subjectively according to the 
breadth of the jet orifice on colour flow floppier of the aortic valve on a parasternal 
short axis view. This was graded as either mild or significant - this being anything 
degree greater than mild.
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The presence of prosthetic valves was noted on review of the real-time video tapes.
2.7 Twelve-Lead Electrocardiogram
This was recorded in a standard fashion at a paper speed of 25mm per second on a 
Siemens Sicard 440 electrocardiograph (Siemens Elema, Stockholm, Sweden) and 
transmitted to the E.C.G. laboratory at Glasgow Royal Infirmary for storage on a central 
Mingocaie data base (Siemens Elema, Stockholm, Sweden). They were subsequently 
coded by computer algoritlim (Macfarlane, 1998) according to the Minnesota ECG 
code (Prineas et al. 1982) for the presence of Q/QS waves (codes 1.1-1.3), left bundle 
branch block (7.11), ST segment depression (4.1-4.4), left ventricular hypertrophy (3.1, 
3.3, 3.4) or atrial flutter/fibrillation (8.31, 8.32). All E.C.G. results were verified by 
visual inspection.
2.8 Treadmill Exercise Testing
Symptom limited treadmill exercise testing was carried out after the echocardiogram in 
the absence of standai'd contraindications - unstable angina, significant aortic stenosis or 
hypertrophic obstructive cardiomyopathy, recent myocardial infarction or a systolic 
blood pressure >220 mmHg or a diastolic blood pressure >110 mmlig. The 
Standardised Treadmill Exponential Exercise Protocol (S.T.E.E.P.) was used 
(Nortlu'idge et al. 1990).
A short demonstration was given by a technician and this and all further instruction was 
standardised for all participants. Participants were asked to continue for as long as they 
could and further standard encouragement was given every two minutes. A 12 lead
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E.C.G. was recorded and blood pressure measured 10 seconds before the end of each 
two minute stage and at 1,3 and 5 minutes following the end of exercise. Participants 
were encour aged to exercise for a further 30 seconds, if they could, after they indicated 
that they wished to stop. The test was terminated by the technician or supervising 
doctor if they felt standard criteria for termination had been met (Froelicher, 1994). 
The participant's reasons given for asking to stop were recorded.
2.8.1 Analysis of Exercise Electrocardiographs
All exercise tests were analysed independently by two coders for the presence of ST 
segment depression according to the Mimiesota Coding Manual (Prineas et al. 1982) 
with discrepancies in coding being arbitrated by a third coder. ST segment 
measurements were made on the resting E.C.G. and peak exercise E.C.G.s taking the 
measurement at 80 msecs beyond the J point.
2.9 Venous Blood Sampling
Following 20 minutes supine rest a venous blood sample was taken for the following 
analyses.
2.9.1 Venous Blood Glucose
This was a random sample measured in whole blood by a photometric method using 
Glucotide reagent strips read by a Glucometer 4 meter (Bayer Diagnostics, Newbury, 
England) with a range of 0.6 to 33.3 mmolL'\ Quality control was maintained by 
monthly validation of the meter and reagent strips by the hospital's Clinical Chemistry 
Dept, using test standard glueose solutions (Bayer Diagnostics, Newbury England).
2.9.2 Plasma Cholesterol
A 10ml sample of venous blood was collected in a tube with a small amount of 
potassium-EDTA and sent to the Clinical Chemistry laboratory of the Western
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Infirmary, Glasgow for measurement of plasma total cholesterol, triglycerides and the 
HDL fi-action of cholesterol, if possible, according to standards validated by the Royal 
College of Pathologists.
2.9.3 Neurohormones
(a) Sample Handling and Plasma Extraction
A 10ml sample of blood was placed into a pre-chilled tube containing potassium-EDTA 
(1 mg/ml blood) and aprotonin (50 I.U./ml blood). The sample was stored on ice and 
centrifuged at 3000 r.p.m. for 10 minutes at 4° C within 30 minutes of collection. The 
plasma was immediately frozen and stored at -70° C. until assay.
Both N-terminal atrial natriuretic peptide (N-ANP) and brain natriuretic peptides (BNP) 
were measured in plasma after extraction. The plasma was acidified with an equal 
volume of trifluoroacetic acid (T.F.A.) and then centrifuged. The supernatant was 
then allowed to pass slowly tlirough a Sep-Pak C l8  mini column (Waters Associates 
Ltd., Watford, England) which had been preconditioned with methanol (5ml), then 1% 
T.F.A. (5ml) and finally a fiirther two aliquots of 1% T.F.A. (3ml). The column was 
then washed with 1% T.F.A. (5ml) followed by 0.1% T.F.A. (2ml). The eluted peptides 
were dried by rotary vacuum and redissolved in buffer for assay. Recoveries were 87% 
and 82% for N-ANP and BNP respectively.
(b) N-Terminal ANP Assay - Indirect
N-ANP was measured after dilution (1/100) by radioimmunoassay using an antibody - 
RAS 9129 (Peninsula Laboratories, Belmont, California, USA) - raised against the 1 to 
30 N-terminal fragment. This antiserum has no detectable cross reaction with either C- 
terminal ANP or BNP and has an IC50 of 18 pg. per tube in the assay. The within-assay
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and between-assay coefficients of variation (Cvs) for this assay were 15% (n=16) and 
16% (n=48) respectively (Lang et al. 1993).
(c) BNP Assay - Indirect
BNP \yas measured in the extract (1/4 dilution) using a radioimmunoassay kit for 
human BNP - RIK 9086, (Penninsula Laboratories, Belmont, California, USA). This 
has an IC50 of 20 pg. per tube. The within-assay and between-assay Cvs were 18% 
(n""16) and 15% (n=46) respeetively.
(d) BNP Assay - Direct
BNP was also assayed in unextracted plasma using a direct immunoradiometric assay 
kit (Shionoria BNP kit) supplied by Shionogi & Co, Ltd. (Osaka, Japan) (Kono et al.
1993). This uses two monoclonal antibodies which recognise the carboxyl terminal 
sequence and the ring structure of human BNP, respectively, and measures BNP by 
sandwiching it between the two antibodies without plasma extraction (Yasue et al.
1994). The minimum detectable quantity of human BNP is 2 pg./ml and the degree of 
cross reactivity with human ANP is less than 0.001% on a molar basis (Tsutamoto et al.
1997). The within-assay and between-assay Cvs were both <5%.
2.10 Definitions
So that comparisons could be drawn, and for consistency, the definitions used were, in 
the main, those used by McDonagh in her previous study of this population (McDonagh 
et al. 1997) and as presented in her MD thesis based on the same study (McDonagh
1998).
2.10.1 Ischaemic Heart Disease
Ischaemic heart disease was defined as the presence of one or more of: 1. a prior 
physician-made diagnosis of myocardial infarction or angina; 2 . the current use of
56
nitrates; or 3. ECG evidence of isehaemic heart disease according to the Minnesota 
coding system (Prineas et al. 1982) using codes for pathological Q waves (codes 1.1 - 
1.3) , ST segment depression (4.1 - 4.4) or left bundle branch block (7.11).
2.10.2 Hypertension
Hypertension was principally defined as the presence of one or more of the following: 
I. a systolic blood pressure exceeding 160 mmHg; 2. a diastolic blood pressure 
exceeding 95 mmHg; or 3. the current use of specific antihypertensive medication.
For comparison, hypertension was also defined using the cut-off points for blood 
pressure as defined in the Sixth Report of the Joint National Committee on Prevention, 
Evaluation and Treatment of High Blood Pressure (Joint National Committee on 
Prevention, Evalaution and Treatment of High Blood Pressure 1997) - the JNC VI 
guidelines. Hypertension [JNC VI] was thus defined as the presence of one or more of 
the following: 1. a systolic blood pressure > 140mmHg; 2. a diastolic blood pressure 
>90mmHg; or 3. the use of specific antihyp eft ensive medication.
2.10.3 Diabetes Mellitus
Diabetes mellitus was defined as the presence of one or more of the following: 1. a 
prior physician-made diagnosis of diabetes mellitus; 2. the current use of either insulin 
or oral hypoglycaemic agents, or 3. a random venous blood glucose >11.1 mmolL'\
2.10.4 Excessive Alcohol Intake
This was assessed from the alcohol diary and was defined as a typical alcohol intake of 
greater than the 9 5 percentile for the population which was 56 units per week.
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2.11 Statistical Analysis
Statistical analyses were performed using Minitab for Windows (Minitab Inc, 
Pennsylvania, U.S.A.) . Variables with normal distributions are described by the mean 
and the standard deviation (SD) and means were compared using a two sample t test. 
Valuables with a skewed distribution which could not be transformed easily were 
described by the median value and interquartile range. The median values for two 
groups were compared using the Maim-Whitney U test. The proportions of individuals 
in two or more groups were compared by the Chi-square test or where appropriate 
Fisher's exact te s t. Univariate and multivariate linear regression analyses were used to 
determine the relationship between a variable or a set of variables and a single outcome. 
A P value of <0.05 was taken to be significant.
2.12 Ethics
The study was approved by the West Glasgow Ethics Committee. All participants gave 
their written consent to each part of the study visit after having been given prior written 
information with the invitation and a verbal explanation at the time of their visit.
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3. Characteristics of Study Population and Risk 
Factors for Ischaemic Heart Disease.
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3.1 Introduction
The MONICA population of North Glasgow (Tunstall-Pedoe et al. 1994) is an inner- 
city population with a high degree of both social and material deprivation (Tunstall- 
Pedoe et al. 1996), having a socioeconomic status well below that for the rest of 
Scotland (Morrison et al. 1997). It is characterised by a high event rate for myocardial 
infarction and coronary death in both males and females (Tunstall-Pedoe et al. 1996). 
Since the majority of left ventricular (L.V.) dysfunction, both systolic and diastolic, in 
the Western world today can be attributed to the effects, either singularly or in 
combination, of ischaemic heart disease (l.H.D.) and hypertension (Cowie et al. 
1997a; Madsen et al. 1994; Brogan et al. 1992; Judge et al. 1991; Echeverria et al. 
1983) this population was chosen in which to define the prevalence, causes and 
characteristics of both abnormal systolic and diastolic L.V. function.
A previous study looking at L.V. systolic dysfunction in this population had been 
carried out some tliree years prior (McDonagh et al. 1997) and looked at a wide age 
range - 25 to 75 years. It showed, as have other studies (Schocken et al. 1992; Ho et 
al. 1993a; Ho et al. 1993b), that the prevalence of L.V. systolic dysfunction rises with 
age, and particularly steeply so after the age of 55 years. Therefore this current study 
concentrated on the older age range of 55 to 74 year olds recognising that morbidity and 
mortality in this group is both premature and still impacts greatly on the individual and 
community, since individuals at this point in life, being increasingly freed from the ties 
of employment and family, expect to enjoy a good quality of life.
It was the aim of this study to recruit and study a well characterised random sample of 
this high risk population. This chapter describes in detail the study population
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characteristics with particular emphasis on established coronary risk factors
3.2 Methods
These are described in detail in Chapter 2 but briefly the theoretical population was all 
men and women resident within the city of Glasgow, north of the River Clyde aged 
between 55 and 74 years. By means of a two stage, stratified, random sampling 
process, and by over sampling where required, 125 males and females within each 
five year age band were studied. Each attendee completed questionnaires regarding 
demographics, past medical history and current medication. Both height and weight 
were measured and body mass index was calculated as weight (kg) 4- height^ (m). 
Blood pressure was measured as the average of two readings using a random-zero 
sphygmomanometer (Hawksley and Sons, Ltd., West Essex, England) after ten minutes 
seated rest. A random, non-fasting, blood sample was taken for measurement of total 
serum cholesterol and blood glucose by a photometric method using Glucotide reagent 
strips read by a Glucometer 4 meter (Bayer Diagnsotics, Newbury, England) with a 
range of 0.6 to 33.3 mmolL"\ Finally a 12 lead resting ECG was recorded and 
Minnesota coded (Prineas et al. 1982).
3.2.1 Definitions
Hypertension: current treatment with antihypertensive medication and/or a systolic 
blood pressure >160 mmHg and/or a diastolic blood pressure >95 mmHg.
Hypertension [JNC VI]: current treatment with antihypertensive medication and/or a 
systolic blood pressure >140 mmHg and/or a diastolic blood pressure >90 mmHg. 
Hypertension is fiiither subdivided into Stage 1: BP 140-159/90-99 and Stage 2:
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>160/>100 mmHg.
Ischaemic Heait Disease: the presence of one or more of: (a) a prior physician-made 
diagnosis of myocardial infarction or angina; (b) the current use of nitrates; (c) ECG 
evidence of possible l.H.D. - pathological Q waves (codes 1.1 - 1.3) , ST segment 
depression (4.1 - 4.4) or left bundle branch block (7.11).
Diabetes Mellitus (D.M.): either (a) a prior physician-made diagnosis of diabetes
mellitus or (b) the current use of either insulin or oral hypoglycaemic agents or (c) a 
random venous blood glucose >11.1 mmolL'\
3.2.2 Statistical Analysis
Values with a normal distribution are quoted as the mean ± standard deviation (S.D.). 
Other values are quoted as the median and interquartile range (I.Q.R.). Student's t test 
(two-tailed) was used to compare means, the Mann Whitney U test to compare medians 
and the Chi-squared test or Fisher’s exact test, where appropriate, was used to compare 
the proportions of individuals within two or more groups. A P value of <0.05 was 
taken to be significant.
3.3 Results
3.3.1 Response Rates and Non-Attenders
From the general practice lists 2404 individuals were selected of which 285 (11.9%) 
were excluded by their G.P. and a further 139 (5.8%) were found subsequently to have 
moved out of the area. Of the 1688 people invited 1009 (59.8%) finally attended - the 
age and sex breakdown of which is shown in Table 3-1. The response was greater in 
men than in women - 63.1% v 56.8%, P=0.008 - and fell with increasing age; being 
greater in the first ten compared to the second ten years of the age range -
62
Table 3-1 - Age and Sex Distribution o f Attendees
AGE GROUP MALE FEMALE TOTAL
55 - 59 yrs 123 131 254
60 - 64 yrs 128 133 261
65 - 69 yrs 122 124 246
70 - 74 yrs 127 121 248
Totals 500 509 1009
Table 3-2 - Response Rate by Age and Sex 
N=1009
AGE GROUP MALE FEMALE TOTAL
55 - 59 yrs 65.1% 64.2% 64.6%
60 - 64 yrs 69.9% 60.5% 64.8%
65 - 69 yrs 64.2% 53.4% 58.3%
70 - 74 yrs 55.2% 50.4% 52.8%
63.1% 56.8% 59.8%
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64.7% V 55.4%, P<0.001 - Table 3-2 & Figure 3-1. The poorest response was seen in 
the oldest age group of females - 50.4%. A detailed summary of the characteristics of 
the attendees is presented in Table 3-3. The deprivation categories for the entire study 
cohort, based on the postcode sectors for the attendees’ addresses, are shown in Table 
3-3, and are compared to those of the entire Scottish population in a frequency 
distribution histogram -  Figure 3-2 . Over half the cohort (52.7%) were in the most 
deprived categories -  Depcat 6 or 7 -  compared to just 15% of the whole Scottish 
population.
General practice casenotes for 462 (56.5%) of the non-attenders were made available 
for study. In 27 (5.8%) individuals a hospital diagnosis of heart failure was recorded of 
which six had echocardiographic evidence of L.V. systolic dysfunction.
3.3.2 Risk Factors For Ischaemic Heart Disease Within The Population
Overall there was a liigh prevalence of risk factors for ischaemic heart disease within 
the study population - Tables 3-4a to 3-4c.
(a) Blood pressure and Hypertension
The mean systolic and diastolic blood pressures in participants were 147.0 ± 24.9 
mmHg and 80.5 ± 12.9 mmHg respectively, with males having a higher mean diastolic 
pressuie than females - 81.5 ± 13.4 mmHg v 79.5 ± 12.3 mmHg, P=0.014. The 
frequency distributions of systolic and diastolic blood pressures within the population 
are shown in Figure 3-3. The prevalence of hypertension, as defined by our definition, 
was 44.1%, being equal in males and females, but showed a significant age gradient 
with it being higher in the second ten years of the age range compared with the first ten 
- 36.5% V 52.0% (P<0.001).
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Figure 3-1 - Attendance Rates by Age and Sex
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Table 3-3 - Characteristics of Participants 
(n=1009)
Body Mass Index 26.9 ±4.4 Kg/m^
Systolic Blood Pressure 147.0 ± 24.9 mmHg
Diastolic Blood Pressure 80.5 + 12.9 mmHg
Total Cholesterol 5.99+1.12 mmolL"
Number %
• Diabetes Mellitus 67 6.6%
Diet controlled 24 2.4%
Oral hypoglycaemic agents 26 2.6%
Insulin 6 0.6%
New diagnosis 11 10.9%
• Hypertension 445 44.1%
Currently on medication 240 23.8%
• Hypertension (JNC VI) 677 67.1%
Currently on medication 240 23.8%
• Ischaemic Heart Disease 443 43.9%
Self Reported M.l. 108 10.7%
Self Reported Angina 165 16.4%
Nitrate Use 100 9.9%
Q/QS pattern 67 6.6%
Major E.C.G. Ischaemia 266 26.4%
• Cigarette Smoking
Current 91 9.0%
Ex-smoker 604 59.9%
Never 306 30.3%
Not known 8 0.8%
• Alcohol Consumption
< 21 units / week 654 64.8%
> 21 units / week 95 9.4%
Not known 260 25.8%
• Current Medication
Aspirin < 300mg /day 182 18.0%
Beta Blockers 126 12.5%
Calcium Channel Blockers 114 11.3%
Nitrates incl. S/L GTN 100 9.9%
ACE inhibitors 46 4.6%
Loop diuretics 58 5.7%
Warfarin 15 1.5%
Digoxin 20 2.0%
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Table 3-3 - (Cent.)
Highest Level of Education Attained 
University degree 
Professional / Technical Diploma 
Secondary School 
Primary School 
Not Known
Number
20
120
804
44
21
%
2 .0%
11.9%
79.7%
4.4%
2 . 1%
Housing Tenure 
Owner Occupier 
(Private Sale)
Owner Occupier 
(former Local Authority) 
Local Authority Leasing 
Private Renting 
Not Known
208
246
512
24
17
20 .6%
24.4%
50.7%
2.4%
1.7%
Current Employment Status
Males (n=500) Females (509)
n % n %
Full-time 77 15.4% 26 5.1%
Part-time 11 2.2% 49 9.6%
Unemployed 37 7.4% 9 1.8%
Long-term sick 86 17.2% 36 7.1%
Retired 280 56.0% 310 60.9%
Housewife N/A 71 13.9%
Unknown 9 1.8% 8 1.6%
^privation Category - By postcode sector
n %
Cat. 1 119 11.8%
Cat. 2 89 8.8%
Cat. 3 67 6.6%
Cat. 4 156 15.5%
Cat. 5 44 4.4%
Cat. 6 329 32.6%
Cat. 7 203 20.1%
Not Known 2 0.2%
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Figure 3-2 -  Deprivation categories for cohort and for the Scottish population 
based on the 1991 Census Data
Frequency Distribution of Deprivation Categories in 
Scotland (1991) and Study Cohort
cg3
3aoQ.
1 3 4 5
Deprivation Category
□ Cohort 
■  Scotland
Notes:
Category 1 - Most affluent to Category 7 -  Greatest deprivation
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Table 3-4a - Prevalence of Risk Factors for Ischaemic Heart Disease in 
Whole Cohort
Risk Factor No. Prevalence
Hypertension 445 44.1%
Hypertension [JNC VI] 677 67.1%
Diabetes Mellitus 56 5.6%
Cholesterol > 6.5 mmolL'^ 291 28.8%
Smoker - Ex 604 60.4%
Current 91 9.1%
Family History 199 19.7% (N=1009)
Table 3-4b - Risk Factors in Male and Female Attendees
Males n=500 Females n=509
BMI (kg/m^) 26.7 (23.9 - 28.9) 26.6 (23.7- 29.8)
Cholesterol (mmolL"^) 5.65 + 1.04 6.34 + 1.09 **
Systolic BP (mmHg) 148.2 + 24.2 145.5 ±26.4
Diastolic BP (mmHg) 81.5 + 13.4 79.4 ± 12.8**
Alcohol (units / week) 8.0 (0-21.0) 2.0 (0 - 5.0) **
Hypertension 44.0% 44.2%
Hypertension [JNC VI] 69.0% 65.2%
Diabetes Mellitus 7.8% 5.5%
Cigarette Smoking
-Ex 70.2% 49.5% **
Current 8.2% 10.0%
Cholesterol > 6.5 mmolL"^ 18.0% 39.5% **
Lipid Lowering Therapy 1.4% 2.9%
Family History of l.H.D. 15.8% 23.6% **
* P<0.05 ** P<0.01
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Table 3~4c - Risk Factors for Ischaemic Heart Disease by Age Group
Prevalence
Age Group Diabetes Hypertension Hypertension [JNC VI]
55- 59 yrs 6.7% 33.9% 54.3%
60 - 64 yrs 6.5% 39.1% 62.1%
65 - 69 yrs 9.8% 51.6% 79.7%
70 - 75 yrs 3.6% 52.4% 73.0%
Change in prevalence with age: Diabetes - not significant, P=0.06
Hypertension - P<0.001
Age Group Systolic BP Diastolic BP Total Cholesterol
(yrs) (mmHg) (mmHg) (mmolL'^)
55 - 59 yrs 140.4 + 21.6 81.1 ± 11.8 6.14 ± 1.08
60 - 64 yrs 142.8 +24.3 80.2 ±13.0 5.95 ± 1.03*
65 - 69 yrs 152.3 ±24.4** 81.6± 12.9 6.00± 1.17
70 - 75 yrs 153.0 ±26.7** 79.2 ±13.7* 5.88± 1.19*
P<0.05 ** P<0.01 compared to the 55 - 59 years age group
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Figure 3-3 - Distribution of Systolic and Diastolic Blood Pressure in Study 
Population
Dstribution of Systolic Hood Pressure in Study Population
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Antihypertensive medication was currently being taken by 240 individuals (23.8%) i.e. 
treated hypertension - Figure 3-4. A further 205 (20.3%) individuals in the absence of 
antihypeitensive medication had a systolic blood pressure in excess of 160 mmHg 
and/or a diastolic blood pressure in excess of 95 mmHg - i.e. untreated hypertension. 
Of those who were already treated 125 (52.1%) had both a systolic blood pressure <160 
mmHg and a diastolic blood pressure <90 mmHg - i.e. had treated and controlled 
hypertension. Of tlie untreated hypertensives 45 (22.0%) reported having been told by a 
physician at some point that they had hypertension i.e. detected but untreated 
hypertension.
Amongst those with hypertension the mean cholesterol was 6.05 ± 1.16 mmolL'^ with a 
range of 2.89 to 9.85 mmolL’^  and lipid lowering agents were being taken by 14 
individuals. Diabetes mellitus was present in 38 (8.5%) individuals. Current cigarette 
smoking was reported by 34 (7.6%) individuals and 277 (62.2%) were former smokers.
(b) Hypertension -  JNC VI based Definition
Using the blood pressure limits for normality as set out in the JNC VI guidelines 677 
(67.7%) people were considered to be hypertensive.- Tables 3-4a to 3-4c and 3-5. Of 
these, 437 persons were not currently receiving antihypertensive treatment; 242 of 
whom were defined as having stage 1 hypertension (BP 140-159 / 90-99 mmHg) and 
195 of whom were defined as having stage 2 (BP > 160/100 mmHg). A further 119 
individuals had a high/normal blood pressure (BP 130-139 / 85-89 mmHg) in the 
absence of antihypertensive therapy. Of the 240 individuals receiving antihypertensive 
treatment 176 (73.3%) still had a blood pressure >140/90 i.e. were not adequately 
controlled according to the JNC VI guidelines -  although these had not been published
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Figure 3-4 -  Detection and Control of Hypertension Amongst Hypertensive 
Individuals
Hypertensives Within Population 
N=445
100.0%
90.0%
80.0%
70.0%
60.0%
50.0%
40.0%
30.0%
20 .0%
10.0%
0 .0%
Treated -  Controlled 
125
25.8%
28.1%
36.0%
Treated -  Uncontrolled 
115
Untreated -  Undetected 
160
Untreated - Detected 
45
Definitions
Hypertension- Systolic BP >160 mmHg and / or 
Diastolic BP >95 mmHg and / or 
Currently on antihypertensive medication.
Controlled - Systolic BP <160 mmHg - on treatment 
Diastolic BP <90 mmHg - on treatment
Detected - Previous physician diagnosis
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Table 3-5 - Prevalence of Hypertension byJNC VI Guidelines
Blood Pressure 
Category All
Antihypertensive Therapy 
Current None
Normal
<130/85
249 (24.7%) 36 (3.6%) 213 (21.1%)
High Normal 
130-139/85-89
147 (14.6%) 28 (2.8%) 119 (11.8%)
Stage 1 
140-159/90-99
321 (31.8%) 79 (7.8%) 242 (24.0%)
Stage 2 
>160/>100
292 (28.9%) 97 (9.6%) 195 (19.3%)
Total 1009 240 (23.8%) 769 (76.2%)
N (% of entire cohort)
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at the time this study was performed.
(c) Diabetes Mellitus
The prevalence of diabetes was 6.6% in this study with no gender difference. A 
previous physician-made diagnosis was reported by 56 people (5.6%) and this was 
being treated by diet alone in 24 individuals, oral hypoglycaemic agents in 26 and 
insulin therapy in six. In addition 11 (1.1%) individuals had a random venous blood 
glucose of > 11.1 mmolL'^ without a prior diagnosis of diabetes.
Of those with diabetes 38 (56.7%) were hypertensive, and the mean cholesterol was 
5.61 ± 0.88 nnnolL-^; range 3.51 to 8.46 mmolL-\ Four were currently taking lipid 
lowering drugs. Only one individual still smoked regularly but 49 were former regular 
cigarette smokers.
(d) Cholesterol Levels
A plasma cholesterol level was measured in 989 people and the mean was 5.99 ± 1.12 
mmolL'^; range 2.68 to 9.88 mmolL"\ The frequency distribution of total cholesterol in 
the study population is shown in Figure 3-5. Males had a lower mean cholesterol than 
females - 5.65 ± 1.04 mmolL'^ v 6.34 ± 1.09 mmolL"% P<0.001. A level of > 6.5 
mmolL'* was taken to indicate significant hypercholesterolaemia and was found in 291 
(28.8%) of the cohort. Lipid lowering drugs were being taken by 22 individuals whose 
mean cholesterol was 6.16 ± 0.87 mmolL"^ which was not significantly different from 
the mean level for the cohort as a whole.
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Figure 3-5 - Distribution of Total Cholesterol In Study Population
Distribution of Total Cholesterol in Study Population
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(e) Cigarette Smoking
Of the 1001 people who answered the smoking questionnaire 306 ( 30.6%) had never 
smoked cigarettes regularly. Of the remainder 91 (9.1%) were cui'rent smokers - 
smoking a median of fifteen cigarettes a day - and 604 (60.4%) were former regular 
smokers.
(f) Family History
As to whether or not they had a parent or sibling suffer from heart disease before the 
age of 60 years 199 people (19.7%) answered in the affirmative.
(g) Multiple Risk Factors
Two or more of the above risk factors for ischaemic heart disease were present in 
57.3% of the population - Table 3-6.
3.3.3 Ischaemic Heart Disease Within the Population
The overall prevalence of ischaemic heart disease (I.H.D.) within the study population 
was 43.9% and rose with age from 37.8% in the 55 to 59 years age group to 51.6% in 
the 70 to 75 years age group (P=0.002) - Table 3-7. There was no significant gender 
difference.
Clinical I.H.D. - i.e. either self-reported or treated with nitrates - was present in 212 
individuals (21.0%) - Table 3-8 - of whom 101 (47.6%) reported a diagnosis of angina, 
44 (20.8%) a previous M.I. and 64 (30.2%) both. A further three individuals were
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Table 3-6 - Prevalence of Two or More Risk Factors for Ischaemic Heart 
Disease Within the Study Population
Diabetes
38 Hypertension
(3.8%)
50 311 Smoker
(5.0%) (30.8%) Current/ Ex
6 135 186 Cholesterol
(0.6%) (13.4%) (18.4%) > 6.5mmolL“^
14 77 123 59 Family
(13.9%) (7.6%) (12.2%) (5.8%) History
N=1009
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Table 3-7 - Prevalence of Ischaemic Heart Disease by Age and Sex 
N=1009
AGE GROUP MALE FEMALE TOTAL
55 - 59 yrs 35.0% 40.5% 37.8%
60 - 64 yrs 45.3% 35.3% 40.2%
65 - 69 yrs 50.0% 42.7% 46.3%
70 - 74 yrs 49.6% 53.7% 51.6%
45.0% 42.8% 43.9%
Table 3-8 - Proportion of Ischaemic Heart Disease Which Is Clinical 
N=1009
AGE GROUP MALE FEMALE TOTAL
55 - 59 yrs 41.9% 43.4% 42.7%
60 “ 64 yrs 51.7% 40.4% 46.7%
65 - 69 yrs 52.5% 37.7% 45.6%
70 - 74 yrs 63.5% 46.2% 54.7%
63.5% 46.2% 54.7%
Male V Female P=0.164
Clinical I.H.D. - Reported physician diagnosis of ischaemic heart disease or 
myocardial infarction or current use of nitrates.
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currently using nitrates but did not report a prior physician diagnosis of I.H.D. The 
difference between the proportion of males and females who were symptomatic did not 
reach statistical significance nor did the difference across the age ranges. Of the 67 
individuals with E.C.G. evidence of previous M.I. only 22 (32.8%) reported clinical 
I.H.D. and of the 266 with major ischaemia only 80 (30.0%) reported clinical I.H.D.
Diabetes mellitus and hypertension were both more prevalent amongst those with
I.H.D. than amongst those without: diabetes 9.0% v 4.8% (P<0.01) and hypertension 
53.1% V 37.1% (P<0.001). Smoking, both current and previous, was no more 
prevalent amongst those with I.H.D. (69.1%) than those without (68.7%). The mean 
cholesterol for individuals with I.H.D. was 5.99 ± 1.20 mmolL'^ which is not 
significantly different to the mean for individuals without I.H.D - 5.99 ±1.06 mmolL'\
Diabetic individuals compared to non-diabetic individuals had a higher prevalence of 
both ischaemic heail disease (59.7% v 42.9%, P<0.01) and hypertension (56.7% v 
43.2%, P<0.05). Hypertensive individuals compared with those considered
normotensive had a higher prevalence of botli diabetes (8.5% v 5.1%, P<0.05) and 
ischaemic heart disease (52.8% v 36.9%, P<0.001).
3.4 Discussion
This study succeeded in its primary aim of assembling and studying a cohort of
individuals from the community. The overall response rate was lower than might have
been expected. The previous study undertaken in the same population (McDonagh et
al. 1997) achieved a response rate of 83% but this was both amongst second time
responders and across a wider age range including younger individuals who were
shown, in that study and in this present one, to be more likely to attend. A community
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based study looking at an older age group (Morgan et al. 1999) achieved a response 
rate of 77.4% but found, like this study, that non-attenders were more likely to be older 
and female.
There are several factors which are likely to have influenced attendance. The major one 
may have been the need, because of the size of echocardiographic equipment, to use a 
single study site to cover what is a wide geographical area. Although travel costs were 
reimbursed, ' individuals from several of the furthest areas are likely to have been 
deterred from attending by distance. This might have explained the especially low 
percentage response amongst older females - a group least likely to travel far. Newer, 
more portable, echocardiographic equipment should allow future studies to be 
conducted in local communities.
There is the potential that those who did not attend suffered from more cardiovascular 
disease than those who did. Whether it was this that deterred them from attending or 
whether it was some other disease, possibly with an aetiology common also to 
cardiovascular disease such as smoking related airflow obstruction or diabetes, we do 
not Imow. The attempt to quantify this by looking at the general practice casenotes of 
non-attenders proved too difficult an exercise. Being an addendum to the original 
study protocol it ran into problems regarding consent and confidentiality. What it did 
suggest however was that there was at least as high a prevalence of heart failure in the 
non-attenders and so it is likely that any prevalence estimate in the study cohort will not 
be an overestimate for the whole population.
In this current study we set out to replicate the methods (apart from the
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echocardiographic equipment) and definitions used by McDonagh in her previous study 
of this population (McDonagh et al. 1997; McDonagh 1998). Undoubtedly how one 
chooses to define a condition will influence its prevalence. Equally a condition whose 
signs may change on a daily basis, such as hypertension or diabetes mellitus, may be 
difficult to obtain a true prevalence for, based on a single clinical visit. In this study 
the aim was that the definitions used should be more exclusive than inclusive to avoid 
overestimating prevalences. Considerable importance was therefore attributed to 
previous physician-made diagnoses in view of the single clinical visit. Clearly there 
was no way of validating such prior diagnoses; however future programmes set up to 
screen for the presence of L.V. dysfunction are likely to have to use similar criteria and 
definitions for identifying individuals at risk and so this current study's methods seem 
appropriate.
The definition of hypertension used in this current study was the same as used in the 
1994 Health Survey for England (Colhoun et al. 1998) and was based on the 1993 
British Hypertension Society Guidelines (Sever et al. 1993) which were in force at the 
time of this study and wliich recommended, on the basis of three separate readings, 
treating a systolic blood pressure in excess of 160 mmHg and a diastolic blood pressure 
in excess of 90 to 100 mmHg depending on the presence of other factors. Once treated, 
the guidelines reconimended a target systolic blood pressure of 160 mmHg or less and 
a diastolic blood pressure of 90 mmHg. The latest guidelines from the British 
Hypertension Society (Ramsay et al. 1999) are broadly similar with a threshold of 
>160/100 mmHg taken for the initiation of antihypertensive drug therapy except in the 
presence of cardiovascular complications, target organ damage (L.V.H., proteinuria 
etc), or a calculated ten-year coronary heart disease risk of >15%, when a level of
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>140/90mmHg is advised as the threshold for pharmacological intervention.
Using the definition of hypertension as set out in the JNC VI guidelines (Joint National 
Committee on Prevention, Evaluation and Treatment of High Blood Pressure 1997) 
gives an even greater prevalence of hypertension in our cohort. Undoubtedly on the 
basis of a single visit we are likely to over estimate the true prevalence of hypertension, 
and this proportion of false positive diagnoses will increase as we lower the cut-off 
values of blood pressure, in untreated individuals, for the diagnosis of hypertension. 
This is because, in spite of our study protocols, we are likely to see some “white coat” 
effect on blood pressure. Hence the reason why, for the major part, we have taken 
160/95 as our cut-off for the diagnosis of hypertension in the untreated individual. In 
doing so we ackowledge that lower levels of blood pressure may not necessarily be 
normal, and that there is a continuum of risk for coronary heart disease across an 
increasing range of blood pressure from high-normal to clearly abnormal (Joint 
National Committee on Prevention, Evaluation and Treatment of High Blood Pressure
1997).
Hypertension was common in the study group although it was no more common than 
that found in the 1994 Health Survey for England (Colhoun et al. 1998) which showed 
the prevalence in the age group 55 to 64 years to be ~ 34%, with a slight excess in 
males compared to females, rising to 52.4% for men and 57.0% for women in the age 
group 65 top 74 years. The prevalence in this study was 36.5% in the age group 55 to 
64 years and 52.0% in the 65 to 74 years olds.
In 1972 the "Rule of Halves" with regard to hypertension in the community was
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conceived (Wilber and Barrow, 1972). This states that half of hypertension is 
undetected; half of those detected are untreated and in half of those treated 
hypertension is not controlled. This rule was shown to hold for Scotland between 1984 
and 1986 (Smith et al. 1990) using the same definition as this current study. This 
present study showed that in 1994/1996 only 36% of the hypertension was undetected 
which may reflect the greater emphasis placed in primary care on screening and primary 
prevention. Of those treated 47.9%, however, were not controlled, based on a single 
visit, suggesting that whilst detection has improved follow-up may not have.
The prevalence of diabetes mellitus was lower than would be expected from previous 
studies in Caucasian populations: 6% in the 45 to 65 years age group and 11% in the 
over 65 years group (Harris, 1998). The definition of diabetes mellitus, incorporating a 
non-fasting blood glucose concentration, will almost certainly have underestimated its 
true prevalence. Depending on the interval elapsed since, and the nature of, the last 
meal the blood glucose in a diabetic individual may be less than or equal to 11.0 
mmoIL"’. The recognition that, not only in epidemilogic studies, but also in clinical 
practice there is a potential to under-diagnose the condition, especially in its milder 
forms, has led to a recent change in the diagnostic criteria for diabetes mellitus 
contained within the most recent guidelines (Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus, 2000). These guidelines recommend that the 
diagnosis should be based on the results of a fasting plasma glucose; with the condition 
being diagnosed if the glucose is > 7.0 mmolL'*. They also recommend that this 
measurement, in the absence of clear metabolic upset attributable to diabetes, should be 
repeated before a definite diagnosis is made. The guidelines do allow the diagnosis to 
be made when a non-fasting plasma glucose is >11.1 mmolL"^ but only in association
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with the symptoms of diabetes. The same diagnostic criteria, the guidelines state, 
should be used in epidemiologic studies. Clearly not having measured a fasting plasma 
glucose in tliis study does not allow us to comply with these guidelines, which were 
published subsequent to the completion of this study. We have therefore had to use the 
available data collected to make some form of estimation of prevalence. The decision 
to use a non-fasting glucose of >11.1 mmolL'^ was in accordance with what was 
accepted clinical practice at the time this study was performed, and is in general 
agreement with the latest guidelines with regard to non-fasting levels, although we did 
not talce into account the presence or absence of symptoms.
Population studies of diabetic patients in Finland, Framingham and Wisconsin, USA 
have shown that coronary heart disease increases with increasing levels of glycaemia 
(Kuusisto et al. 1994; Wilson et al. 1991; Klein, 1995). In this present study no 
assessment was made of glycaemic control in diabetic individuals nor of duration of 
disease. In future studies the measurement of glycosylated haemoglobin levels in 
blood might go part way to both detecting diabetes in the context of a normal random 
blood glucose and yielding information on glycaemic control in the medium term.
The level of total cholesterol which was taken to represent hypercholesterolaemia was 
based on the level of 6.5 mmolL'^ required for inclusion in the first stages of the 
WOSCOPS study (Shepherd et al. 1995; The WOSCOPS Study Group, 1995). In the 
Scottish Heart Health Study the mean cholesterol in men aged 45 to 59 years was 6.4 
ramolL'*. A decade later the finding of a mean cholesterol of 5.99 mmoIL'* in this 
study's population may have more than one explanation. One is selection bias: the more 
health conscious are likely to attend for a study, such as this one, with a perceived
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benefit to the individual Although, tliis does not seem to have been evident in other 
risk factors. The other is that individuals with high cholesterol levels may have already 
died from their premature coronary event.
The diagnosis of the presence of ischaemic heart disease without recourse to coronary 
angiography can never be totally accurate and any method used, whether it be 
questionnaires or electrocardiographs, is but a screening test with its own sensitivity 
and specificity. Our definition of I.H.D. is therefore, to a greater or lesser extent, 
flawed; as is that used by most epidemiologic studies. E.C.G. findings, with possibly 
the exception of large q waves, are not completely specific for ischaemia; the same 
finding may result from other myocardial diseases or simply the extremes of 
physiological variation (Rose et al. 1978). This is particularly true of left bundle 
branch block and ST segment depression, both of which may accompany left 
ventricular hypertrophy rather than I.H.D. As an isolated feature the Framingham 
study found that T wave inversion was of no significance (Higgins et al. 1965). The 
decision to exclude T wave inversion as a marker of I.H.D. will have undoubtedly 
lowered the overall prevalence of the condition and have led to an unspecified number 
of false negative diagnoses. Equally the inclusion of ST segment depression and left 
bundle branch block will have led to a number of false positive diagnoses being made. 
Relying upon patient recall of previous physician-made diagnoses is also inherently 
flawed. Firstly the diagnosis may not be correct, and there is no way of corroborating 
it, and secondly the recall may be inaccurate. In one study only one in five men with 
evidence on questionnaire or on E.C.G. criteria of I.H.D. recalled having been told by a 
physician that they had angina (Shaper et al. 1984). Other studies have used a chest 
pain questionnaire (the Rose questionnaire (Rose et al. 1977)) to diagnose ischaemic
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heart disease (Bainton et al. 1988). The use of this in this present study would have 
improved the sensitivity of the definition used for diagnosing ischaemic heart disease. 
In futui'e studies this should be included and its exclusion from this analysis was 
perhaps an oversight. In any study, however, the definition of I.H.D. based on simple 
clinical and electrocardiographic criteria will always be arbitary.
Accepting that the definition of I.H.D. in this study has at least impaired sensitivity, the 
prevalence of I.H.D. was still relatively high and agrees with what we Imow about the 
high coronary event rate in this population. It shows a rise with age in both sexes as 
would be expected. Previous studies using the Rose questionnaire and wider E.C.G. 
criteria have shown the prevalence to be lower in other populations. The Caerphilly and 
Speedwell studies (Bainton et al. 1988) in 1978, looking only at men, showed a 
prevalence of I.H.D. in the age group 55-59 years of between 24.4 - 29.9% compared 
with a prevalence of 35.0% in this present study. The prevalence in these published 
studies was higher amongst the unemployed suggesting a effect of socioeconomic 
status. In this north Glasgow geographical population it has been shown previously, for 
both men and women, that the risk of myocardial infarction increases with increasing 
deprivation (Morrison et al. 1997). This "socioeconomic gradient" is acting within a 
population which is already skewed towards the lower end of the socioeconomic scale. 
We demonstrated in this study that the cohort studied certainly had an overall 
socioeconomic status which was heavily skewed towards deprivation.
Therefore tliis study's well characterised population not only has a high, and possibly 
underestimated, prevalence of I.H.D., and its recognised risk factors, but is also 
socioeconomically disadvantaged - an additional risk factor in its own right.
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4. Prevalence and Aetiology of Left Ventricular
Systolic Dysfunction
4.1 Introduction
Much work has been carried out to establish the epidemiology of the clinical syndrome 
of clironic heart failure (C.H.F.) in the U.K., Europe and perhaps most famously in the 
U.S.A. Less has been done to determine the epidemiology of the major contributor to 
the syndrome namely left ventricular systolic dysfunction (L.V.D.). To date only two 
such studies have been carried out in the U.K. McDonagh et al showed that in 1992 
the prevalence of L.V.D. within the population of north Glasgow, aged between 25 and 
74 yeai's, by echocardiography was 2.9% although it was higher in the older decades. 
A more recent study from Dorset showed the prevalence to be 7.5% within an older age 
group of 70 to 84 year olds. In both studies L.V.D. was mainly attributable to 
ischaemic heart disease (I.H.D.).
Following on from McDonagh's study, and seeking to replicate its methods but using 
more advanced echocardiographic equipment, this study aimed to establish the 
prevalence, aetiology and characteristics of L.V.D. within a larger random sample of 
1000 individuals resident witliin the population of north Glasgow aged between 55 and 
74 yeai’s. The characteristics of the study cohort are described in detail in Chapter 3.
4.2 Methods
These are described in detail in Chapter 2 but briefly each individual attended the study 
centre for one visit during which they completed questionnaires regarding past medical 
history, medication and the M.R.C. breathlessness questionnaire (Fletcher et al. 1959); 
which distinguishes dyspnoea possibly due to chronic bronchitis from that possibly 
cardiac in origin. Their seated blood pressure was taken as the average of two readings 
after 10 minutes rest using a random zero sphygmomanometer (Hawksley and Sons,
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Ltd., West Essex, England). A random venous blood sample was taken for 
measurement of glucose concentrations in whole blood by a photometric method using 
Glucotide reagent strips read by a Glucometer 4 meter (Bayer Diagnsotics, Newbury, 
England) with a range of 0.6 to 33.3 mmolL'\
A full two-dimensional echocardiogram was performed using an Acuson 128 
ultrasound machine (Acuson Inc., Mountain View, CA, USA). At least three single­
cycle loops of both the apical 4- and 2-chamber views were digitised and transferred 
onto optical discs using an off-line digital image processing and analysis system 
(Tomtec Imaging System Inc., Boulder, Colorado, USA). The left ventricular ejection 
fraction (L.V.E.F.) was measured using a biplane algorithm ("method of discs 
summation") - Simpson's rule (Schiller et al. 1979) - as an average of three cycles. To 
be suitable for analysis at least 80% of the endocardium had to be visible. End-diastole 
was defined as the frame with the largest L.V. cavity at the initial systolic coaptation of 
the mitral valve, and end-systole as the subsequent frame with the smallest cavity area 
(Badano et al. 1996).
A 12 lead electrocardiograph was recorded in a standard fashion at a paper speed of 
25mm per second on a Siemens Sicard 440 electrocardiograph (Siemens Elema, 
Stocldiolm, Sweden) and subsequently coded by computer algorithm (Macfarlane,
1998) according to the Minnesota E.C.G. code (Prineas et al. 1982) for the presence of 
Q/QS waves (codes 1.1-1.3), left bundle branch block (7.11), ST segment depression 
(4.1-4.4), left ventricular hypertrophy (3.1, 3.3, 3.4) or atrial flutter/fibrillation (8.31, 
8.32). All ECG results were verified by visual inspection.
90
4.2.1 Definitions
Hypertension: current treatment with antihypertensive medication and/or a systolic 
blood pressure >160 mmHg and/or a diastolic blood pressure >95 mmHg.
Hypertension [JNC VI]: current treatment with antihypertensive medication a systolic 
blood pressure > HOramHg; 2. a diastolic blood pressure >90mmHg; or 3. the use of 
specific antihypertensive medication.
Ischaemic Heait Disease: the presence of one or more of: (a) a prior physician-made 
diagnosis of myocardial infarction or angina; (b) the current use of nitrates; (c) ECG 
evidence of possible I.H.D. - pathological Q waves (codes 1.1 - 1.3) , ST segment 
depression (4.1 - 4.4) or left bundle branch block (7.11).
Diabetes Mellitus (D.M.): either (a) a prior physician-made diagnosis of diabetes
mellitus or (b) the current use of either insulin or oral hypoglycaemic agents or (c) a 
random venous blood glucose >11.1 mmolL“*.
Cardiac-type dyspnoea: Breathlessness reported on the M.R.C. questionnaire in the 
absence of symptoms of chronic bronchitis.
Abnormal E.C.G.: the presence of at least one of: Q/QS waves, ST segment depression, 
left bundle branch block or atrial flutter/ftbrillation.
4.2.2 Statistical Analysis
Values with a normal distribution are quoted as the mean ± standard deviation (S.D.). 
Other values are quoted as the median and interquartile range (I.Q.R.). Student's t test 
(two-tailed) was used to compare means, the Mann Wliitney U test to compare medians 
and the Chi-squared test or Fisher's Exact test where appropriate, the proportions of 
individuals within two or more groups. A P value of <0.05 was taken to be significant.
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4.3 Results
4.3.1 Availability of the L.V. Ejection Fraction Within the Population
Of the 1009 participants 750 (74.3%) had an echocardiogram suitable for calculation of 
an L.V. ejection fraction - Table 4-1. The availability of a measured L.V.E.F. fell with 
age being greater in the 55 to 64 years age range than in the 65 to 75 years age range 
(77.3% V 71.3%, P=0.029). Compared to the group with a measured L.V.E.F., the 
group without an L.V.E.F. had a greater prevalence of both I.H.D. (54.8% v 40.1% 
P<0.01) and diabetes mellitus (10.8% v 5.2% P<0.01) but not hypertension which was 
equally prevalent in both groups - Table 4-2.
4.3.2 Definition of Left Ventricular Systolic Dysfunction
The distribution of L.V.E.F. for the whole population was skewed to the right with a
median value of 50.7% (45.0 - 54.7%) and a range of 12.0% to 67.7%; mean 49.0 ± 
8.1% - Figure 4-1. A subgroup of 144 individuals from the cohort with no evidence of 
cardiovascular disease, or its major risk factors (except for smoking) - the "normal" 
subgroup was identified. The L.V.E.F. in this group was also slightly positively skewed 
with a median of 51.8% (47.8 - 55.7%) - Figure 4-2 - and with females having a 
higher median L.V.E.F. than males - 53.7% (49.7 - 56.7%) v 50.0% (45.5 - 54.5%), 
P<0.01. Mean values were: females - 50.7 ± 7.3%, males 47.3 ± 8.5%. There was no 
significant effect of age.
The normal range of values for the L.V.E.F. was defined as the range from the 2.5^ '^  to 
the 9 7 .5 “' percentiles inclusive for the normal subgroup: 37.2% to 61.6%. An 
L.V.E.F. of < 35% was therefore taken to represent significant left ventricular systolic 
dysfunction (L.V.D.).
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Table 4-1 - Availability o f Simpson's Left Ventricular Ejection Fraction by Age
and Sex
AGE GROUP MALE FEMALE TOTAL
5 5 -5 9 75.6% 77.9% 76.8%
60 — 64 82.0% 73.7% 77.8%
6 5 -6 9 69.7% 81.5% 75.6%
7 0 -7 4 70.1% 63.6% 66.9%
74.4% 74.3% 74.3%
N=1009
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Table 4-2 - Comparison Of Individuals With and Without a Measured L  V.E.F.
Parameter LVEF
(n=750)
No LVEF 
(n=259)
Age (yrs) 65.0 (60.0 - 69.0) 66.0 (61.0-71.0)
Sex - Male 49.6% 50.8%
Diastolic B.P. (mmHg) 80.6+12.9 79.9 ±13.7
Systolic B.P. (mmHg) 147.2 ±25.0 146.1 ±26.2
B.M.I. (Kg/m^) 26.3 ±4.0 28.7 ±5.1 **
Cholesterol (mmolL'^) 6.00± 1.1 5.96 ± 1.1
% I.H.D. 40.1% 54.8% *
% Hypertension 42.8% 47.9%
% Hypertension [JNC VI] 66.5% 68.7%
% Diabetic 5.2% 10.8%*
Previous M.I. 10.0% 12.4%
Smoker 68.5% 69.9%
P<0.05 ** - P <0.001
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Figure 4-1 - Distribution of Left Ventncular Ejection Fraction Within Whole 
Population
0) 100
30 40
LVEF %
N=750
50 60
Figure 4-2 - Distribution of Left Ventricular Function in Normal Subgroup
60 - 1
50 -
35 41 47 53 59 65
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4.3.3 Prevalence of Left Ventricular Systolic Dysfunction
The prevalence of L.V.D. was 6.7% within the population with an L.V.E.F. measured; 
being greater in males than in females - 9.4% v 4.0%, P=0.004, and rising with age - 
Table 4-3 & Figure 4-3. The median age for those with L.V. dysfunction was higher 
than for those with normal L.V. function - 69.0 years v 65.0 years , P=0.017. There 
was no difference in terms of blood pressure, body mass index, plasma cholesterol or 
alcohol consumption between those with L.V.D. and those without - Table 4-4.
4.3.4 Symptomatic and Asymptomatic L.V. Systolic Dysfunction
L.V.D. was defined as being symptomatic if there was a need for loop diuretic therapy 
and/or reported cardiac-type dyspnoea on the breathlessness questionnaire. Of those 
with L.V.D. 45.0% were considered to be symptomatic and this proportion did not 
differ significantly between the age groups - Table 4-5 & Figure 4-4 . The median 
L.V.E.F. for the symptomatic group was lower than for the asymptomatic group - 28.0 
(28.7-34.7%) % V 33.0 (18.7-35.0%) %, P=0.003.
4.3.5 Aetiology of L.V. Dysfunction
The commonest underlying disease was I.H.D. with it accompanying 78.0% (P<0.001)
of cases of L.V.D. - Tables 4-4 and 4-6. Both a previous physician-made diagnosis of
myocardial infarction and angina were strongly associated with the presence of L.V.D. -
being present in 46.0% (P<0.001) and 44.0% (P<0.001) of cases respectively. L.V.D.
was common amongst individuals reporting a previous M.I. with 30% having L.V.D. -
Table 4-6. Approximately one person out of every eight with I.H.D. had L.V.D. In
the absence of I.H.D., hypertension -  both definitions, valvular heart disease and
diabetes were all no more prevalent in individuals with L.V.D. than in those without. In
fact the prevalence of L.V.D. in isolated hypertension [JNC VI] - in the absence of
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Table 4-3 - Prevalence of Left Ventricular Systolic Dysfunction by Age and
Sex
Age / Sex MALE FEMALE TOTAL
55 -  59 yrs 5 / 9 3  5.4% 4/ 102  3.9% 9/195 4.6%
60 -  64 yrs 8 / 105  7.6% 3 / 9 8  3.1% 11 /203 5.4%
65 -  69 yrs 6 / 8 5  7.1% 4/101 4.0% 10/186 5.4%
70 -  74 yrs 16/89 18.0% 4 / 7 7  5.2% 20/166 12.0%
35/372 9.4% 15/378 4.0% 50/750 6.7%
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Figure 4-3 - Prevalence of Left Ventricular Systolic Dysfunction by Age and 
Sex
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Table 4-4 - Comparison Between Participants With and Without LV. 
Dysfunction
Parameter No LV Dysfunction 
(n=700)
LV Dysfunction 
(n=50)
Age (yrs) 65.0 (60.0 - 69.0) 69 .0 (61 .0 -71 .0 )*
Sex - Male 48.3% 70.0% *
Diastolic B.P. (mmHg) 80.4 ± 12.7 84.1 ± 15.7
Systolic B.P. (mmHg) 147.0 ±25.1 150.3 + 25.0
B.M.I. (Kg/m^) 26.22 + 5.6 26.78 + 3.8
Cholesterol (mmolL’ )^ 5.96 + 1.3 6.13 + 1.1
Alcohol Intake (Units/wk) 3.0 (0-11.0) 8 .0 (0 -14 .0)
Diabetes 5.1% 6.0%
Previous M.l. 7.6% 46.0% **
Angina 12.0% 44.0% **
I.H.D. 37.4% 78.0% **
Hypertension 42.1% 52.0%
Hypertension [JNC VI] 66.0% 74.0%
Valve Defects 9.7% 34.0% **
I.H.D. & Hypertension 19.9% 40.0% *
Isolated Hypertension 22.3% 12.0%
Isolated HBP [JNC VI] 37.9% 18.0%*
Isolated I.H.D. 17.4% 38.0% *
Isolated valve defects 3.6% 0%
P <0.05 P<0.001
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Table 4-5 -  Asymptomatic and Symptomatic LV. Dysfunction By Age Group
L.V. Dysfunction
Age Group Asymptomatic (%) Symptomatic (%)
55-59 yrs 5 (55.6%) 4 (44.4%)
60-64 yrs 6 (54.5%) 5 (45.5%)
65-69 yrs 5 (50.0%) 5 (50.0%)
70-75 yrs 11 (55.0%) 9 (45.0%)
27 (54.0%) 23 (46.0%)
Notes:
Symptomatic - Need for loop diuretic therapy and/or reported cardiac-type 
dyspnoea on questionnaire (excludes symptoms of chronic bronchitis).
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Figure 4-4 - Asymptomatic and Symptomatic Left Ventricular Systolic 
Dysfunction
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Table 4-6 -  Prevalence of Left Ventricular Dysfunction in Various Conditions.
Condition Number with an 
L.V.E.F.
Prevalence of L.V. 
Dysfunction
I.H.D. - All 301 13.0%**
Hypertension - All 321 8.1%
Hypertension [JNC VI] 499 7.4%
Isolated I.H.D. 173 14.6%**
Isolated Hypertension 162 3.7%
Isolated Hyped [JNC VI] 274 3.3%**
I.H.D. & Hypertension 159 12.6%**
Diabetes 39 7.7%
Reported M.l. 76 30.3% **
Reported Angina 106 20.8% **
E.C.G. M .l/ 46 8.7%
E.C.G. Major 
Ischaemia
183 14.8%**
E.C.G. Any Ischaemia^ 198 16.2%**
* P<0.05 **P<0.001
Compared to remainder of population without the condition.
Notes
 ^Presence of Q/QS waves.
 ^Presence of ST segment depression or left bundle branch block.
 ^Presence of Q/QS waves, ST segment depression or left bundle branch 
block.
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I.H.D. - was only 3.3% and this was significantly less than the prevalence in the 
remainder of the population.
4.3.6 Electrocardiographic Findings and L.V. Dysfunction
An abnoiTnal E.C.G. was present in 78% of people with L.V.D. compared with 37.7% 
of people with normal L.V. function (P<0.001). Both significant E.C.G. evidence of 
I.H.D. (54.0% V 22.3% - P<0.001) and atrial fibrillation (10.0% v 1.3% - P=0.003) were 
more common in the L.V.D. group but pathological Q waves were no more common 
(8.3% V 6.1%, P-0.710).
4.4 Discussion
This current study has shown that in individuals in whom an L.V.E.F. could be 
calculated L.V.D. was relatively common and was more common than previous studies 
have suggested. Like other studies the prevalence increased with age and was higher in 
men than in women. The principle aetiological associate of L.V.D. in this population 
was I.H.D. and L.V.D. was common in individuals with I.H.D.
4.4.1 Availability of Echocardiographic Ejection Fraction
Only one published study has described the epidemiology of L.V.D. within a population 
by calculating an echocardiographic L.V. ejection fraction (McDonagh et al. 1997). 
Other large studies such as the Cardiovascular Health Study (Gardin et al. 1995) have 
relied upon a qualitative assessment of L.V. systolic function. This latter approach 
whilst allowing an assessment of L.V. systolic function in a greater proportion of the 
population may introduce a subjective component which makes it difficult to define a 
standard for L.V.D. Calculating an L.V.E.F. reduces the availability of a measure of
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L.V. systolic function but does allow a population to be objectively and clearly divided 
into individuals with normal and individuals with impaired L.V. systolic function.
In this study its was possible to calculate an L.V.E.F. in 75% of individuals and, in 
some age and sex groups, fewer. This is a lower figure than reported in studies by 
McDonagh et al. (89.5%) (McDonagh et al. 1997) and Morgan et al. (82%) (Morgan et 
al. 1999), although higher than in a study of post-M.I. patients (67%) (Breekland et al. 
1997). In McDonagh's study the group with the lowest availability (86.2%) of a 
measured L.V.E.F. - males aged 65 to 74 years - still had a higher availability than any 
age/sex group in this study.
The main limiting factors to calculating a biplane L.V.E.F. in this study were the ability 
to trace the endocardium over at least 80% of the L.V. contour and the availability of a 
suitable apical two-chamber view. These limitations are not peculiar to this study being 
well recognised drawbacks of the technique (Rumberger et al. 1997) and have been 
shown in other studies (Breekland et al. 1997). It had been hoped that with improved 
echocai'diographic equipment there would be greater endocardial definition and so an 
increased availability of an L.V.E.F. compared to McDonagh et al. To that end this 
study did not succeed. It may have been a product of chance and the nature of the 
subjects who attended or else we were not as skilled in acquiring images as 
McDonagh's group.
Compared with the group of individuals in whom an L.V.E.F. was able to be measured 
the group of people without a measured L.V.E.F. had a higher body mass index, were 
twice as likely to suffer from diabetes and had higher prevalences of both I.H.D. and 
treated hypertension. This mirrors findings by McDonagh et al. The implication of
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this being that the true prevalence of L.V.D may have been underestimated in the entire 
cohort.
4.4.2 Definition of L.V. Systolic Dysfunction
Both McDonagh's study and this study chose to define a normal range for L.V.E.F. 
based on our study population and a subgroup of "normal" individuals from within it. 
This statistical approach to defining abnormal allows for systematic differences in 
methodology and teclmique between research groups. Such a difference in technique 
may explain why an L.V.E.F. of < 30% defined L.V.D. in McDonagh's study and an 
L.V.E.F. < 35% in this study.
Comparing the distribution of L.V.E.F. in the "noimal" subgroups for the two studies 
shows differences between the studies which are unlikely to be due to methodology 
alone. In McDonagh's study the L.V.E.F. was normally distributed in the “normal” 
subgroup whereas in this study it was slightly skewed to the right with a longer tail 
extending towards the lower range of L.V.E.F. The reason for this may be that all 
individuals with slightly impaired L.V. systolic function as a result of subclinical I.H.D. 
were not able to be removed from the "normal" subgroup. Previous autopsy studies 
have suggested that, especially in the older population, the prevalence of clinical I.H.D. 
is about one third of the true prevalence at determined post mortem (Elveback and Lie, 
1984). Had wider criteria for the definition of I.H.D. been used - by using the Rose 
chest pain questionnaire (Rose et al. 1977) and by including T wave inversion as an 
electrocardiograplric sign of ischaemia (Minnesota codes 5.1-5.3) - a greater proportion 
of subclinical I.H.D. might have been excluded. In McDonagh's study whilst they 
used the same criteria as this study did by which to select the "normal" subgroup it was
105
a much larger and younger group and is likely therefore to have had fewer people with 
subclinical I.H.D, and a mildly reduced L.V.E.F.
The decision to take an L.V.E.F. of < 35% to represent L.V.D. was justified both 
statistically, as it lies below the 2.5^ *’ percentile for the "normal" subgroup, and from 
previous studies which have shown that L.V.D. defined by this cut-off point for the 
L.V.E.F. is associated with morbidity and mortality, and benefits from pharmacological 
treatment (The SOLVD Investigators, 1991; The SOLVD Investigators, 1992). 
Wlrether this range of L.V.D. represents biologically important L.V.D., accompanied by 
increased morbidity and mortality, will only be revealed in follow-up studies. Similarly 
whether the value of 35% corresponds to the value quoted in outcome and treatment 
studies is unclear but this problem of standardisation for L.V.E.F. exists within every 
clinical department quoting an echocardiographic L.V.E.F. and yet most cardiologists 
are willing to act upon such a figure.
4.4.3 Prevalence of Systolic Dysfunction
The prevalence of L.V.D. in this cohort was higher than previously found in 
McDonagh's study of this population. In men the prevalence in this study was 6.6% in 
the 55 to 64 yrs age group and 12.6% in the 65 to 74 yrs age group. This compares to 
5.7% and 6.4% for the similar age groups in McDonagh's study. For women the 
prevalence was 3.5% and 4.4% for the two 10 year age bands compared with a 
prevalence of 2.0% and 4.9% in McDonagh's study. Why these two studies in the same 
geographical population should have arrived at such differing results is not clear. 
McDonagh's study used a lower L.V.E.F. to represent L.V.D. so there is the potential 
that that study missed a proportion of L.V.D or else that the definition of L.V.D. in this
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present study was not rigorous enough. Again only follow-up data will reveal the 
significant level of L.V.E.F. in each study. There could have been a selection bias in 
favour of individuals with L.V.D. in this present population given both the lower 
response rate and availability of L.V.E.F. This would however require both the 
presence of volunteer bias in favour of individuals with cardiovasculai' disease and the 
presence of a higher prevalence of I.H.D. in the group with an L.V.E.F. measured. The 
first of these assumptions seem unlikely and the second is not supported by the data.
The prevalence was higher than that found in other populations. Morgan et al in Dorset 
found the prevalence to be 9.4% in males and 2.2% in females aged 70 to 74 yrs 
(Morgan et ai. 1999). The Cardiovascular Health Study found a prevalence of 2.3% in 
65 to 69 yrs olds and 3.6% in 70 to 74 yrs olds (Gardin et al. 1995). It is difficult to 
make direct comparisons with these studies since the methods of assessing L.V. systolic 
function were fundamentally different. In addition, one would expect the prevalence to 
vary considerably between populations studied reflecting the difference in the 
prevalence of I.H.D. and in particulai* myocardial infarction - both of which are likely to 
be higher in North Glasgow than in the populations of rural Dorset and California.
Like other echocardiographic studies there was a clear sex difference in the prevalence 
of L.V.D. with it being much greater in men - more than twice as great. This is a 
similar sex difference to that quoted by McDonagh although Morgan found that the 
prevalence was four times higher in males than in females. The sex difference in the 
prevalence of L.V.D. is likely to reflect the sex difference in myocardial infarction with 
reported previous myocardial infarction being over twice as common in males as in 
females in this study; although no difference was evident in the rates of either reported
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angina or E.C.G. evidence of I.H.D.
4.4.4 Asymptomatic L.V. Dysfunction
It is laiown that asymptomatic L.V.D. may be the precursor to overt chronic heart 
faihu’e (Pfeffer and Braunwald, 1990; Gaudron et al. 1993). In both this study and 
McDonagh's study approximately half of L.V.D. was asymptomatic and so not readily 
detected without screening tests. In this current study, unlike McDonagh's study, the 
proportion of L.V.D. which was symptomatic did not rise with age. McDonagh's data 
suggests that there may be a transition within individuals over time from asymptomatic 
to symptomatic L.V.D. In this present study's older population this transition may not 
be so evident because of an equilibrium reached between the generation of new cases of 
asymptomatic L.V.D., the transition from asymptomatic to symptomatic L.V.D. and 
the death of cases of symptomatic L.V.D. Longitudinal follow-up should provide data 
on incidence, mortality and the transition between asymptomatic and symptomatic 
L.V.D.
4.4.5 Aetiology of L.V. Dysfunction
In this study I.H.D. was common in people with L.V.D., with a reported previous 
myocardial infarction being six times more prevalent and angina almost four times 
more prevalent in those with L.V.D. compared to those without. Hypertension, not 
accompanied by I.H.D. and as defined by both definitions, was no more common in 
individuals with L.V.D., and infact, in the case of hypertension, as defined by the JNC 
VI criteria, it was substantially less common. Diabetes mellitus was similarly no more 
prevalent in the group with L.V.D.. If hypertension and diabetes ai'e exerting an effect 
is therefore likely to be through an increased risk, and hence prevalence, of I.H.D. 
within the population. We must, however, also consider the effect that L.V.D. and its
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treatment may have on blood pressure. An individual previously hypertensive once 
they develop L.V.D. may have a blood pressure which falls to within the normal range; 
whether as a result of the reduced cardiac output, or as result of the medication used. 
Therefore, we may have underestimated the true prevalence of hypertension in the 
group with L.V.D., and may have understated its importance as a aetiological factor for 
L.V.D. in its own right, separate from being a risk factor for I.H.D..
Our findings underscore what previous studies have shown about the aetiology of 
L.V.D. at the end of the twentieth century. McDonagh showed that in the north 
Glasgow population the independent predictors of the presence of L.V.D., besides male 
sex, were a reported history of angina, E.C.G. evidence of ischaemia or infarction, and 
hypertension. In Morgan's older cohort the predictors were a history of M.L or angina 
(Morgan et al. 1999) and the Cardiovascular Health Study showed that both clinical 
I.H.D. and hypertension were independent predictors of L.V.D. (Gardin et al. 1995). 
Over the past forty years there has been a shift in the aetiology of C.H.F. from 
hypertension as was reported by the Framingham Heart Study in the 1950's and 1960's 
(Kamiel et al. 1972) to I.H.D (Kannel et al. 1994). It is likely that this change in 
aetiology has occurred as a result of the improved detection and treatment of 
hypertension and the increase in the number of patients who survive their myocardial 
infarction but do so at the expense of having L.V.D.
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5. Treatment and Effects of Left Ventricular Systolic
Dysfunction
no
5.1 Introduction
Whilst doctors are often primarily concerned with the high mortality and the large 
number of hospital admissions in chronic heart failure (C.H.F.), the patient may be 
more concerned about the impact that the syndrome has on their quality of life (Q.O.L.), 
including their ability to perform daily activities and conduct a normal social life. 
Previous reseai'ch has shown that both clinical C.H.F. and left ventricular systolic 
dysfunction (L.V.D.) have significant deleterious effects on Q.O.L. (Stewart et al. 
1989; Fryback et al. 1993; Rogers et al. 1994; Jenkinson et al. 1997). Quality of life 
may be assessed by means of questionnaires which can either be specific for a disease 
or generic; the latter allowing comparison of Q.O.L. in different disease states. The 
Short Form 36 (SF-36) questionnaire is a generic measure of Q.O.L. wliich was 
developed as an instrument for evaluating the impact of different illnesses upon 
functioning and well-being (Garratt et al. 1993) (Ware et al. 1993).
A major contributor to this impaired Q.O.L. is effort intolerance which is one of the 
commonest problems experienced by patients (Franciosa et al. 1979) and will be one of 
the main prompts for them to seek medical help (Franciosa et al. 1979). It is not due 
solely to cardiac dysfunction but rather due to peripheral factors, particularly changes in 
skeletal muscle (Wilson et al. 1995; Franciosa et al. 1979; Mancini et al. 1992; 
Harrington et al. 1997). Effort capacity may be measured either by symptom-limited 
exercise testing or by submaximal walking tests such as the six-minute walk test.
Treatment with angiotensin-converting enzyme (A.C.E.) inhibitors in L.V.D. has been 
shown to reduce mortality, if symptoms are present, and the need for hospitalisation 
even if the condition is asymptomatic (Garg and Yusuf, 1995); as well as being cost-
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effective (McMurray and Davie, 1996). However it has been suggested previously that 
they are being underused in both L.V.D. and C.H.F.
This present study looked at the effects of L.V.D. on exercise capacity as measured by 
symptom-limited, maximal treadmill exercise testing, and on Q.O.L. using the SF-36 
questionnaire. It also examined whether individuals with L.V.D. were being treated 
according to the trial evidence.
5.2 Methods
These are described in detail in Chapter 2 but briefly 1009 individuals, aged between 
55 and 74 years, from the population were randomly selected (response rate 59.8%). 
Each individual completed a questionnaire regarding demography; past medical 
diagnoses, drug therapy, and the M.R.C. Breathlessness Questionnaire (Fletcher et al. 
1959). Their height and weight were measured and the body mass index (B.M.I.) 
calculated as weight (Kg) divided by height (m) squared. A left ventricular ejection 
fraction (L.V.E.F.) was calculated by echocardiography using a biplane algorithm 
("method of discs summation") , Simpson's rule (Schiller et al. 1979). A standard 
graded treadmill exercise test was performed using the Standardised Treadmill 
Exponential Exercise Protocol (S.T.E.E.P.) (Northridge et al. 1990).
The SF-36 questionnaire - the Brazier/Sheffield version (Brazier et al. 1992) - was 
issued, checked for completeness of information during the study visit and if need be it 
was administered in part or in full by interview. It was subsequently scored according 
to the scoring manual from the Medical Outcomes Trust (Medical Outcomes Trust, 
1994). A scale score was calculated if the respondent had answered at least half of the 
items in a multi-item scale (or half plus one in the case of scales with an odd number of
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items).
5.2.1 Definitions:
Left ventricular systolic dysfunction - an L.V.E.F. measured as < 35%.
Cardiac-type dyspnoea - the presence of dyspnoea in the absence of symptoms 
suggestive of clironic bronchitis as assessed by the M.R.C. questionnaire. 
Asymptomatic L.V.D. - the absence of both reported cardiac-type dyspnoea and current 
treatment with loop diuretics.
Symptomatic L.V.D - either reported cardiac-type dyspnoea or current treatment with 
loop diuretics.
5.2.2 Statistical Analysis
Values with a normal distribution are quoted as the mean ± standard deviation (S.D.). 
Other values are quoted as the median and interquartile range (I.Q.R.). Student's t test 
(two-tailed) was used to compare means, the Mann Whitney U test to compare medians 
and the Chi-squared or Fisher's exact test where appropriate was used to compare the 
proportions of individuals within two or more groups. Univariate and multivariate 
analysis was performed using Minitab for Windows. A P value of <0.05 was taken to 
be significant.
5.3 Results
5.3.1 Medication Use in Left Ventricular Systolic Dysfunction
The use of cardioactive medication including A.C.E. inhibitors, beta-blockers, loop
diuretics and nitrates was higher in the group of fifty individuals with L.V.D. than in the
group with normal L.V. systolic function - Table 5-la. Overall only 16% of people
with L.V.D. were currently being treated with an A.C.E. inhibitor and of the fifteen
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Table 5-1 - Medication Use in Left Ventricular Systolic Dysfunction 
Table 5-1 a - Comparison Between Normal and Impaired L. V. Function
L.V. Systolic Dysfunction 
(n=50)
Normal L.V. Function 
(n=700)
Loop Diuretic 30.0% ** 4.0%
ACE inhibitor 16.0% ** 3.4%
Digoxin 10.0% ** 1.0%
Nitrate 36.0% ** 7.3%
Beta-blocker 22.0% * 9.9%
Table 5-1 b - Medication and Breathlessness in L.V. Dysfunctioi
Breathless# Not Breathless 
(n=15) (n=35)
Loop Diuretic 46.7% 22.9%
ACE inhibitor 26.7% 11.4%
Digoxin 13.3% 8.6%
Nitrate 26.7% 40.0%
Beta-blocker 13.3% 8.6%
# Reported on M.R.C Breathlessness questionnaire, excluding symptoms of 
chronic bronchitis
Table 5-1 c -  Medication and Symptomatic L.V. Dysfunction
Symptomatic Asymptomatic
(n=23) (n=27)
ACE inhibitor 30.4%* 3.7%
Digoxin 17.4% 3.7%
Nitrate 43.5% 29.6%
Beta-blocker 17.4% 25.9%
Symptomatic - includes reported breathlessness and/or current use of loop 
diuretics
* P<0.05 ** P<0.001
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people who were currently treated with a loop diuretic only seven (46.7%) were also 
receiving treatment with an A.C.E. inhibitor. A greater proportion of people with 
L.V.D. who reported cardiac-type dyspnoea were currently being treated with a loop 
diuretic or A.C.E. inhibitor than people who did not report dyspnoea, but this did not 
reach statistical significance; and still more than half of breathless individuals with 
L.V.D. were not receiving treatment with a loop diuretic - Table 5-lb. The use of 
A.C.E. inliibitors amongst people with asymptomatic L.V.D. was very low at only 3.7% 
and even in symptomatic L.V.D. they were being taken by only 30% - Table 5-lc.
5.3.2 Exercise Capacity and Left Ventricular Systolic Dysfunction
The treadmill exercise test was attempted by 605 participants of whom 32 had L.V.D. - 
25 males and 7 females. Of the individuals with L.V.D. 11 were considered to be 
symptomatic and 21 asymptomatic. The median exercise time for those with L.V.D. 
was lower than for those with normal L.V. function - 467.5 (279.0 - 631.0) secs v 627.0 
(490.5 - 729.5) secs , P<0.001 - Figui'e 5-1. This was true for both females 324.0 (197.0 
- 491.0) secs V 608.0 (438.0 - 679.0) secs, P<0.05, and for males 498.0 ( 361.5 - 637.5) 
secs V 665.5 (553.8 - 772.5) secs, P<0.001. Median exercise times for those with 
symptomatic and asymptomatic L.V.D. were not significantly different 435.0 (264.0 -
619.0) secs V 474.0 (295.5 - 650.0) secs, P=0.648. Compared to individuals with 
normal L.V. systolic function, individuals with asymptomatic L.V.D. had a lower 
exercise capacity 474.0 (295.5 - 650.0) secs v 627.0 (490.5 - 729.5) secs, P=0.007.
5.3.3 Limiting Symptoms on Treadmill Exercise Testing
There was no difference between the group of people with L.V.D. and the group with 
normal L.V. frmction with regard to the proportion who gave breathlessness as their 
primary reason for stopping exercising on the treadmill - Table 5-2. Similarly there
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Figure 5-1 - Left Ventricular Systolic Dysfunction and Exercise Time
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Table 5-2 - Principle Reason Given by Participant for Stopping Exercise Test
L.V. Systolic Dysfunction Normal L.V. Functii
Reason n % n %
Chest Pain 2 6.3% 5 0.9%
Breathlessness 9 28.1% 145 25.3%
Fatigue 4 12.5% 133 23.2%
Leg Pain / Fatigue 10 31.3% 163 28.4%
Other* 7 21.9% 127 22.2%
TOTAL 32 573
* Includes those cases where the test was stopped primarily on the decision of 
the supervising technician.
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was no difference in the proportion of individuals with symptomatic L.V.D. who 
stopped because of breathlessness compared to those with asymptomatic L.V.D.
5.3.4 Determinants of Effort Capacity Within the Population
In both males and females univariate linear regression analysis - Table 5-3 - showed
that the L.V.E.F. was positively correlated with total exercise time whereas both age 
and the B.M.I. were negatively correlated. In females when these tliree variables were 
put in a multivariate analysis - Table 5-3 - all remained as significant predictors of effort 
capacity but described only 14% of the variation in exercise time. For males only age 
and the L.V.E.F. remain significant independent predictors of effort capacity in 
multivariate analysis describing only 11% of the variation. The correlation between the 
L.V.E.F. and exercise time in the population was poor, however, - for males 0.26 and 
females 0.17 - Figure 5-2.
5.3.5 Left Ventricular Dysfunction and Quality of Life
Satisfactory completion of the SF-36 questionnaire to allow computation of scores for
six of the dimensions - Table 5-4 - was achieved in 48 participants with L.V.D. and in 
684 with normal L.V. function. The median scores for these six dimensions in both 
groups are shown in Table 5-5 and in Figure 5-3. The group of people with L.V.D. had 
significantly lower scores in the dimensions measuring physical functioning - 52.5 (20.0 
- 75.0) V 75.0 (50.0 - 90.0) P<0.001 - ,  role physical - 37.5 (0.0 - 100.0) v 100.0 (25.0 -
100.0), P<0.05 - ,  general health - 47.5 (30.0 - 75.0) v 65.0 (50.0 - 80.0), P<0.01 - and 
social functioning 78.7 (60.6 - 100.0) v 100.0 (67.5 - 100.0), P<0.05. The degree of 
systolic dysffmction did not have a major effect on the Q.O.L. scores. Dividing the 
L.V.D. group in two based on the L.V.E.F. (< or > 30.8%) showed that the only 
significant difference in scores between those in the upper and lower halves was in the
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Table 5-3 -  Determinants of Exercise Time -  Regression Analyses
Females
Variable 
L.V.E.F.(%) 
B.M.I. (Kg/m^) 
Age (Yrs)
Univariate 
P value
0.004 + 
0.008 - 
< 0.001 -
Multivariate 
P value (adj)
0.001
0.006
0.001
14.3%
Males
Variable 
L.V.E.F (%) 
B.M.I. (Kg/m^) 
Age (Yrs)
Univariate 
P value
< 0.001 +  
0.028 - 
< 0.001 -
Multivariate 
P value (adj)
0.001
0.067
0.001
10.9%
Notes:
+ Positive association 
~ Negative association
R^(adj) = the square of the multivariate correlation coefficient adjusted for the 
expected chance prediction when the null hypothesis is true. It indicates how 
much of the variation is explained by the factors in the model.
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Figure 5-2 - Correlation Between Effort Capacity and Left Ventricular Systolic 
Function
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Table 5-4 - Health concepts measured by six SF-36 scales
Concept Summary of Content
Physical Functioning Extent to which health limits physical 
activities such as self-care, walking, 
climbing stairs, bending, lifting, and 
moderate and vigorous exercises.
Role Functioning - Physical Extent to which physical health 
interferes with work or other daily 
activities, including accomplishing 
less than wanted, limitations in the 
kind of activities, or difficulty in 
performing activities.
General Health Personal evaluation of health, 
including current health, health 
outlook, and resistance to illness.
Vitality Feeling energetic and full of life 
versus feeling tired and worn out.
Social Functioning Extent to which physical health or 
emotional problems interfere with 
normal social activities.
Role Functioning - Emotional Extent to which emotional problems 
interfere with work or other daily 
activities, including decreased time 
spent on activities, accomplishing 
less, and not working as carefully as 
usual.
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Table 5-5 - Median Quality of Life Scores in Normal and in Impaired L. V. 
Function
Normal LV Function 
n=684
Impaired LV Function 
n=48
Physical Functioning 75.0 
(50.0 - 90.0)
52.5 ** 
(20.0 - 75.0)
Role Physical 100.0 
(25.0- 100.0)
37.5*
(0.0-100.0)
General Health 65.0 
(50.0 - 80.0)
47.5*
(30.0-75.0)
Vitality 60.0 
(45.0 - 75.0)
51.7 
(40.0 - 70.0)
Social Functioning 100.0 
(67.5- 100.0)
78.7* 
(60.6- 100.0)
Role Emotional 100.0 
(33.3- 100.0)
100.0 
(33.3- 100.0)
P <0.05 P<0.001
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Figure 5-3 -  Quality of Life Scores in Left Ventricular Systolic Dysfunction
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dimension measuring role physical - 0.0 (0.0 - 93.8) v 100.0 (6.3 - 100.0), P=0.03.
5.3.6 Effect of Breathlessness on Quality of Life in L.V. Dysfunction
Of the individuals with L.V.D. 14 reported symptoms of cardiac-type dyspnoea. 
Compared to the individuals without dyspnoea (whether as a result of being rendered 
symptom free by diuretic therapy or not) these individuals had a lower median score for 
vitality - 42.5 ( 23.8 - 55.0) v 55.0 (45.0 - 75.0), P<0.05 - Table 5-6. They also tended 
to have lower scores in other dimensions but none reached statistical significance.
Comparing the group with L.V.D. who had no dyspnoea with the group with normal 
L.V. function revealed a reduction in the dimension measuring physical functioning - 
57.5 (20.0 - 86.3) v 75.0 (50.0 - 90.0), P<0.05 - Table 5-6. Furthermore compared to a 
group with both normal L.V. function and no dyspnoea they had not only significantly 
lower scores in the dimension measuring physical functioning 57.5 (20.0 - 86.3) v 80.0 
(55.0 - 90.0), P<0.05 but also in the dimensions measuring role physical 75.0 (0 -
100.0) V 100.0 (50.0 - 100.0), P<0.05 and general health 47.5 (33.8 - 80.0) v 70.0 (50.0 
- 80.0), P<0.05.
5.3.7 Effect of Treated L.V. Dysfunction on Quality of Life
The need for treatment with a loop diuretic in 15 people with L.V.D. was associated 
with a greater degree of impairment of Q.O.L. compared to those not requiring diuretic 
therapy - Table 5-6. Median scores were lower for dimensions measuring role physical 
0.0 (0 - 75.0) V 100.0 (0- 100.0), P=0.04 and general health 35.0 ( 20.0 - 60.0) v 55.0 
(35.0 - 80.0), P=0.025. The median L.V.E.F. for those on diuretic therapy was lower 
than for those not on diuretics 27.7% (21.0 - 32.0%) v 32.3% (28.7 - 34.2%), P=0.008.
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Table 5-6 - Quality of Life Scores for Subgroups of L.V. Dysfunction Group
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5.3.8 Com parison of L.V. Dysfunction with Other Chronic D iseases
The median scores for individuals with L.V.D. who reported breathlessness were 
compared to the scores for individuals identified Eom the study cohort with normal 
measured L.V. function but with either a previous physician diagnosis of asthma or 
angina (the two conditions were taken to be mutually exclusive) - Table 5-7. 
Compared to the group with asthma the L.V.D. group had a lower median score for the 
dimension measuring physical fiinctioning 36.7 (15.0 - 58.8) v 65.0 (32.5 - 85.0), 
P=0.03 but there was no significant difference between the two groups in the other 
dimensions. The group with angina did not differ significantly from the L.V.D. group 
with breathlessness with respect to any dimension.
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Table 5-7 - Median Quality o f Life Scores for Three Chronic Conditions
Dimension
L.V. Dysfunction 
Breathless 
N=14
Angina 
(Normal LV) 
N=75
Asthma 
(Normal LV) 
N=54
Physical
Functioning
36.7
(15.0-58.8)
50.0 
(30.0 - 70.0)
65.0* 
(32.5 - 85.0)
Role Physical 12.5
(0.0-81.2)
25.0
(0.0-100.0)
50.0
(0.0-100.0)
General Health 45.0
(23.8-62.5)
50.0 
(35.0 - 70.0)
52.5
(38.8-70.0)
Vitality 42.5 
(23.8 - 55.0)
45.0 
(30.0 - 65.0)
55.0 
(35.0 - 70.0)
Social Functioning 70.0 
(50.6- 100.0)
67.5 
(35.0- 100.0)
90.0 
(58.8- 100.0)
Role Emotional 100.0 
(91.7 - 100.0)
66.7
(0.0-100.0)
100.0
(0.0-100.0)
'P=0.03 for difference compared to breathless L.V. dysfunction.
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5.4 Discussion
5.4.1 Medication Use in Left Ventricular Systolic Dysfunction
This study confirms the findings of other investigators showing that L.V.D. and heart 
failme is undertreated (O'Connell and Bristow, 1994; McMurray, 1998). Although this 
study was carried out between 1994 and 1996 the results of the large trials of A.C.E. 
inliibitor treatment in L.V.D. had been known for at least three years prior to its 
commencement (The CONSENSUS Trial Study Group, 1987; Cohn et al. 1991; The 
SOLVD Investigators, 1991; The SOLVD Investigators, 1992). By definition it is 
impossible to ensure appropriate treatment in asymptomatic L.V.D. without screening 
programmes being in place, but in this study less than half of patients with treated heart 
failure (L.V.D. and loop diuretic treatment) were receiving treatment with an A.C.E. 
inliibitor. This proportion fell to less than one third if those who were either breathless 
and/or being treated with a loop diuretic were included. Whilst the picture will have 
improved since 1996 with respect to treating overt heart failure, as yet there is no 
screening programme for asymptomatic L.V.D. therefore undertreatment must be 
continuing. These results underscore the need for screening programmes - both to 
identify asymptomatic L.V.D. and also to identify patients being treated with loop 
diuretics so that it can be established whether or not they have systolic dysfunction and 
so determine the need for A.C.E. inhibitors.
5.4.2 Exercise Testing
This study showed that, compared to individuals with normal L.V. systolic function, 
individuals with L.V.D., whether apparently symptomatic or not, have a poorer effort 
capacity as measured by treadmill exercise testing. By dichotomising the range of 
exercise times based on the L.V.E.F. (35% in this case) an effect of L.V. systolic
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function on effort capacity was shown. In multivariate analysis the L.V.E.F. was still 
shown to be an independent factor in determining effort capacity for both males and 
females. The amount of interindividual variation in effort capacity attributable to the 
L.V.E.F. was however small - by univariate analysis 2.4% in females and 6.4% in males 
- and the correlation between L.V.E.F. and exercise time was extremely poor.
The fact that the L.V.E.F. has relatively little influence on effort capacity within the 
whole population does not come as a surprise. It is only one factor in a complex 
interplay of variables which contribute to effort capacity including respiratory, cardiac, 
peripheral vascular and musculoskeletal function; as well as body habitus and 
psychological factors including motivation and tolerance of discomfort. Individuals 
who are obese are more likely to experience symptoms than patients who are not obese 
(Wilson et al. 1995) and in this study both body mass index and age were significant 
independent determinants of effort capacity. Even in C.H.F. effort capacity does not 
correlate with indices of cardiac function and central haemodynamics (Franciosa et al. 
1981; Higginbotham et al. 1983; Lipkin et al. 1986). The mechanism for effort 
intolerance may be related to changes in skeletal muscle mass, structure (Mancini et al. 
1992) and function (Harrington et al. 1997).
A significant finding was that asymptomatic L.V.D. was associated with a reduced 
effort capacity. The number of individuals in this group was small and it is difficult to 
be sure that this was not the effect of other factors such as physical deconditioning, 
ischaemic heart disease or peripheral vascular disease, all of which may affect patients 
with an ischaemic aetiology for their L.V.D. (Clark et al. 1997). However one other 
study has shown tliat asymptomatic L.V.D. was associated with a reduced peak aerobic
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capacity (LeJemtel et al. 1994). Therefore patients whilst reportedly asymptomatic 
during the course of their normal daily activities show abnormalities on objective 
testing. It has been hypothesised that in such patients the impairment is secondary to 
cardiac dysfunction rather than peripheral factors (LeJemtel et al. 1994).
The fact that breathlessness was as common a limiting symptom in the normal group as 
in the L.V.D. group demonstrates how non-specific the symptom is. It is not a 
particularly good measure on maximal exercise testing as it will be heavily influenced 
by physical conditioning in both groups. Heart failure patients have been shown to 
report similar levels of dyspnoea across various classes of haemodynamic severity 
(Wilson et al. 1995). Patients with I.H.D. - and this will include many in the 
asymptomatic L.V.D. group - regardless of their L.V. function, may complain of 
breathlessness on exercise as a manifestation of coronary ischaemia even in the absence 
of chest pain or EGG changes of ischaemia (Cook and Shaper, 1989; Clark et al. 1997).
A major limitation of this study was the small number of individuals with L.V.D. and 
the even smaller number who exercised, which was not altogether surprising given the 
age range being studied. This prevented control for confounding factors. Had a six- 
minute walk test been used more people in whom the limiting factor was not cardiac, 
but for example musculoskeletal disability, might have been able to exercise. In 
addition using a form of submaximal testing such as the six-minute walk test may have 
more effectively evaluated the impairment and functional status during daily activities 
(Brunner-La Rocca et al. 1999).
5.4.3 Quality of Life
This study showed that, compared with the remainder of the population, and over and
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above the effects of any concomitant clironic illnesses, the presence of L.V.D. was 
associated with poorer Q.O.L. scores in dimensions measuring physical functioning and 
activity, perception of general health, and social functioning. The presence of 
breathlessness caused an additional impairment in vitality. Even in the individuals who 
did not currently report breathlessness, whether this was the result of treatment or not, 
there was still a measurable reduction in physical functioning suggesting that 
breathlessness is not the only mechanism for impainnent of physical functioning. The 
degree of impairment was even greater if one controlled for the presence of 
breathlessness and compared this group to individuals with both normal L.V. function 
and no breathlessness. Treated heart failure resulted in the greatest impact on quality of 
life probably because the need for treatment is a marker of a greater severity of 
symptoms and poorer functional class.
Previous epidemiological studies have assessed the impact of clinical chronic heart 
failure rather than L.V.D. on Q.O.L.. Two of the largest and earliest were carried out 
in North America - the Medical Outcomes Study (M.O.S.) in 1986 (Stewart et al. 1989) 
and the Beaver Dam Health Outcomes Study (B.D.H.O.S.) (Fryback et al. 1993) in 
1990. The B.D.H.O.S. used the SF-36 questionnaire and the M.O.S. used its 
forerumier. Both studies showed that C.H.F. resulted in the greatest impairment of 
Q.O.L. of all the clironic conditions studied. In terms of the dimensions affected by 
C.H.F. they showed similar results to this current study; with the M.O.S. showing 
impairment in scores for physical functioning, role physical and social functioning, 
and the B.D.H.O.S. showing an effect also on general health. These findings have been 
confirmed more recently in the U.K. using the SF-36 questionnaire in C.H.F. patients 
aged 60 years or over (Jenkinson et al. 1997). Symptomatic C.H.F. impacted greatly
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upon all eight dimensions and had an additive effect over and above the presence of 
other chronic illnesses.
This present study and these previous studies are not directly comparable as both 
previous studies looked at the syndrome of C.H.F. which by its very definition causes 
symptoms. The individuals in these published studies are probably best compared to 
the group with both L.V.D. and breathlessness in this present study. None of the 
published studies assessed the severity of heart failure or indeed confirmed that it was 
the result of systolic dysfunction.
The S.O.L.V.D. investigators, as part of their treatment trials (The SOLVD 
Investigators, 1991; The SOLVD Investigators, 1992), looked at the impact of both 
symptomatic and asymptomatic L.V.D. (Rogers et al. 1994) on Q.O.L.. They found 
that asymptomatic L.V.D. was associated with impaired Q.O.L. although the degree of 
impairment was not as great as that seen in symptomatic. This present study was able 
to show some impairment attributable to L.V.D. in the absence of reported 
breathlessness; although some of these individuals may have only been asymptomatic 
as the result of diuretics and are therefore not directly comparable to the S.O.L.V.D. 
asymptomatic group. These results suggest that although, by current clinical definition, 
L.V.D. may exist in an "asymptomatic" form, this may only be because we do not 
include impairment of Q.O.L. in our definition of symptomatic.
With a small number of individuals with L.V.D. it was not possible in this study to 
control for the presence of concomitant disease which explains why comparisons with 
other disease groups showed only a minor difference. The impact of L.V.D. on Q.O.L.
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in this study will have been diminished somewhat by the presence of concomitant 
clu'onic diseases in both the L.V.D group and the whole population. One might expect 
this to be the case in a group of 55 to 74 year olds from a socially deprived population. 
In fact this may be a strength of the present study as, by using the background 
population as a control group rather than a control set of normative data from another 
study as Jenldnson et al used (Jenkinson et al. 1997), it was able to show an additive 
effect of L.V.D.; that is over and above any background impairment of Q.O.L. in the 
population.
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6. Left Ventricular Diastolic Filling and Left Ventricular
Mass
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6.1 Introduction
It is now recognised that the syndrome of chronic heart failure may arise in the absence 
of any abnormality of left ventricular (L.V.) systolic function (Grossman, 1991; 
Brutsaert et al. 1993; Goldsmith and Dick, 1993; Gaasch, 1994). In such patients 
abnormalities of L.V. diastolic filling may have a major role in producing signs and 
symptoms (Nishimura and Tajik, 1997) and this has led to use of the term "diastolic 
heart failme" (Brutsaert et al. 1993). Diastolic filling is a complex phenomenon 
determined by numerous factors both physiological and pathological acting either in 
isolation or in a complex interplay (Vasan et al. 1996; Eui'opean Study Group on 
Diastolic Heart Failure, 1998; Taylor and Waggoner, 1992).
Doppler echocai'diography has become well accepted as a reliable, reproducible and 
practical non-invasive method for the diagnosis and longitudinal follow-up of patients 
with diastolic dysfunction (Nishimura and Tajik, 1997). All ventricular filling indices 
by echocardiography are however indirect measures of diastolic function (Vasan et al. 
1996) and have largely have been based on transmitral flow velocity curves (Appleton 
et al. 1988). Two main patterns of abnormal flow velocity curves have been described 
(Appleton et al. 1988; Olmo et al. 1994; Nishimura and Tajik, 1997). An abnormal / 
impaired L.V. relaxation pattern is characterised by a reduction in the peak velocity of 
early diastolic filling (the E wave), an increase in the peak velocity of late diastolic 
filling (the A wave), resulting in a reduction in the ratio of these velocities (E: A ratio), 
and accompanied by an increase in the deceleration time of the peak E wave velocity 
curve (M.V.D.T.). A pattern of restrictive L.V. filling is shown by an increase in the 
peak E velocity, a decrease in the peak A velocity, an increase in the E:A ratio and a 
reduction in the M.V.D.T.
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The determinants and correlates of L.V. diastolic filling were assessed by transmitral 
Doppler flow velocity curves both in the entire cohort attending this study and in 
subgroups with cardiovascular pathology. The hypothesis that individuals reporting 
cardiac-type dyspnoea in the absence of L.V. systolic dysfunction (L.V.D.) and 
pulmonary disease would have evidence of abnormal L.V. diastolic filling on Doppler 
echocardiography was also tested.
6,2 Methods
These are described in detail in Chapter 2 but briefly each individual completed a 
questionnaire regarding demography; past medical diagnoses, drug therapy, and the 
M.R.C. breathlessness questionnaire (Fletcher et al. 1959). Their blood pressure was 
measured as was their height and weight. The body mass index (kg/m^) was calculated 
as the weight (kg) divided by the height (m) squared. Spirometry was performed and a 
blood sample was taken for a random blood glucose level. A twelve-lead EGG was 
recorded and coded according to the Minnesota EGG code (Prineas et al. 1982) and a 
treadmill exercise test was performed using the Standardised Treadmill Exponential 
Exercise Protocol (Northridge et al. 1990) with manual ST segment analysis carried out 
on the 12 lead E.G.G. during exercise and the recovery period according to the 
Minnesota Coding Manual - (Prineas et al. 1982).
A full two-dimensional and Doppler echocardiogram was performed with an L.V. 
ejection fraction (L.V.E.F.) calculated from a biplane algorithm (Simpson's rule) 
(Schiller et al. 1979). M-mode measurements were taken as the average of three cycles 
and were made according to the conventions established by the American Society of 
Echocardiography using a ieading-edge-to-leading-edge method (Sahn et al. 1978) and
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the criteria of Schieken et al (Schieken et al. 1979) were used to determine the 
acceptable technical quality for M-Modes. The left ventricular mass was calculated 
using the Penn Cube formula (Devereux et al. 1986) as:
LV Mass (g) = 1.04 [(IVSd+LVEDD+LVPWd)^ - LYEDD^] -13.6 g . IVSd -
Interventricular septum in diastole; LVEDD - LV end diastolic dimension; LVPW - 
LV posterior wall.
The L.V. mass index (g/m) was calculated by dividing the L.V. mass by the height (m). 
The relative L.V. wall thickness (R.Th.) expresses the proportion of the L.V. radius in 
diastole which is L.V. wall: [(IVSd + LVPWd) /2] 4- [LVEDD /2],
Transmitral Doppler flow velocity curves were measured as the average of five cycles 
and traced at the outer edge of the spectral envelope. Wliere the deceleration slope of 
the E wave could not be distinguished from the A wave measurements were not made. 
The M.V.D.T. was measured from the peak of the E wave to a point on the baseline 
where by extrapolation the slope would have intersected it.
6.2.1 Definitions:
Hypertension - a systolic blood pressure >160mmHg systolic or a diastolic > 95 mmHg 
(Korotkoff phase V) or the current use of antihypertensive medication.
Hypertension [JNC VI]: as above, but using the cut-off points for blood pressure as 
defined in JNC VI guidelines (Joint National Committee on Prevention, Evalaution and 
Treatment of High Blood Pressure 1997) which are a systolic blood pressure of 
>140mmHg and/or a diastolic blood pressure > 90mmHg.
Diabetes mellitus - previous physician-made diagnosis or the current use of insulin or 
oral hypoglycaemic agents or a random venous glucose >11.1 mmolL"'.
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Ischaemic heart disease - at least one of 1) a previous physician diagnosis of angina 
pectoris or myocardial infarction 2) an ECG showing myocardial infarction or major 
ischaemia 3) current use of nitrates including sublingual glyceryl trinitrate.
Cardiac dyspnoea - reported breathlessness on the M.R.C. Breathlessness questionnaire 
in the absence of symptoms of chronic bronchitis.
Left ventricular systolic dysfunction (L.V.D.) - an L.V.E.F. < 35%.
6.2.2 Statistical Analysis
Statistical analyses were performed using Minitab for Windows (Minitab Inc, 
Pennsylvania, U.S.A.). Where variables such as the transmitral Doppler indices were 
not normally distributed the median value and interquartile range is used for descriptive 
purposes and non-parametric tests - the Mann Whitney U test and the Kruskal Wallis 
test - were used to compare medians. The proportions of individuals in two groups 
were compared by the Chi-square test or Fisher's Exact test where appropriate. 
Univariate and multivariate linear regression analyses were used to determine the 
independent relationships between a set of variables and a single outcome. A P value of 
<0.05 was taken to be significant.
6.3 Results
6.3.1 Transmitral Doppler Indices in the Whole Population
Transmitral Doppler indices were suitable for analysis in 910 individuals - 468 female 
and 442 males - Table 6-1. The median values for the peak velocities of both the E 
wave and the A wave were higher in females than in males - peak E: 0.60 (0.52 - 0.69) 
ms ' V 0.58 (0.48 - 0.67) ms'', P=0.003; peak A: 0.71 (0.62 - 0.83) ms'' v 0.69 (0.60 - 
0.79) ms-', P=0.021. There was no gender difference seen in eitiierthe M.V.D.T. or the 
E: A ratio.
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Table 6-1 - Transmitral Doppler Indices for Whoie Cohort
Index Maies (n=442) Females (n=468)
Peak E Wave (m s’ ) 0.58 (0.48 - 0.67) 0.60* (0.52 - 0.69)
Peak A Wave (m s') 0.69 (0.60 - 0.79) 0.71* (0.62 - 0.83)
E:A Ratio 0.83 (0.71 - 0.97) 0.84 (0.70 - 0.98)
M.V. Dec.TIme. (msecs) 218.0 (185.0 - 259.0) 214.5 (185.3 - 249.8)
Ail values expressed as median (interquartile range).
* P<0.05
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6.3.2 Establishing Normal Ranges for the Population
A subgroup of 138 "healthy" participants were identified who were considered free of 
cardiovascular' disease and its major risk factors, had no L.V.D. and had analysable 
transmitral Dopplers. The median values for the transmitral doppler indices in this 
group are shown in Table 6-2. The normal range for the whole population was defined 
as encompassing and including the 2.5 '^’ and 97.5^ *' percentiles for this subgroup.
6.3.3 Characteristics o f Individuals with Abnormal Mitral Valve Doppler 
Indices
The 52 individuals with an abnormally low E:A ratio (<0.56) compared to the 
remainder of the population were older, had a higher body mass index, a higher systolic 
and diastolic blood pressure, a lower L.V.E.F., a higher relative L.V. wall thickness 
and were more likely to suffer from ischaemic heart disease and L.V. systolic 
dysfunction - Table 6-3.
The 40 individuals with a higher than normal E:A ratio (>1.28) had compared to the 
remainder of the population a higher prevalence of both L.V.D. and I.H.D - Table 6-3. 
The same was true of the 33 people with an abnormally prolonged mitral valve 
deceleration time (>328.6 msecs) in whom the prevalence of I.H.D. was 50% higher 
than in the remainder of the population - Table 6-4. This group were also older, had a 
higher systolic blood pressure and had a greater proportion of individuals with 
hypertension (using 160/95 as a cut-off) than the remainder of the population.
6.3.4 Mitral Valve Doppler Indices in Disease States
From the 701 individuals with both a measured L.V.E.F. and transmitral Doppler 
indices four groups with cardiovascular disease were identified as follows:
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Table 6-2 - Transmitral Doppler Indices for Normal Subgroup with Normai Left 
Ventricular Systolic Function
Index Median (I.Q.R.) Percentiles
2.5*'’ ST.S*"
Peak E Wave (ms"^) 0.57 (0.51 - 0.66) 0.38 0.87
Peak A wave (ms‘ )^ 0.67 (0.59 - 0.75) 0.47 0.91
E:A Ratio 0.86 (0.76- 1.00) 0.56 1.28
M.V. Dec.Tlme, (msecs) 211.0 (181.0-243.8) 128.3 328.6
N=138
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Table 6-3 - Characteristics of individuals with An Abnormal E:A Ratio
Low E:A Ratio (<0.56) High E:A Ratio (>1.28)
No
N=840
Yes
N=52
No
N=852
Yes
N=40
Age
(yrs)
65.0
(60.0-69.0)
70.0 ** 
(65.3 - 72.8)
65.0
(60.0-70.0)
64.5
(59.0-71.0)
B.M.I.
(Kg/m^)
26.6 
(23.7 - 29.2)
27.4* 
(25.2 - 30.5)
26.6 
(23.9 - 29.4)
25.1 
(22.6 - 28.8)
Diastolic B.P. 
(mmHg)
80.0
(71.0-87.0)
84.5* 
(75.3 - 92.0)
80.0 
(72.0 - 88.0)
73.0* 
(64.3 - 82.0)
Systolic B.P. 
(mmHg)
144.0 
(129.0- 160.0)
154.0* 
(135.8- 179.3)
145.0
(129.0-161.0)
145.5 
(128.8- 159.0)
L.V.E.F.
(%)
51.0 
(46.3 - 54.7)
48.0*
(39.3-51.3)
51.0 
(46.3 - 54.7)
49.0
(41.0-53.7)
L.V. Mass 
Index (g/m)
122.0 
(97.0- 156.0)
149.0
(113.0-183.0)
123.0 
(97.3- 156.0)
140.5 
(102.8- 174.7)
R.Th. 0.42
(0.35-0.50)
0.48* 
(0.45 - 0.56)
0.43
(0.34-0.51)
0.42 
(0.28 - 0.47)
I.H.D 41.7% 55.8% * 41.7% 60.0% *
H.B.P. 42.6% 51.9% 42.8% 50.0%
HBP [JNCVI] 65.6% 78.8% 66.2% 70.0%
ECG L.V.H. 14.4% 23.1% 14.7% 20.0%
Diabetic 5.8% 11.5% 6.2% 5.0%
L.V.D. 3.5% 9.6% * 3.4% 12.5%* ,
Measurements expressed as median (interquartile range). 
* P<0.05 **P<0.001
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Table 6-4 - Characteristics of Individuals with An Abnormal Mitral Valve 
Deceleration Time
Short MV Dec Time (<128.3) Long M.V. Dec.Time (>328.6)
No
N=876
Yes
N=16
No
N=861
Yes
N=31
Age
(yrs)
65.0 
(60.0 - 70.0)
64.0
(59.0-68.8)
65.0 
(60.0 - 70.0)
70.0 ** 
(66.0-72.0)
B.M.I.
(Kg/m^)
26.6
(23.9-29.3)
23.9* 
(21.1 -27.1)
26.6 
(23.8 - 29.3)
25.7 
(23.3 - 28.7)
Diastolic B.P. 
(mmHg)
80.0
(71.0-88.0)
80.0 
(75.0 - 82.8)
80.0 
(72.0 - 87.0)
77.5 
(66.8 - 90.3)
Systolic B.P. 
(mmHg)
145.0
(129.0-161.0)
141.5
(121.0-158.3)
144.0 
(129.0- 160.0)
150.5* 
(139.5- 173.3)
L.V.E.F.
(%)
123.0 
(98.0- 157.0)
121.0 
(94.0- 177.0)
123.0 
(98.0- 156.5)
160.5 
(96.0- 190.0)
L.V. Mass 
Index (g/m)
0.43
(0.35-0.51)
0.38 
(0.35 - 0.55)
0.43
(0.35-0.51)
0.44 
(0.30 - 0.64)
R.Th. 50.7 
(46.3 - 54.7)
42.7 
(39.3 - 56.3)
50.7 
(46.3 - 54.7)
50.3
(41.7-54.3)
I.H.D 42.6% 50.0% 42.0% 63.6% *
H.B.P. 42.8% 45.0% 42.2% 60.6% *
HBP[JNCVI] 67.2% 75.0% 66.9% 80.6%
ECG L.V.H. 15.3% 15.0% 15.1% 21.2%
Diabetic 6.2% 5.0% 6.0% 9.1%
L.V.D. 4.0% 15.0% 4.5% 0.0%
Measurements expressed as median (interquartile range). 
* P<0.05 **P<0.001
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(1) Evidence of I.H.D. but without hypertension (Isolated I.H.D.) - 128 individuals.
(2) Hypertension but without I.H.D. - Isolated hypertension (160/95 cut-off) - 138 
individuals; and isolated hypertension [JNC VI] (140/90 cut-off) -  239 individuals.
(3) Both hypertension and I.H.D. - I l l  individuals.
(4) L.V. systolic dysfunction - 39 individuals.
Individuals with either L.V.D. and/or significant valve defects were excluded from the 
first tliree categories.
Comparing the median values for the transmitral Dopplers for the four disease 
categories with the "healthy" group - Table 6-5 - shows that individuals with isolated 
I.H.D. have a longer M.V.D.T. - 224.5 (196.5 - 252.8) msecs v 211.0 (181.0 - 243.8) 
msecs (P<0.05). The group with isolated hypertension have both a higher peak A 
wave velocity - 0.71 (0.62 - 0.83) ms'^ v 0.67 (0.59 - 0.75) m s'\ P<0.01 and a longer 
M.V.D.T. - 226.0 (194.8 - 259.5) msecs v 211.0 (181.0 - 243.8) msecs, P<0.05 although 
the effect on the M.V.D.T. was not significant if hypertension was defined using the 
.INC VI criteria. Individuals with both hypertension and I.H.D. show the greatest 
increase in both the M.V.D.T. - 228.0 (195.0 - 264.0) msecs v 211.0 (181.0 - 243.8) 
msecs, P<0.05 - and the peak A wave velocity - 0.74 (0.65 - 0.87) ms'^ v 0.67 (0.59 - 
0.75) ms"% P<0.01. This has the effect of producing a significant reduction in the E:A 
ratio - 0.78 (0.67 - 0.96) v 0.86 (0.76 - 1.00), P<0.01. The only significant difference 
shown in the group with L.V.D. was an increase in the peak A wave velocity to 0.75 
(0.61 - 0.87) ms'^ P<0.05, and although there was a trend for the median M.V.D.T. to 
be shorter and the peak velocity of tlie E wave to be higher neither of these reached 
significance.
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Table 6-5 - Median Values for Transmitral Flow Dopplers In Various Disease 
States
PeakE 
ms ^
Peak A
ms'^
E:A Ratio M.V.D.T.
msecs
Normals^ 0.57 0.67 0.86 211.0
N=138 (0.51 -0.66) (0.59 - 0.75) (0.76 - 1.00) (181.0-243.8)
All 0.59 0.70* 0.83 216.0
N=910 (0.51 -0.68) (0.61 - 0.82) (0.70 - 0.97) (185.0-254.0)
IHD Only^ 0.59 0.68 0.84 224.5 *
N=128 (0.49 - 0.67) (0.61 - 0.79) (0.73 - 0.98) (196.5-252.8)
HBP Only^ 0.61 0.71 ** 0.83 226.0*
N=138 (0.52 - 0.67) (0.62 - 0.83) (0.70-0.98) (194.8-259.5)
HBP[JNC Vl]^ 0.59 0.70** 0.82 220.0
Only N=239 (0 .51-0.67) (0.62 -  0.82) (0.71-0.98) (190.0-254.0)
IHD and HBP^ 0.61 0.74 ** 0.78 ** 228.0 *
N=111 (0.51 -0.71) (0.65 - 0.87) (0.67 - 0.96) (195.0-264.0)
L.V.D 0.67 0.75* 0.81 188.0
N=39 (0.46 - 0.78) (0.61 -0.87) (0.61 - 0.98) (170.0-227.0)
* P<0.05 P<0.01 compared to normals
 ^ Excluding those with an L.V. ejection fraction of < 35% and/ or significant 
valvular disease.
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6.3.5 D eterm inants of Transm itral Doppler Indices in The Population
The possible effects of several clinical variables on transmitral Doppler indices were 
analysed by univariate regression analyses - Table 6-6. Age was positively associated 
with both the M.V.D.T, and the peak A velocity and negatively with the E:A ratio. The
B.M.I. similarly increased the pealc A wave velocity and so decreased the E:A ratio.
The different blood pressure variables showed differing effects on transmitral Doppler 
indices. The systolic, diastolic and mean blood pressures all exert similar effects; 
increasing the M.V.D.T. and the A wave, and so decreasing the E:A ratio. The diastolic 
pressure and the mean pressure additionally decrease the E wave. The pulse pressure 
although it increases the peak A wave velocity also increases the peak E velocity and so 
has no significant effect on the E:A ratio. It does however like the other variables 
increase the M.V.D.T..
Neither the L.V. mass nor L.V. mass index exerted a significant effect on the Doppler 
indices but the relative L.V. wall thickness was positively associated with the peak A 
velocity and so negatively with the E:A ratio. The relative wall thiclmess also acts to 
increase the M.V.D.T. The L.V.E.F. was not associated with any of the mitral valve 
Doppler indices.
Wlien the variables which were significant by univariate analyses were combined into a 
multivariate analysis - Table 6-7 - it was shown that both the diastolic blood pressure 
and the pulse pressure remained significantly associated with the peak E wave velocity. 
Inclusion of both the systolic and diastolic blood pressures in a model looking at the 
determinants of the peak A velocity shows that the diastolic blood pressure no longer 
exerts a significant effect. The model which describes the greatest variation
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Table 6-6 - Determinants of Transmitral Doppler Indices - Univariate
Regression Analysis
P values
Peak E 
(ms' )^
Peak A 
(ms' )^
E:A M.V.D.T.
(msecs)
Age (yrs) 0.871 <0.001 + <0.001 - <0.001 +
B.M.I. (Kg/m )^ 0.315 0.004 + 0.005 - 0.635
S.B.P.
(mmHg)
0.276 <0.001 + <0.001 - <0.001 +
D.B.P.
(mmHg)
0.001 - <0.001 + <0.001 - 0.005 +
M.A.P.
(mmHg)
0.191 <0.001 + <0.001 - <0.001 +
Pulse P. 
(mmHg)
<0.001 + <0.001 + 0.214 <0.004 +
L.V. Mass (g) 
Male
0.425 0.555 0.438 0.570
L.V. Mass (g) 
Female
0.184 0.586 0.154 0.589
Mass Index 
(g/m) Male
0.579 0.839 0.570 0.621
Mass index 
(g/m) Female
0.144 0.415 0.194 0.662
R.Th. 0.846 <0.001 + 0.002 - 0.003 +
L.V.E.F. (%) 0.680 0.103 0.880 0.840
+ Positive association 
- Negative association 
S.B.P. - Systolic blood pressure D.B.P. - Diastolic blood pressure 
M.A.P. - Mean blood pressure Pulse P. - Pulse pressure
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Table 6-7 - Determinants of Transmitral Doppler Indices - Multivariate
Analysis.
P values
Peak E Peak A E:A M.V.D.T.
Age <0.001 0.016 0.001
B.M.I. n.s. 0.014 0.031
S.B.P. n.s. n.s.
D.B.P. <0.001 n.s. n.s.
Pulse Press. <0.001
M.A.P. 0.019
R.Th. 0.047 0.027 n.s.
R' (adj) 2.8% 10.6% 5.4% 6.3%
Notes:
R^(adj)= the square of the multivariate correlation coefficient adjusted for the 
expected chance prediction when the null hypothesis is true. It indicates how 
much of the variation that is explained by the factors in the model.
S.B.P. - Systolic blood pressure D.B.P. - Diastolic blood pressure 
M.A.P. - Mean blood pressure Pulse Press. -  Pulse Pressure
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(10.6%) in the pealc A velocity is the one which includes age, mean blood pressure and 
the relative wall thickness; which were all positively associated. The model looking 
at the E:A ratio shows that none of the blood pressure variables remain significant when 
combined with other variables. The factors which are significantly associated, all 
negatively, with the E:A ratio are age, B.M.I. and the relative L.V. wall thickness. 
The main determinants of the M.V.D.T. were age and B.M.L. As with the E:A ratio, 
none of the blood pressure variables remain significant when combined in a 
multivariate analysis looking at the M.V.D.T. and neither does the relative L.V. wall 
thiclcness.
6.3.6 Left Ventricular Mass within The Population
A satisfactory M-mode echocardiogram was obtained in 374 (37.1%) people with the 
availability reducing with age from 44.9% in individuals aged 55 to 59 years to 34.7% 
in those aged 70 to 74 years ,P=0.02. A gender difference was also seen with fewer 
males -  167/500 (33.4%) having an M-mode measured than females - 207/509 
(40.7%), P=0.017.
In the healthy subgroup 63 individuals - 28 males and 35 females - had their L.V. mass 
measured by Mmode. In the males the median L.V. mass was 222.7 (194.2 to 267.7)g, 
and the median L.V. mass index was 132.5 (113.5 to 157.0)g/m. In the females the 
median L.V. mass and L.V. mass index were both significantly less than in the males: 
148.4 (130.4 to 188.6)g, P<0.05, and 92.0 (82.0 to 115.0) g/m, P<0.05, respectively. 
Increased L.V. mass was defined as that exceeding the 97.5^ '^  percentile for this 
subgroup i.e. an L.V. mass > 364.0g in males and an L.V. mass > 242.8g in females; 
and an L.V. mass index > 210.6g/m in males and an L.V. mass index >151.8g/m in
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females.
The relative wall thicloiess did not show a gender difference (males:0.41 v females: 
0.40) and the median RTh for the normal subgroup was 0.40 (0.34 to 0.45) with an 
abnormally high RTh being taken to be greater than the 97.5 ’^^ percentile: 0.67.
The relative L.V. wall thiclcness was increased in the group with hypertension - 0.47 
(0.35 -  0.48) V 0.42 (0.36 -  0.55), P=0.002 , although the difference is small. In males 
with hypertension the L.V. mass and L.V. mass index both tended to be higher than in 
non-hypertensive males but the differences did not reach significance: 257.1 (211.8 -  
313.5)g V 240.0 (202.5 -  285.6)g:, P= 0.148 and 153.5 (123.5 -  183.5)g/m v 143.0 
(119.0 -  169.0)g/m, P=0.135. In hypertensive females, however, both the L.V. mass 
and L.V. mass index were significantly higher than in the non-hypertensive females: 
187.9 (155.7-244.4)g v 160.2 (131.1 -  195.4)g, P<0.001 and 120.5 (97.5 -  157.0)g/m 
V 99.0 (83.5 -  122.5)g/m, P<0.001.
6.3.7 Characteristics of Individuals with Increased L.V. Mass
There was no significant difference in any of the transmitral Doppler indices of L.V. 
diastolic filling between either the group of 42 people (11.2%) with an increased L.V. 
mass or the group of 44 people (11.8%) with an increased L.V. mass index, and the 
remainder of the cohort - Table 6-8. The prevalence of both hypertension and E.C.G. 
evidence of L.V.H. were greater in the groups of individuals with an increased L.V. 
mass or L.V. mass index -  table 6-9. The prevalence of hypertension [JNC VI 
definition] was however not significantly higher in these groups.
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Table 6-8 - Characteristics of individuais with Abnormal indices of L.V. Mass
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Table 6-9 - The Relationship between L  V. Mass and Hypertension
L.V. Mass
Increased n=42
Hypertension 61.9%
Hypertension [JNC VI] 66.7%
E.C.G. L.V.H. 33.3%
Normal n=332
40.4%*
62.3%
14.5%*
L.V. Mass Index
Increased n=44
Hypertension 61.4%
Hypertension [JNC VI] 70.5%
E.C.G. L.V.H. 34.1%
Normal =329
40.4%*
62.0%
" 14.3%*
L.V. Wall Thickness
Increased n=21
Hypertension 71.4%
Hypertension [JNC VI] 62.0%
E.C.G. L.V.H. 33.3%
Normal n=353
40.9%*
76.2%
15.6%*
* P<0.05 P<0.001
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An increased relative L.V. wall thickness was found in 21 individuals (6.3%) who 
compared with the remainder of the population, were older 71 (63.5 - 72.0) v 64 (60.0- 
69.0) yrs, P=0.006, and had a higher prevalence of both hypertension (71.4% v 40.9%, 
P<0.01) and E.C.G. evidence of L.V.H. (33.3% v 15.6%, P<0.05), but not hypertension 
[JNC VI criteria] (76.2% v 62.0%, P=0.245). They had a higher mean diastolic and 
systolic blood pressure - systolic 166.6 ± 30.3 v 145.0 ± 24.0 mmHg (P=0.004) and 
diastolic 88.0 ± 15.2 v 78.9 ±11.9 mmHg (P=0.015). Their median peak A wave 
velocity was increased - 0.75 (0.67 - 0.98) ms"' v 0.67 (0.59 - 0.79) ms"*, P=0.004, but 
the peak E wave velocity was not different. This had the effect of reducing the median 
E:A ratio to 0.71 (0.57 - 0.81) v 0.89 (0.75 - 1.01), P<0.001). The median M.V.D.T. 
was increased 237.0 (206.5 - 281.0) msecs v 208.0 (177.0 - 238.0) msecs P=0.009.
6.3.8 Breathlessness Without L.V. Systolic Dysfunction
A group of 449 individuals were identified in whom L.V.D. had been excluded by 
demonstrating an L.V.E.F. >35% and normal L.V. systolic function verified on visual 
assessment. Significant airflow obstruction was excluded by spirometry by showing an 
F.E.V I >75% of the predicted value based on age, sex and height. None was receiving 
treatment with respiratory medication and none had significant valvular abnormalities. 
Within tills group 54 people (12.0%) either reported cardiac-type dyspnoea or were in 
receipt of treatment with a loop diuretic. Comparing this symptomatic group with the 
remainder - Table 6-10 - showed that there were no significant differences between the 
two groups with respect to any of the transmitral Doppler indices. A greater proportion 
of symptomatic than asymptomatic people had evidence of I.H.D. (59.3% v 32.7%, 
P<0.001) but there was no difference in the proportions with hypertension. During 
treadmill exercise testing the symptomatic individuals exercised for a shorter median
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Table 6-10 - Comparison between breathless and asymptomatic individuals 
with normal L. V. systolic function and no airflow obstruction.
Variable Asymptomatic Breathless
N=395 N=54
Age 64.0 62.0
(yrs) (60.0-68.0) (58.8-68.0)
B.M.I. 26.0 28.1 **
(Kg/m^) (23.7 - 28.5) (25.5-31.2)
Exercise Time 653.0 561.0 **
(secs) (549.5 - 746.3) (444.0 - 653.0)
Peak E 0.59 0.55
(ms’'') (0.51 - 0.67) (0.48 - 0.66)
Peak A 0.69 0.68
(ms"'') (0.60 - 0.80) (0.61 - 0.77)
E:A Ratio 0.85 0.84
(0.73 - 1.00) (0.72 - 0.93)
M.V. Dec Time 216.5 226.0
(msecs) (188.0-252.8) (188.0-261.0)
L.V.E.F. % 51.7% 49.7%
(47.7 - 55.7) (46.1 -53.0)
Systolic B.P. 147.0 134.0
(mmHg) (131.0-164.0) (122.3- 154.5)
Diastolic B.P. 81.0 79.5
(mmHg) (73.0 - 89.0) (70.8 -86.0)
I.H.D. 32.7% 59.3% **
Hypertension 43.0% 42.6%
I.H.D. Only 19.2% 35.2% *
Hypertension Only 25.3% 16.7%
ST segment Shift on -0.4 -0.5
exercise (mm) (-0.9-0.0) (-1.0 - -0.1)
* P<0.05 'P<0.001
Notes
Includes only those with measured normal L.V. systolic function and excludes 
all taking respiratory medication or with an F.E.Vi of <75% predicted value, or 
with valvular disease.
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time - 561.0 (444.0 - 653.0) secs v 653.0 (549.5 - 746.3) secs, P=0.001 - but the 
median level of electrocardiographic ST segment shift was not significantly different 
between the two groups . The symptomatic group had a higher median B.M.L 28.1 
(25.5 - 31.2) Kg/m^ v 26.0 (23.7 - 28.5) Kg/m^ P<0.001.
Removing individuals with I.H.D. from the analysis left 288 people - Table 6-11. The 
symptomatic proportion of these, 22 people, now had a lower median peak velocity of 
the E wave 0,51 (0.45 - 0.63) ms"* v 0.58 (0.51 - 0.67) ms"* , P=0.038 with no change in 
the peak A wave velocity and so they had a significantly lower E:A ratio 0.77 (0.71 -
0.87) V 0.87 (0.74 - 1.00) P<0.05. Both the proportion with hypertension and the mean 
age did not differ between groups. The difference in median exercise times was no 
longer present once individuals with I.H.D. had been removed.
6.4 Discussion
This study looking at 55 to 74 year olds from the general population confiims the 
results of previous studies showing that transmitral Doppler indices of L.V. diastolic 
filling are affected by several biological variables and disease states including gender, 
age, body mass index, blood pressure, relative L.V. wall thickness, hypertension, 
ischaemic heart disease and L.V. systolic dysfunction.
An increased L.V. mass and relative wall thickness were shown to be associated with a 
higher prevalence of E.C.G. evidence of L.V.H. and hypertension. The association 
with hypertension was only seen with hypertension defined by a 160/95 mmHg cut-off. 
This may be because the stricter 140/90 mmHg criteria, when applied to a single 
observation, includes a number of people with spuriously raised blood pressure -  the
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Table 6-11 - Comparison between breathless and asymptomatic individuals 
with normal L.V. systolic function, no evidence of I.H.D. and no airflow 
obstruction
Variable Asymptomatic Breathless
N=266 N=22
Age 64.0 64.0
(yrs) (60.0 - 68.0) (59.0 - 68.5)
B.M.I. 25.4 27.2
(Kg/m^) (23.6-28.1) (24.7-29.9)
Exercise Time 668.0 638.5
(secs) (596.5-773.0) 508.5 - 694.5)
Peak E 0.58 0.51 *
(ms"') (0.51 - 0.67) (0.45 - 0.63)
Peak A 0.68 0.68
(m s') (0.60 - 0.79) (0.59 - 0.75)
E;A Ratio 0.87 0.77*
(0.74-1.00) (0.71 - 0.87)
M.V. Dec Time 214.0 227.0
(msecs) (186.0-247.8) (179.0-258.0)
L.V.E.F. % 51.7% 51.0%
(47.7 - 55.7) (44.1 - 53.9)
Systolic B.P. 144.0 137.5
(mmHg) (129.0-161.3) (118.5-165.3)
Diastolic B.P. 81.0 83.0
(mmHg) (72.0 - 89.0) (75.0 - 87.0)
I.H.D. 37.6% 40.9%
Max ST segment -0.30 -0.35
Shift on Ex. EGG (-0.8 - 0.0) (-1.1 --0.1)
(mm)
P<0.05 'P<0.001
Notes
Includes only those with measured normal L.V. systolic function and excludes 
all taking respiratory medication or with an F.E.Vi of <75% predicted value, or 
with valvular disease, or with evidence of I.H.D.
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“Wliite Coat” effect. Equally it may well be that lower levels of blood pressure, as 
included in the JNC VI definition, are not sufficient to cause a demonstrable increase in 
L.V. mass; large enough to be detected in our study using echocardiography. 
Ultimately the biological importance of a certain level of blood pressure is only shown 
by its longterm effects, not only on the myocardium but on the wider cardiovascular 
system; which this study cannot demonstrate.
6.4.1 Effect of Biological Variables
Looking at the whole cohort with measured transmitral Dopplers in this study showed 
that females had higher median values for both the pealc E and A wave velocities with 
no difference in the E: A ratio. The magnitude of the difference was small - ~3% greater 
than median values for males. A similar gender effect has been found in other larger 
studies looking at both people in the third and fourth decades (Xie et al. 1995) and aged 
65 years and over (Gardin et al. 1998). The explanation for this observation is unclear. 
It may be due to females having smaller mitral valve orifices and hence a lower valve 
orifice to cardiac output ratio although the Cardiovascular Health Study showed that 
females actually had lower stroke volumes than men (Gardin et al. 1998). It remains a 
possibility that there are fundamental differences in the physiology of diastole between 
men and women.
A consistent finding in epidemiological studies is that age affects transmitral Doppler 
indices. In this study multivariate analysis showed age to be positively associated with 
the peak A velocity and the M.V.D.T. and negatively associated with the E:A ratio. The 
Framingham Heart Study over a sixty year age range found age to be the strongest
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determinant of transmitral Doppler indices (Benjamin et al. 1992) and even the 
C.A.R.D.I.A. study looking at an age range of only ten years found the same 
associations with age as this study found (Kronmal et al. 1996). Logistic Regression 
Analysis in the large Cardiovascular Health Study showed, that with all other factors 
held equal, for each ten year increase in age there was an increase in the peak A velocity 
of 0.065ms"* (Gardin et al. 1998).
These results suggest that with age there is progressive impairment of early left 
ventricular diastolic relaxation and a shift to a greater reliance upon left atrial systole for 
L.V. filling. This is in keeping with experimental evidence that ageing is associated 
with greater stiffness of the L.V. and impaired relaxation (Templeton et al. 1979; 
Kitzman et al. 1991). This may explain why the elderly do not tolerate as well the loss 
of atrial function as occurs with the onset of atrial fibrillation.
Body mass index in other studies has been shown to be associated with abnormalities of 
L.V. diastolic filling. Xie et al. looking at body weight found, like as this study did, 
that it was associated with the peak A velocity although in that study it also affected the 
E;A ratio (Xie et al. 1995). Kangro looking at 50 yr. old women found that the B.M.L 
was negatively associated with the E:A ratio (Kangro et al. 1996). In this present study 
this effect was independent of blood pressure. It may be that the effect is as a result of 
increased pericardial fat reducing the compliance of the myocardium.
6.4.2 Blood pressure, L.V. Mass and Hypertension
The blood pressure variables studied in this study population have different, 
independent, effects on the various transmitral Doppler indices but the general picture
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is that increasing levels of blood pressure - both systolic and diastolic - are associated 
with changes in transmitral Doppler indices indicating increasing impairment of L.V. 
diastolic filling. These effects were independent of both the L.V. mass and the relative 
L.V. wall thicloiess.
Previous studies have also shown blood pressure variables to have differing effects on 
transmitral Dopplers but have found, as this study did, that the trend is for increasing 
levels of blood pressur e to be associated with impairment of L.V. diastolic filling. The
C.A.R.D.I.A. study found, as this study did, that the systolic blood pressure was 
positively associated with the peak A velocity (Xie et al. 1995). The Cardiovascular 
Health Study postulated that the effect of blood pressure might be due to the pulse 
pressure since, in that study, both the systolic and diastolic blood pressures had equal 
but opposite effects on both the peak E and peak A wave; with the systolic positively 
related to them and the diastolic inversely (Gardin et al. 1998). Whilst a study by 
Kangro could find no association with systolic blood pressure it did find that the 
diastolic blood pressure was inversely related to the E:A ratio (Kangro et al. 1996).
A diagnosis of isolated hypertension (using a 160/95 cut-off) in this study was 
associated with both a higher peak A velocity and a longer deceleration time 
suggesting impaired L.V. diastolic filling. Similar changes were shown in the 
Cardiovascular Health Study where hypertension was associated with an increased A 
wave and a decreased E:A ratio (Gardin et al. 1998). This has been shown to be true 
for people with borderline hypertension even in the absence of L.V. mass changes 
(Kapuku et al. 1993). This suggests that the effect of hypertension may be at least at 
first related to loading conditions on the left ventricle or to microscopic changes in the
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myocardium such as increased fibrosis (Kapuku et al. 1993; Chen et al. 1996)
Neither the L.V.. mass nor the L.V. mass index appeared to exert an effect on 
transmitral Dopplers in this population. This lack of effect by L.V. mass has been 
noted in other studies (Benjamin et al. 1992; Voutilainen et al. 1991; Graettinger et al. 
1987). This study did find, however, that the relative L.V. wall thiclcness by univariate 
analysis was significantly associated with the peak A velocity, the E:A ratio and the 
M.V.D.T.; and in multivariate analysis it was independently associated with the pealc A 
velocity and the E;A ratio. Other studies have found the L.V. wall thickness to 
correlate with markers of diastolic filling. Kangro found that, in normal individuals, it 
influenced L.V. filling whereas the L.V. mass did not (Kangro et al. 1996). The 
Cardiovascular Health Study found that the L.V. wall thickness was associated with an 
increased A wave velocity (Gardin et al. 1998) and Xie found in females not only tliis 
but also that it was associated with a decreased E:A ratio (Xie et al. 1995).
It appears, therefore, that rather than the total mass of the left ventricle influencing 
diastolic filling it is the relative degree to which the L.V. wall is hypertrophied or not. 
This may be a more accurate reflection of pathophysiology as it both makes allowance 
for small hearts which may not have a high total mass but which are relatively 
hypertrophied, and it takes into account the degree to which the left ventricular cavity 
is encroached upon and restricted by any myocardial hypertrophy.
6.4.3 Ischaemic Heart Disease
Individuals with I.H.D. with or without concomitant hypertension were shown to have 
changes in the transmitral Dopplers suggesting impaired relaxation with longer 
deceleration times and increased peak A velocities compared to normals.
160
Abnormalities of L.V. diastolic filling have been shown previously in individuals with
I.H.D. whether or not they have had a previous myoeardial infarction (Grossman, 1991; 
Hirota, 1980). This may be due, in part, to ischaemia impairing calcium handling and 
the energy-dependent process of diastolie relaxation and, in part due, to replacement of 
infarcted myocardium by inelastic fibrous tissue (Grossman, 1991).
6.4.4 L.V. Systolic Dysfunction
The number of individuals with L.V.D. and measurable transmitral Doppler indices in 
this cohort was small. Looking at them as a group they displayed evidence of impaired 
diastolic relaxation with liigher median peak A wave velocities. There was also a trend, 
although not significant, for the deceleration time to be shorter and for the peak E 
velocity to be higher suggesting a higher prevalence of a restrictive pattern of 
transmitral Doppler indices. Looking at the group of individuals with a restrictive 
pattern of transmitral Doppler indices there was a higher prevalence of L.V.D. 
compared to people with a non-restrictive pattern. Therefore there is a suggestion that 
L.V.D. in this small group can be associated with either pattern.
The mechanisms responsible for impaired diastolic function, particularly in ischaemic 
cardiomyopathy, are multifactorial (Brutsaert et al. 1993) and includes the effects of 
ischaemia, abnormal calcium handling at cellular level (Gwatlimey et al. 1987), left 
ventricular remodelling (Pfeffer and Braunwald, 1990) and elevated filling pressures 
(Brutsaert et al. 1993). Individuals with L.V.D. and a restrictive pattern of transmitral 
Doppler indices have been shown to have elevated L.V. filling pressures (Pozzoli et al. 
1996) whereas individuals with a non-restrictive pattern or a pattern of abnormal 
relaxation usually have normal or near-normal L.V. filling pressures at rest (Appleton et 
al. 1988). The presence of a restrictive pattern is associated with greater symptoms and
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effort intolerance (Xie et al. 1996).
One limitation of this current study, which will be clarified by follow-up, was the 
inability to differentiate between a normal and a pseudonormal pattern of transmitral 
Doppler indices. The latter is a transition state between an abnormal relaxation pattern 
and a restrictive filling pattern and is associated with increased L.V. filling pressures 
(Iga et al. 1990; Nishimura and Tajik, 1997). This transition may occur as a disease 
involving the myocardium progresses from being initially associated with impaired 
relaxation to later reducing the effective chamber compliance and so increasing the left 
ventricular and then left atrial pressures (Nishimura and Tajik, 1997). Therefore it is 
likely that the group with L.V.D. was composed of a mix of individuals with all three 
patterns of transmitral Dopplers depending on the stage of the disease process. The 
only way that normal and pseudonormal patterns could have been differentiated would 
have been to have recorded Doppler signals from the pulmonary veins (Nishimura and 
Tajik, 1997).
6.4.5 Breathlessness With Normal Systolic Function
Exertional breathlessness is a common complaint made by patients attending both 
cardiology and respiratory clinics and is one of the cardinal symptoms of the syndrome 
of heart failure; whether due to systolic or diastolic dysfunction (The Task Force on 
Heart Failure of the European Society of Cardiology, 1995). Looking at individuals 
with both normal L.V. systolic function and spirometry, and using the M.R.C. 
breathlessness questionnaire to detect exertional dyspnoea, this study was unable to 
find a difference in transmitral Doppler indices between those who reported 
breathlessness and those who did not. Those who reported breathlessness did show a 
poorer effort capacity when this was tested formally by treadmill testing; with them
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exercising for a median of VA minutes less than those who were asymptomatic. Thus 
one can be sm*e that the questionnaire did detect a real symptom with real consequences 
in term of objective effort intolerance.
There aie a number of possible reasons as to why this study did not detect any 
difference in L.V. diastolic filling. The most obvious is that the dyspnoea was not due 
to diastolie dysfunction and may not even have been due to cardiac causes at all. 
Dyspnoea is a non specific symptom and can be produced by a number of other cardiac 
and non-cardiac conditions (Vasan et al. 1996). Although spirometry was measured 
and individuals taking bronchodilators and theophyllines were excluded this does not 
rule out the possibility of untreated episodic bronchospasm. This study showed a higher 
median B.M.L for the breathless group suggesting that obesity may have at least been a 
contributory factor. The dyspnoea in the study group was accompanied by a higher 
prevalence of I.H.D. raising the possibility that the questionnaire was actually detecting 
symptomatic angina presenting with exertional dyspnoea whether accompanied by 
chest pain or not. Equally individuals with I.H.D., who have reversible myocardial 
ischaemia on exertion, may as a result of this on exertion have reversible systolic 
and/or diastolic myocardial dysfunction (Vasan et al. 1996). Such people may show 
no abnormalities of either L.V. systolic or diastolic function at rest.
These findings support previous research which has suggested that the high false- 
positive rate for the diagnosis of heart failure in primary care may be related to obesity, 
pulmonary disease or unrecognised ischaemia (Remes et al. 1991). A review of 
published studies looking for diastolic filling abnormalities in patients with C.H.F. and 
normal systolic function (Vasan et al. 1995) found them to be present in between only
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20% (Soufer et al. 1985) and 62% (Aguirre et a l 1989). Equally the prevalence of 
coronary artery disease in this condition has been reported as being as high as 67% 
(Judge et al. 1991).
After removing individuals with I.H.D. from the analysis a small difference in the E:A 
ratio was evident between those with and those without reported dyspnoea. One eannot 
automatically assume that this study had identified a group of individuals with diastolic 
dysfunction since the other major aetiologieal factor besides I.H.D. for this condition, 
namely hypertension, was no more prevalent in the symptomatic group. Equally if a 
real condition had been found, an objective impact upon effort capacity could not be 
demonstrated; although numbers were small.
In conclusion abnormalities of L.V. diastolic filling can be demonstrated in the 
population but their impact upon the individual and their contribution to symptoms is 
not clear.
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7. Natriuretic Peptides and Their Reiationship to Left 
Ventricular Function and Mass
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7.1 Introduction
Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are circulating 
cardiac hormones which are secreted predominantly by atrial and ventricular 
myocardium, respectively, in response to volume expansion and cardiac pressure 
overload (Yasue et al. 1994). They have similar physiological actions - natriuresis, 
arterial and venous vasodilatation, and antagonism of the renin-angiotensin-aldosterone 
system (Strutliers, 1994). This has the effect of reducing the circulating volume and 
thus cardiac preload (Wei et al. 1993). ANP is synthesised and stored in granules in 
atrial myocytes (de Bold et al. 1981) as a 126 amino acid prohormone which is cleaved 
into two fragments: the 28 amino acid carboxyl-terminal (C-terminal) peptide and the 
98 amino acid N-terminal-ANP (N-ANP) (Glembotski et al. 1988). The N-terminal 
has a much longer plasma half-life than the C-terminal (Thibault et al. 1988) and so 
circulating levels are about ten to twenty-fold higher than those of C-terminal ANP 
(Sundsfiord et al. 1988).
Both N-ANP and BNP have been shown to be elevated in L.V. systolic dysfunction 
(L.V.D.) (Wei et al. 1993; Burnett et al. 1986; Cody et al. 1986; MeDonagh et al. 
1998; Dickstein et al. 1995; Lerman et al. 1993; Davidson et al. 1996; Friedl et al. 
1996) and several studies have looked at the possibility of using them as screening 
blood tests for its presence within the general population (MeDonagh et al. 1998; 
Cowie et al. 1997b; McClure et al. 1998; Davidson et al. 1996; Friedl et al. 1996). 
They have also been shown to be elevated to differing degrees in other conditions such 
as diastolic dysfunction (Pontremoli et al. 1993; Wilkins et al. 1997; Lang et al. 1994) 
and left ventricular hypertrophy (Kohno et al. 1992; Kohno et al. 1995; Yoshibayashi 
et al. 1993).
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The aims of this study were to investigate the determinants of levels of N-ANP and 
BNP within an unselected population; to examine the effects of L.V. systolic and 
diastolic dysfunction on peptide levels and to explore the possibility of using either N- 
ANP or BNP as screening blood tests for the presence of L.V.D. Recently a direct 
immunoradiometric assay (I.R.M.A.) kit (Shionoria BNP kit, Shionogi &Co, Ltd, 
Osaka, Japan) for detecting BNP levels in unextraeted plasma (Kono et al. 1993) has 
become available and it was decided to compare the results for BNP levels obtained by 
this method with those obtained from extracted plasma using a radioimmunoassay kit 
for human BNP - RIK 9086, (Penninsula Laboratories).
7.2 Methods
Each person completed questionnaires regarding demographics, past medical history, 
current medication, and the presence of breathlessness - M.R.C. questionnaire. Their 
height, weight, blood pressure and spirometry were measured and a 12-lead E.C.G. was 
recorded and Minnesota coded (Prineas et al. 1982). Next a full two-dimensional and 
Doppler echoeardiogram was performed using an Acuson 128 ultrasound machine 
(Acuson Inc., Mountain View, CA, USA) with calculation of a left ventricular ejection 
fraction (L.V.E.F.) using a biplane algorithm ("method of discs summation", Simpson's 
rule) (Schiller et al. 1979), and transmitral Doppler signals recorded and analysed.
The left ventricular mass was calculated from M-mode using the Penn Cube formula 
(Devereux et al. 1986). The L.V. mass index was calculated by dividing the L.V. mass 
by the height (m). The relative L.V. wall thickness (R.Th.) expresses the proportion of 
the L.V. radius in diastole which is L.V. wall.
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A 10ml blood sample was taken, after 20 minutes of supine rest, and placed into a pre­
chilled tube containing potassium-EDTA (1 mg/ml blood) and aprotonin (50 I.U./ml 
blood) for measurement of natriuretic peptides. The sample was stored on ice and 
centrifuged at 3000 r.p.m. for 10 minutes at 4° C within 30 minutes of collection. The 
plasma was immediately frozen and stored at -70° C. until assay. Both N-ANP and 
BNP were measured in plasma after extraction. N-ANP was measured after dilution 
(1/100) by radioimmunoassay using an antibody - RAS 9129 (Peninsula Laboratories, 
Belmont, California, USA) - raised against the 1 to 30 N-terminal fragment. BNP was 
measured in the extract (1/4 dilution) using a radioimmunoassay kit for human BNP - 
RIK 9086, (Penninsula Laboratories). BNP was also assayed in unextraeted plasma 
using a direct immunoradiometric assay kit (Shionoria BNP kit) supplied by Shionogi 
& Co, Ltd. (Osalca, Japan) (Kono et al. 1993). This uses two monoclonal antibodies 
which recognise the carboxyl terminal sequence and the ring structure of human BNP, 
respectively and measures BNP by sandwicliing it between the two antibodies without 
the need for prior plasma extraction (Yasue et al. 1994).
7.2.1 Definitions
Hypertension: current treatment with antihypertensive medication and/or a systolic 
blood pressure >160 mmHg and/or a diastolic blood pressuie >95 mmHg.
Hypertension [JNC VI]: as above, but using the eut-off points for blood pressure as 
defined in JNC VI guidelines (Joint National Committee on Prevention, Evalaution and 
Treatment of High Blood Pressure 1997) which are a systolic blood pressure of 
>140mmHg and/or a diastolic blood pressure > 90mmHg.
Ischaemic Heart Disease: the presence of one or more of: (1) a prior physician-made 
diagnosis of myocardial infarction or angina; (2) the current use of nitrates; (3) ECG
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evidence of possible ischaemic heart disease according to the Minnesota coding system 
using eodes for pathological Q waves (1.1, 1.2, 1.3), ST segment depression (4.1, 4.2, 
4.3, 4.4), or left bundle branch block (7.11).
Abnormal E.C.G. -  defined as the presence of atrial fibrillation or atrial flutter 
(8.31,8.32), or Q waves (1.1, 1.2, 1.3), or ST segment depression (4.1, 4.2, 4.3, 4.4), or 
left bundle branch block (7.11) , or left ventricular hypertrophy (3.1, 3.3, 3.4) or T wave 
inversion (5.1, 5.2, 5.3).
Cardiac breathlessness - reported as breathlessness on the M.R.C. questionnaire 
(Fletcher et al. 1959) in the absence of symptoms of chronic bronchitis - defined as 
breathlessness associated with a cough occurring on most days during at least tliree 
winter months each year.
Left Ventricular Systolic Dysfunction: a measurable L.V.E.F. of 35% or less. 
Symptomatic L.V. Systolic Dysfunction: a measurable L.V.E.F. of 35% or less and 
either reported cardiac breathlessness or current treatment with a loop diuretic. 
Asymptomatic L.V. systolic Dysfunction: a measurable L.V.E.F. of 35% or less in the 
absence of both reported cardiac breathlessness and current treatment with a loop 
diuretic.
Increased L.V. mass, mass index and relative L.V. wall thickness (R.Th.) : >97.5*'^  
percentile for each measurement in a healthy subgroup - an L.V. mass >364.0g in 
males, and >242.8g in females; an L.V. mass index > 210.6g/m in males, and 
>151.8g/m in females; and a R.Th. >0.67 in both sexes.
7.2.2 Statistical Analysis
Statistical analyses were performed using Minitab for Windows (Minitab Ine, 
Pemisylvania, U.S.A.) . Variables with normal distributions are described by the mean 
and the standard deviation (S.D.) and means were compared using a two sample t test.
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Variables with a skewed distribution which could not be transformed easily were 
described by the median value and interquartile range. Medians were compared using 
the Mami-Whitney U test. The proportions of individuals in two groups were compared 
by the Chi-square test or where appropriate Fisher's exact test. Univariate and 
multivariate linear regression analyses were used to determine the relationship between 
a variable or a set of variables and a single outcome.
A P value of <0.05 was taken to be significant.
7.3 Results
7.3.1 Natriuretic peptides in the whole population
Median peptide levels and ranges for the whole population are shown in Table 7-1. 
BNP measured by the Shionoria I.R.M.A. method (Sh-BNP) showed the greatest spread 
with values ranging from 1.0 to 750.0 pg./ml. The correlation between N-ANP and 
BNP and between N-ANP and Sh-BNP was only moderate; r= 0,59 and 0.63 
respectively - Figure 7-1. The two methods of measuring BNP correlated reasonably 
well ( i-  0.81) - but the Sh-BNP tended to yield higher results in the same individual 
with the regression equation being Sh-BNP = 2.41 (BNP) - 4.61. However, a plot of the 
agreement between paired BNP measurements -  Figure 7-2 , using the method 
described by Bland and Altman (Bland and Altman, 1986), shows that the difference in 
results obtained by the two assays increases linearly with increasing concentrations of 
BNP. Logarithmic transformation does not alter this linear relationship and so the 
limits of agreement between the assays cannot be meaningfully calculated (Bland and 
Altman, 1986).
There was no difference in median values for the three natriuretic peptide
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Table 7-1 - Natriuretic Peptide Measurements in the Population According to
Presence or Absence of Left Ventricular Systolic Dysfunction
N-ANP (ng/ml)
Median
All 2.27
No L.V.D. 2.24 
L.V.D. 3.89**
Interquartile Range
1.50-3.76
1.49-3.53
1.82-7.64
Range
0.20-20.51 
0.32- 12.59 
0.70-16.40
BNP (pg.ml)
Median
All 13.60
No L.V.D. 13.30
L.V.D. 39.35**
Interquartile Range
8.90-22.33
8.50-20.98
16.97-68.37
Range
1.00-247.40
1.00-247.40 
2.80 - 224.00
Sh-BNP (pg./ml)
Median
All
No L.V.D. 
L.V.D.
23.0
22.0 
69.0**
Interquartile Range
12.0-45.0
12.0-41.0
4.0-226.0
Range
1.0-750.0
1.0-586.0
2.0-750.0
P<0.05 P<0.001 compared with No L.V.D. group
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Figure 7-1 - Correlation Between N-ANP and BNP Levels in Whole Population 
N-ANP V BNP CONCENTRATIONS IN THE WHOLE POPULATION
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Figure 1-2 -  Plot of Agreement Between Paired BNP Measurements by 
Penninsula (BNP) and Shionoria (Sh-BNP) Assays
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measurements between individuals with and without a measured L.V. ejection fraction.
7.3.2 L.V. Systolic Dysfunction and Natriuretic Peptides
The presence of L.V.D. was associated with significantly higher levels of all three 
peptide measurements - Table 7-1 & Figure 7-3. Of the 50 people with systolic 
dysfunction 23 were by definition symptomatic and their median L.V.E.F. was lower 
than those who were asymptomatic - 28.0% (24.0 - 32.0) v 33.0% (28.7 - 34.7), 
P=0.003 - but there was no significant difference in the median levels of the three 
peptides - Table 7-2.
The need for treatment with loop diuretics in fifteen individuals with L.V.D. was 
associated with a lower median L.V.E.F, than in those not receiving such treatment - 
27.7% (21.0 - 32.0) v 32.3% (28.7 - 34.3) , P=0.009. Higher levels of circulating N- 
ANP were found in the treated group - 6.20 (3.10 - 10.80) ng/ml v 3.37 (1.66 - 4.72) 
ng/ml, P=0.03 - but whilst the levels of BNP and Sh-BNP also tended to be higher 
these differences did not reach statistical significance.
7.3.3 Using Natriuretic Peptides As A Screening Blood Test to Detect 
the Presence of L.V. Systolic Dysfunction
Receiver operating characteristic (R.O.C.) curves - Figure 7-4 - show that as a screening 
test for the presence of L.V.D. within the whole population a BNP at a concentration of
15.2 pg./ml performs best of the three peptides with a sensitivity of 82.0% and a 
specificity of 57.6% - Table 7-3. N-ANP proved to be the worst. The negative 
predictive value of BNP was high (97.8%) but the positive predictive value was very 
low (12.3%).
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Figure 7-3 - B.N.P. Concentrations in Normai and in impaired L  V. Systolic 
Function.
BNP CONCENTRATIONS IN NORMAL AND IMPAIRED LV FUNCTION
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Notes: Impaired L.V. Function = L.V. Ejection Fraction < 35%.
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Table 7-2 - Natriuretic Peptide Levels in Left Ventricular Systolic Dysfunction 
Symptomatic L.V. Systolic Dysfunction
Median I.Q. Range Range
L.V.E.F (%) 28.0 24.0 - 32.0 12.0-34.0
N-ANP (ng/ml) 4.73 2.37-9.78 1.09- 16.40
BNP (pg./ml) 43.0 21.3-84.3 7.8-180.5
Sh-BNP (pg./ml) 113.0 40.0 - 323.4 2.5 - 750.5
Asymptomatic L.V Systolic Dysfunction
Median I.Q. Range Range
L.V.E.F. (%) 33.0 28.7 - 34.7 18.7-35.0
N-ANP (ng/ml) 3.37 1.66-4.72 0.70-12.50
BNP (pg./ml) 29.8 14.3-53.0 2.8-224.0
Sh-BNP (pg./ml) 51.9 21.9-155.5 3.4 - 445.6
L.V. Systolic Dysfunction Treated with Loop Diuretics
Median I.Q. Range Range
L.V.E.F. (%) 27.7 21.0-32.0 12.0-34.0
N-ANP (ng/ml) 6.20 3.10-10.80 1.09-12.60
BNP (pg./ml) 49.3 31.0-100.7 11.3- 162.6
Sh-BNP (pg./ml) 145.8 51.0-333.5 2.5-750.5
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Figure 7-4 - Receiver Operator Characteristic Curves for Natriuretic Peptides
to Detect L  V. Dysfunction in Whole Population
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Table 7-3 - Concentrations of Natriuretic Peptides for Screening for L  V. 
Dysfunction Within the Population
Peptide Cone. Sensitivity Specificity P.P.V. N.P.V.
N-ANP 1.73 ng/ml 80.0% 31.8% 7.8% 95.6%
BNP 15.20 pg./ml 82.0% 57.6% 12.3% 97.8%
Sh-BNP 22.0 pg./ml 81.6% 50.2% 10.6% 97.4%
Table 7-4 - Concentrations of Natriuretic Peptides for Screening for L  V. 
Dysfunction Within Breathless Individuals
Peptide Cone. Sensitivity Specificity P.P.V N.P.V.
N-ANP 1.84 ng/ml 84.0% 38.3% 16.0% 94.5%
BNP 16.0 pg./ml 88.0% 56.9% 22.2% 97.1%
Sh-BNP 24.0 pg./ml 79.2% 51.8% 18.7% 94.7%
Table 7-5 - Concentrations of Natriuretic Peptides for Screening for L  V. 
Dysfunction In Individuals With Evidence of Ischaemic Heart Disease
Peptide Cone. Sensitivity Specificity P.P.V. N.P.V.
N-ANP 1.45 ng/ml 94.9% 16.6% 14.5% 95.6%
BNP 8.30 pg./ml 97.4% 20.5% 15.5% 98.2%
Sh-BNP 20.0 pg./ml 92.1% 36.9% 17.9% 96.9%
Table 7-6 - Concentrations of Natriuretic Peptides for Screening for LV. 
Dysfunction In Individuals With A Previous Myocardial Infarction
Peptide Cone. Sensitivity Specificity P.P.V. N.P.V.
N-ANP 2.04 ng/ml 91.3% 30.8% 36.4% 89.1%
BNP 11.0 pg./ml 100.0% 21.2% 35.5% 100.0%
Sh-BNP 18.0 pg./ml 100.0% 30.6% 38.5% 100.0%
Notes:
P.P.V. “ Positive Predictive Value N.P.V. - Negative Predictive Value
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The tliree peptide measurements were examined in a group of 204 individuals with 
breathlessness, whether of cardiac or respiratory origin, all of whom had a measured 
L.V.E.F.. L.V.D. was present in 25 people (12.4%). Once again BNP, at a level of 
16.0 pg./ml, performed best as a screening test with a sensitivity of 88.0% and a 
specificity of 56.9% and N-ANP fared worst - Table 7-4 & Figure 7-5.
The tiiree peptides were also examined in a high risk group for L.V.D. namely the 301 
individuals with evidence of I.H.D, and a measured L.V.E.F.; a subgroup of which 
reported a previous myocardial infarction (76 people). The prevalence of L.V.D. was 
13.0% in the I.H.D. group as a whole and 30.3% in the subgroup with a previous M.I.. 
The sensitivity of BNP at a concentration of 8.3 pg./ml to detect L.V.D. rose to 97.4% 
although the specificity was only 20.5% - Table 7-5 & Figure 7-6. The negative 
predictive value was high at 98.2%. The sensitivity and the negative predictive value 
were both higher in the previous M.I. subgroup - both 100% for a BNP of 11.0 pg./ml 
- Table 7-6 & Figure 7-7. In the previous M.I. subgroup Sh-BNP performed even 
better than BNP with a higher specificity and positive predictive value - 30.6% and 
38.5% respectively. N-ANP was inferior to BNP and Sh-BNP in all respects.
7.3.4 Additional Information from E.C.G. Findings For Screening
Figures 7 - 8  and 7 - 9  show possible strategies for screening for the presence of L.V. 
systolic dysfunction in our cohort; including only the 738 indivdiuals with both a 
measured L.V.E.F. and a BNP. These strategies would involve everyone having both a 
BNP measured and an ECG recorded. By only measuring BNP, and echoing 
individuals found to have a level >15.2 pg/ml, one would miss nine of the 50 cases of 
L.V.D.. By only performing an E.C.G. and echoing the individuals with an abnormal
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Figure 7-5 -  Receiver Operator Curves For BNP and Sh-BNP to Detect L  V.
Dysfunction in Breathless Individuals
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Figure 7-6 - Receiver Operator Characteristic Curves for BNP and Sh-BNP to 
Detect L  V. Dysfunction in Ischaemic Heart Disease
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Figure 7-7 - Receiver Operator Curves for BNP and Sh-BNP to Detect L  V.
Dysfunction in individuals With Previous M.I.
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Figure 7-8 Possible strategy for screening the population for L  V. systolic
dysfunction using BNP and an E. C. G
> 15.2 pg/ml< 15.2 pg/ml
BNP
E.C.G.E.C.G.
Normal Abnormal Normal Abnormal
9/403 = 2.2%
8/176 = 4.5%3/263= 1.1% 6/140 = 4.3%
41/335 = 12.2%
33/159 = 20.8%
Echocardiography
Baseline 
50/738 = 6.8%
Abnormal E.C.G.;
• Atrial fibrillation / flutter
• LV.H.
• Q waves
• ST depression
• T wave inversion
• Left bundle branch
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Figure 7-9 Possible strategy for screening the population for L  V. systolic
dysfunction using BNP and an E. C. G
Normal Abnormal
ECG
BNPBNP
>15.2 pg/ml!>15.2 pg/ml I <15.2 pg/ml<15.2 pg/ml
8/176 = 4.5%3/263 = 1.1% 6/140 = 4.3%
11/439 = 2.5% 39/299 = 13.0%
33/159 = 20.8%
Echocardiography
Baseline 
50/738 = 6.8%
Abnormal E.C.G.:
• Atrial fibrillation / flutter
• LV.H.
• Q waves
• ST depression
• T wave inversion
• Left bundle branch
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E.C.G. (as defined above) we would miss eleven of the cases of L.V.D., If however we 
performed both, and did not refer for echocardiography individuals with both a normal 
E.C.G. and a BNP level < 15.2pg/ml, this would detect 47 of the 50 cases (94%) of 
L.V.D, but at a saving of 263 fewer (35.6% fewer) echocardiograms.
7.3.5 Effects of Increased L.V. Mass
Compared with the remainder of the cohort the 42 people, with an increased L.V. mass 
had higher median plasma levels of all three peptide measurements Table 7-7: N-ANP 
3.04 (2.01 -  6.16) ng/ml v 2.25 (1.52 - 3.38) ng/ml, P=0.002 ; BNP 18.60 (11.40 - 
54.10) pg./mi V 13.60 (98.50 - 21.80) pg./ml, P=0.004 and Sh-BNP 32.0 (16.5 -  168.0) 
pg/ml V 21.0 (11.0 -  43.3) pg/ml. An increased L.V. mass index was found in 44 
people and they had higher median levels of both N-ANP 2.88 (1.88 -  4.97) ng/ml v 
2.26 (1.51 - 3.60) ng/ml, P-0.011 and Sh-BNP 28.0 (16.0 -  167.0) pg./ml v 21.0 (11.0 
- 42.5) pg./ml, P=0.010. An increased relative L.V. wall thickness was found in 21 
individuals but they did not show any difference in the levels of any of the natriuretic 
peptides.
7.3.6 Determinants of Natriuretic Peptide Levels Within the Population
The effect of a number of clinical variables on natriuretic peptide levels within the 
population was analysed by univariate regression analyses - Table 7-8. For all three 
peptide measurements age, systolic blood pressure, pulse pressure, L.V. mass, L.V. 
mass index, peak E wave velocity and E:A ratio were positively associated and the 
L.V.E.F. negatively associated. In addition mean blood pressuie was positively 
associated with both N-ANP and BNP levels, and the mitral valve deceleration time 
was positively associated with N-ANP levels. Combining those variables which were 
significant in univariate analysis into a multivariate analysis - Table 7-9 - showed that
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Table 7-7 - Natriuretic Peptide Levels in Normal And Increased Left 
Ventricular Mass
N-ANP (ng/ml) BNP (pg/ml) Sh-BNP
(pg/ml)
Normal L.V. Mass 2.25
(1.52-3.38)
13.60
(8.50-21.80)
21.0
(11.0-43.3)
High L.V. Mass 3.04* 
(2.01 -6 .16 )
18.60*
(11.40-54.10)
32.0*
(16.5-168.0)
Normal L.V. Mass 
Index
2.26
(1.51-3.60)
13.80 
(8.80 -  22.22)
21.0
(11.0-42.5)
High L.V. Mass 
Index
2.88*
(1.88-4.97)
14.00
(11.10-49.30)
28.0*
(16.0-167.0)
Normal R.Th. 2.27
(1.57-3.80)
13.80
(9.10-22.95)
21.0
(11.4-46.1)
High R.Th. 2.62
(1.71-3.02)
15.00
(11.30-25.00)
23.4 
(18.1 -74.7)
* P<0.05 **P<0.001
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Table 7-8 - Determinants o f Natriuretic Peptides Within the Population.
Univariate Analysis
N-ANP BNP Sh-BNP
P
%
P R^
%
P R2
%
Age (Yrs) <0.001 + 7.8 <0.001 + 4.7 <0.001 + 4.1
L.V.E.F. (%) <0.001 - 5.3 <0.001 - 10.8 <0.001 - 11.8
SBP (mmHg) <0.001 + 1.3 <0.001 + 1.9 0.002 + 1.2
DBP (mmHg) 0.486 0.568 0.670
MAP (mmHg) 0.041 + 0.3 0.032 + 0.5 0.140
Pulse P (mmHg) <0.001 + 2.2 <0.001 + 3.1 <0.001 + 1.8
LV Mass (g) Male 0.028 + 2.5 0.001 + 5.9 <0.001 + 12.0
Female <0.001 + 11.3 <0.001 + 10.2 <0.001 + 16.9
LV Mass Ind. Male 0.044 + 2.0 0.007 + 4.1 <0.001 + 9.9
(g/m) Female <0.001 + 10.6 <0.001 + 11.0 <0.001 + 16.7
R.Th. 0.984 0.915 0.741
Peak E (ms )^ <0.001 + 6.8 <0.001 + 4.2 <0.001 + 4.6
Peak A (ms )^ 0.401 0.177 0.286
E:A <0.001 + 2.7 <0.001 + 7.9 <0.001 + 8.0
M.V.D.T. (msecs) 0.010 + 0.6 0.342 0.052
+ Positive association 
- Negative association 
Notes: 
SBP - Systolic Blood Pressure 
MAP - Mean Arterial Pressure 
LV Mass Ind. - L.V. Mass Index
DBP - Diastolic Blood Pressure 
Pulse P - Pulse Pressure 
R.Th. - L.V. Relative Wall Thickness
R  ^(adj) = the square of the multivariate correlation coefficient adjusted for the 
expected chance prediction when the null hypothesis is true. It indicates how 
much of the variation is explained by the factors in the model.
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Table 7-9 - Determinants of Natriuretic Peptides Within the Population
Multivariate Analysis
Males P Values
N-ANP BNP Sh-BNP
Age (Yrs) 0.001 + 0.019 + 0.005 +
LVEF (%) 0.495 0.001 - 0.035 -
LV Mass Ind. (g/m) 0.051 0.033 + <0.001 +
E:A Ratio 0.012 + <0.001 + <0.001 +
R'(adj) 12.1% 25.2% 33.2%
Females P Values
N-ANP BNP Sh-BNP
Age (Yrs) <0.001 + 0.001 + <0.001 +
LVEF (%) 0.004 - <0.001 + <0.001 +
LV Mass Ind. (g/m) 0.003 + 0.001 + <0.001 +
E:A Ratio <0.001 + <0.001 + <0.001 +
R^(adj) 36.4% 33.8% 56.4%
Notes:
+ Positive association 
- Negative association
(adj) = the square of the multivariate correlation coefficient adjusted for the 
expected chance prediction when the null hypothesis is true. It indicates how 
much of the variation is explained by the factors in the model.
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for all tliree peptides age and E;A ratio were positively associated and L.V.E.F. was 
negatively associated. The L.V. mass index was positively associated with the three 
peptides in females but in males it just failed to reach a significant’association with N- 
ANP but was significantly associated with BNP by both assays. The degree to which 
these four vaiiables described variation in the three peptide measurements varied. In 
females they described a greater degree of the individual variation than in males.
None of the blood pressure variables remained significant in multivariate analysis. The 
pealc velocity of the transmitral Doppler E wave remained significant in multivariate 
analysis but the inclusion instead of the E:A ratio explained a greater degree of the 
variation in peptide levels.
7.4 Discussion
This present study shows that concentrations of peptides in the population are affected 
independently by age, L.V. systolic function, L.V. mass and transmitral Doppler 
indices of L.V. diastolic filling.
With regard to the effect of age on peptide levels these results agree with the results of 
previous studies showing that levels of ANP increase with age independent of any 
changes in L.V. mass or blood pressure (Flickinger et al. 1995; Pontremoli et al. 1993; 
Dutka et al. 1996). By univariate analysis age appeared to explain a greater degree of 
vaiiation in levels of N-ANP (R^=7.8%) than BNP (R^=4.7%) or Sh-BNP (R^=4.1%). 
In one study over a wider age range, approximately 55 years, age accounted for ~ 12 to 
13% of the interindividual variation in plasma ANP (Flickinger et al. 1995). It has 
also been shown that the ANP response to saline loading is exaggerated in older
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individuals (Tan et al. 1990) and taken together these results support the theory that as 
ventricular compliance decreases with age both atrial and ventricular pressures rise 
acting as a stimulus for the release of natriuretic peptides.
7.4.1 Left Ventricular Systolic Dysfunction
Elevated levels of both N-ANP and BNP in L.V.D, have been shown by other studies 
(Wei et al. 1993; Burnett et al. 1986; Cody et al. 1986; McDonagh et al. 1998; 
Dickstein et al. 1995; Leiman et al. 1993; Davidson et al. 1996; Friedl et al. 1996). 
There were however certain differences between the findings of these studies and this 
current study. Firstly there was no difference in peptide levels between individuals with 
symptomatic and asymptomatic L.V.D. even although the symptomatic group had a 
lower median ejection fraction. Other studies have shown that N-ANP levels are 
higher in symptomatic individuals (Lerman et al. 1993) and correlate with the severity 
of symptoms (Dickstein et al. 1995; Wei et al. 1993; Lerman et al. 1993). The reason 
for the lack of any difference in this current study is likely to be in part due to the small 
number of individuals with L.V.D. within each group and the wide spread of peptide 
levels. In addition the severity of symptoms were not quantified and so it could have 
been that all the symptomatic group were in N.Y.H.A. class II i.e. only mildly 
symptomatic. When the subgroup currently treated with loop diuretics were 
specifically looked at higher levels of N-ANP were found compared with the unti'eated 
group. The treated group had a lower median L.V.E.F. although the magnitude of this 
difference is no greater than that seen between the symptomatic and asymptomatic 
groups. It is likely that, regardless of the L.V.E.F., the need for treatment with a loop 
diuretic is a marker of greater symptoms and higher L.V. filling and pulmonary artery 
pressures, both of which have been shown to correlate with higher N-ANP levels 
(Mathisen et al. 1993; Dickstein et al. 1995).
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7.4.2 Use of Peptides a s  Screening Tools for L.V. dysfunction
Like previous studies (McDonagh et al. 1998; Cowie et al. 1997b; McClure et al. 
1998; Davidson et al. 1996; Friedl et al. 1996) this study has shown that BNP was a 
better marker for the presence of L.V.D. than N-ANP within the whole population, 
within breathless individuals, and within a high risk group. Comparing the two BNP 
assays, the results obtained by the Shionoria I.R.M.A. assay were inferior to the 
radioimmunometric assay (R.I.A.). The I.R.M.A. gave a much wider spread of values 
particularly in the higher range of values compared to the R.I.A.. The plot of agreement 
between the two measurements showed that the difference between the two assays 
increases with increasing levels of BNP; with the LR.M.A. consistently giving higher 
measurements. One possible reason for this difference would be if the Shionoria 
LR.M.A. had a certain amount of cross reactivity either a second part of the BNP 
molecule or with another molecule released along with BNP such as N-terminal pro- 
BNP (Hunt et al. 1995).
An ideal screening blood test should have distributions of values for normals and 
abnormals which are distinct from each other since the degree of any overlap will 
inversely correlate with the diagnostic accuracy. The ranges of peptide concentrations 
in this study population for those with and without L.V.D. show considerable overlap. 
In particular the group with no L.V.D. had several high levels of peptides. This will 
undoubtedly have reduced the discriminatory power of peptides.
There are a number of possible explanations for why there was such an overlap between 
the L.V.D. and no L.V.D. groups but the main reason is likely to be the fact that the "no 
L.V.D." group is not the same as a group of "normals" - free from cardiovascular
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disease. A nmnber of other cardiac conditions are laiown to be associated with elevated 
levels of both N-ANP and BNP including left ventricular hypertrophy - secondary to 
hypertension (Kohno et al. 1992; Kohno et al. 1995; Pontremoli et al. 1993), 
hypertrophic cardiomyopathy (Yoshibayashi et al. 1993), or aortic stenosis 
(Yoshibayashi et al. 1993) - diastolic dysfunction (Lang et al. 1994) and mitral 
incompetence. Non cardiac conditions including renal impairment and chronic 
obstructive pulmonaiy disease (Cheung and Kumana, 1998) as well a drugs including 
beta-blockers (Sanderson et al. 1995) may all cause elevations in BNP (Cheung and 
Kumana, 1998). All of these factors could not be adjusted for in this study.
Compared with other studies BNP did not perform as well in this current study cohort 
as a screening test for L.V.D. In a previous study within the same geographical area 
and age group (McDonagh et al. 1998) we found BNP to have a sensitivity of 89% and 
a specificity of 71% compared with 82.0% and 57.6% respectively in this study. The 
corresponding values for the negative and positive predictive accuracies in the earlier 
study were 99.2% and 18.0%, respectively, compared to 97.8% and 12.3% in this 
study. In the previous study there was a narrower range of values for the peptides in the 
L.V.D. and no L.V.D. groups and hence possibly the greater diagnostic accuracy. 
Other studies have achieved even better results than either of these studies but within 
selected populations e.g. from referrals to heart failure clinics (Cowie et al. 1997b) or 
from referrals for radionuclide ventriculography (Davidson et al. 1996). They have 
looked at symptomatic individuals who have sought medical attention and are therefore 
likely to have greater haemodynamic compromise, higher L.V. filling pressui’es and 
consequently higher peptide levels.
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Within a high risk population, individuals with I.H.D., BNP performed much better 
although the specificity was lower because cut-off values were chosen which gave 
greater sensitivity assuming that within a high risk population sensitivity was more 
important than specificity. Compared with our previous study (McDonagh et al. 1998) 
looking at a high risk group the negative predictive values were similar in this current 
study (98.2% v 98.5%) but the positive predictive value was lower (15.5% v 32.0%).
In symptomatic individuals BNP performed reasonably well with a high negative 
predictive value of 98.2% although again the positive predictive value was poorer. In 
acute dyspnoea an elevated BNP has been shown to have a sensitivity and specificity 
both in excess of 90% for detecting the presence of L.V.D. (Davis et al. 1994). 
However such acute left heart failure is likely to be characterised by much greater 
haemodynamic upset and neuroendocrine activation than the clironic, treated phase. 
This possibly explains the greater diagnostic accuracy of peptides in the acute setting.
In this present study, therefore, natriuretic peptides did not discriminate sufficiently 
between those with and without L.V.D. probably because of the high prevalence of 
other conditions which raise levels of one or both of the natriuretic peptides. This does 
not pennit a diagnosis of L.V.D. to be based on the BNP result alone but in the context 
of screening within the general population it may identify those who need further 
investigation for possible cardiac dysfunction. In symptomatic patients and in high risk 
groups a BNP measurement has a very high negative predictive value and does 
therefore allow one to at least exclude the presence of L.V.D.. It is likely that if 
peptides are to be used then different cut-off levels will need to be used in different 
patient groups depending on the level of risk and whether individuals are symptomatic
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or not.
The combination of E.C.G. findings and the BNP measurement in this cohort allows us 
to categorise people into tliree groups, and this may be useful in a strategy for screening 
the whole population. There is a group with a very low probability of L.V.D. (1.1%) 
and this is the group with both a normal E.C.G. and a BNP measurement less than the 
cut-off value (15.2 pg/ml). One could suggest that it would not be worthwhile 
performing routine echocardiography in this group. In this study that would mean 
performing 263 fewer echocardiograms at the expense of performing 439 E.C.G.s. 
There is a second group with a high probability (20.8%) of having L.V.D.; the group of 
individuals with both an abnormal E.C.G. and a BNP above the cut-off value. This 
group almost certainly merits echocardiography with one in five having L.V. systolic 
dysfunction. Finally there is the largest of the three groups; that is the group of 
individuals with one or other of the tests abnormal, which has an intermediate 
probability of having L.V.D. (4.3 to 4.5%). One could simply echo all of this 
intermediate group but that would still be a relatively expensive process. It is therefore 
this group that poses us with the challenge of further refining our screening algorithm.
Although we presented a strategy with everyone having both an E.C.G. and a BNP 
measurement performed, if we accept that we can only exclude the low prevalence 
group from echocardiography (normal E.C.G. and BNP <15.2 pg.ml), then there would 
only be a need to perform both tests in individuals where the first test, whether that be 
the E.C.G. or the BNP, is abnormal. If one found either one of the tests abnormal the 
individual could simply be referred for echocardiography. Performing an E.C.G. 
intially would mean peforming 738 E.C.G.s and subsequently 299 BNP measurements.
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Measuring the BNP first would mean carrying out 738 assays and subsequently 403 
E.C.G.s. Both strategies would involve performing 475 echocardiograms. The order in 
which tests were performed would depend largely on the relative costs of a BNP assay 
and an E.C.G., and the ease and availability of these tests in primary care.
7.4.3 Effects of Increased L.V. Mass and Hypertension
This study demonstrated that individuals with an increased L.V. mass or L.V. mass 
index (based on normal ranges for our cohort) have higher concentrations of both N- 
ANP and BNP. Multivariate analysis shows that the L.V. mass index is independently 
and positively associated with BNP levels in both sexes and with N-ANP in females.
Researchers have shown varying results regarding the relationship of L.V.H. to BNP 
and ANP. Most studies have shown, as has this one, that BNP is elevated in L.V.H. as 
evidenced by an increased L.V. mass or mass index (Kohno et al. 1992; Kohno et al. 
1995; Yoshibayashi et al. 1993), and in one study, increased relative L.V. wall 
thiclcness. Treatment with angiotensin converting enzyme inhibitors has been shown to 
cause regression of this L.V.H. which is accompanied by a parallel reduction in BNP 
levels (Kolmo et al. 1995). There is less agreement regarding the effects of L.V.H. on 
ANP. One study showed that unlike BNP there was no relationship between ANP and 
L.V. mass but found rather that in hypertensives it correlated with the degree of blood 
pressui'e elevation (Kolmo et al. 1995). In another study ANP levels were elevated in 
L.V.H. correlating directly with the L.V. mass index and inversely with the relative 
L.V. wall thickness (Pontremoli et al. 1993). The effect of blood pressure on peptide 
levels in individual studies is even less clear but a meta-analysis of 17 case-control 
studies (Hollister and Inagami, 1991) concluded that there was no significant difference
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between normotensives and untreated hypertensives in the absence of target-organ 
damage and controlling for salt intake.
BNP appears, therefore, to be related to the severity of L.V.H. This is not a surprise in 
view of the ventricular origin of BNP. Since the stimulus to release of ANP is atrial 
stretch (Yasue et al. 1994) the mechanism for elevated levels in L.V.H. may be an 
increase in left atrial pressuies secondary to reduced compliance and relaxation of the 
left ventricle. Although it has been shown already in this study (Chapter 6) that no 
difference could be found in transmitral Doppler indices between individuals with and 
without increased L.V. mass this does not rule out the presence of elevated left atrial 
pressures in L.V.H. since it was not possible in this study to differentiate between 
normal and pseudonormal Doppler patterns; the latter being associated with elevated 
left atrial pressures (Iga et al. 1990; Nishimura and Tajik, 1997).
In this study within the whole cohort the E:A ratio was independently and positively 
correlated with both BNP and N-ANP suggesting that as L.V. filling pressures increase 
the pressure overload stimulates release of both hormones. This has been shown to be 
true for individuals with L.V.D. where the presence of a restrictive pattern of transmitral 
Doppler indices is associated with a much greater elevation of both ANP and BNP than 
if absent (Yu et al. 1996). Other studies have shown that abnormalities of L.V. 
diastolic filling outside the context of systolic dysfunction and in the absence of L.V.H. 
are associated with elevations of ANP (Pontremoli et al. 1993; Wilkins et al. 1997) 
and BNP (Wilkins et al. 1997). In "pure" diastolic heart failure the levels of both 
correlate inversely with the E:A ratio (Lang et al. 1994). The possible explanation 
being that diastolic abnormalities stimulate release of ANP by increased atrial stretch as
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a result of the left atrium contracting against a non-compliant ventricle and they 
stimulate BNP release by pressure overload of the heart because the left ventricular 
diastolic pressure is greater for any given volume (Lang et al. 1994).
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8. General Discussion
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8.1 Principle Findings of Study
This study showed that the prevalence of left ventriculai' systolic dysfunction (L.V.D.) 
in this geographical population was higher than previously shown (McDonagh et al. 
1997) and higher than that found in other populations (Gardin et al. 1995; Morgan et al. 
1999). It is likely that this is a real finding as the L.V.D. was associated with objective 
effort intolerance, impaired quality of life and with neuroendocrine activation.
The aetiological associate of the L.V.D. appears to be predominantly ischaemic heart 
disease (I.H.D.) as reported to be the case in the majority of studies performed in recent 
years (McDonagh et al. 1997; Kannel et al. 1994; Morgan et al. 1999; Gardin et al. 
1995). Once again it has been shown that in as many as half of all cases this L.V.D. 
may be asymptomatic; although tliis is based on the subjective reporting of one 
symptom. More objective testing of effort capacity and possibly also quality of life 
reveals that tliis so-called asymptomatic dysfunction may actually be exerting a 
demonstrable effect on an individual's physical performance. Whilst diastolic 
dysfiuiction may be an important contributor to the clinical syndrome of heart failure 
this study was unable, using transmitral Doppler indices in an unselected population, 
to show a substantial effect. Neuroendocrine activation whilst being a feature of 
L.V.D. also appears to accompany other cardiovascular and non-cardiovascular 
conditions which limits the use of natriuretic peptide levels as a discriminatory blood 
screening test for L.V.D..
Wliat do the two studies performed in this population - McDonagh's previous study 
(McDonagh et al. 1997) - and this current one tell us about the prevalence of L.V.D. in 
North Glasgow? If we ignore absolute values of L.V. ejection fraction used to define
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L.V.D. and assume that systolic dysfunction in both studies was the same biological 
entity, then combining the L.V. function data gives a total study population of 1376 
within the age range 55 to 74 years. The averaged prevalence of L.V.D. from the 
combined data is 4.5% in the 55 to 64 yrs age group and 7.2% in the 65 to 74 yrs age 
range with the corresponding prevalences for males being 6.2% and 9.7% and for 
females 2.9% and 4.7%.
8.2 Strengths of this study
This study was one of the largest echocardiographic studies of L.V. systolic function 
performed in this important age range and certainly the largest conducted in this age 
range in the U.K. Rather than resorting to a subjective or semi-quantitative assessment 
of L.V. systolic function by calculating an L.V. ejection fraction this study has been 
able to present an objective measurement which is universally understood. This has 
been done in an entirely random sample drawn from a well defined population which 
has been studied previously (McDonagh et al. 1997; Tunstall-Pedoe et al. 1994; 
Morrison et al. 1997; Smith et al. 1987) such that a large amount of background 
information is known about it. This study was able to present data on a well 
characterised cohort which like the background population had a high prevalence of risk 
factors for I.H.D. and subsequent L.V.D.. This study has been able to study L.V.D. as it 
presents in the community rather than in hospital series or clinical trials with a few 
surprises regai’ding its higher than expected prevalence.
The strength of such an epidemiological study is not only in reporting point prevalences 
but also in its ability to follow up. A cohort has been recruited, and study methods 
have been used which will allow follow-up studies to be carried out for a number of 
years. The Framingham Heart Study (Dawber et al. 1951) is successful because it has
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continued to follow-up the same population using the same methods over a number of 
years. Follow-up studies will hopefully report on issues such as what was prognostically 
important rather than statistically important L.V.D.; what is the incidence of L.V.D. is 
this population; what factors determine outcome in L.V.D. and what factors predict its 
development in the first place?
8.3 Limitations of this study.
The power of this study was limited by two factors: the suboptimal response rate and 
reduced availability of a measured L.V. ejection fraction. The first of these factors 
could be improved only by use of community venues for the study rather than one 
central point. This is now becoming a reality with the advent of portable 
echocai'diographic equipment. The second is partly dependent on the skill and training 
of the echocardiographer and partly on the age and body habitus of the respondents. 
Tlirough a process of supervision and training it was felt that the first issue had been 
covered but perhaps the number of suitable images obtained should have been reviewed 
periodically during the couise of the study with quality and training issues addressed 
then.
The ability of tliis study to make statements about L.V.D. is limited by the size of the 
group with L.V.D.. This is true in any epidemiology study as opposed to a clinical 
study. McDonaglïs study identified only 43 cases of L.V.D. from a screened 
population of 1640 (McDonagh et al. 1997) and the Cardiovascular Health Study after 
studying 5201 participants had only 195 cases with L.V. ejection fraction abnormalities 
(Gardinetal. 1995).
Were this study to be repeated then changes which should be considered would include
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changing the definition of ischaemic heart disease to incorporate responses obtained 
from the administration of the Rose Chest pain questionnaire (Rose et al. 1977) and 
wider electrocardiographic criteria including the presence of T wave inversion. The 
likely effect of this would be to increase the prevalence of I.H.D. in the community and 
to possibly provide an aetiology for a greater proportion of the L.V.D. found.
The ability to study diastolic L.V. function in this study was limited by not having 
recorded Doppler signals from pulmonary vein flow and as stated elsewhere this may 
have caused the misclassification as normal of an unknown number of people with 
actually pseudonormal transmitral Doppler flows.
The use of symptom-limited treadmill testing limited the ability to determine effort 
capacity in a proportion of the individuals with L.V.D. and this could be avoided in 
future studies by use of the six-minute walk test.
8.4 Impiications of The Study
The clinical syndrome of heart failuie is a major public health problem in the Western 
world. It is associated witli a significant morbidity and mortality and places a 
significant burden on the resources of an healthcare budget costing an estimated $10 
billion to treat annually in the U.S. alone (Bennett et al. 1999). The syndrome is set to 
become more common as the population of the Western world ages and as more people 
survive following myocardial infarction (McMurray and Davie, 1996). We also know 
that treatment of L.V.D., the commonest cause of the syndrome, with angiotensin- 
converting enzyme (A.C.E.) inhibitors reduces the morbidity and mortality (Garg and 
Yusuf, 1995) whilst being cost-effective (McMurray and Davie, 1996). It is estimated
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that some 60,000 deaths and 100,000 hospital admissions would be saved per year in 
the U.S. alone if all eligible patients were to receive A.C.E. inhibitor therapy (Paeker, 
1996a). This study and others have shown that at present not all eligible patients are 
being treated (O'Comiell and Bristow, 1994; McMurray, 1998).
There is therefore a gap between available effective therapy and potential recipients. It 
is this gap that epidemiological studies such as this one, by identifying these recipients 
within the community, should be filling. Ideally one would wish to screen the whole 
population for L.V.D. by means of a blood test and treat them in primary care on the 
basis of the result. The results from this study would suggest that the use of BNP in 
such a setting lacks sufficient discriminatory power to allow treatment to be based on 
this result alone. Therefore, at present, we would still have to examine each individual 
by means of echocardiography to be able to make a confident diagnosis of L.V.D.. It is 
unlikely to be economically viable or practical to echo all of the community but using 
BNP, possibly in combination with E.CG., would reduce the number of individuals 
requiring to be echoed. Additionally we already know who the majority of people with 
L.V.D. within the community are. This study showed a gradient of risk for having 
L.V.D., from having had an M.l. diagnosed with a 30% chance, to having been 
diagnosed as having angina - 20% chance, to having any evidence of I.H.D. - 13% 
chance. All of the individuals with clinical I.H.D. were already known to primary care 
physicians. Further work is therefore required to refine the algorithms for screening to 
possibly take into account the presence of risk factors for L.V.D..
Finally we should come full circle in this thesis and say that if we loiow that the 
majority of L.V.D. is the result of I.H.D. then we must continue to put effort into
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primary prevention with regard to I.H.D. In this inner city population that will not only 
require education and perhaps pharmacological intervention but also a clear social and 
economic policy.
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PHR01 Please affix 
sticker here
PERSONAL HEALTH RECORD
(All information is confidential)
Please answer the questions in this record as far as you are able and bring it with 
you when you attend the examination. Please answer every question, as far as 
you can, (except those you are told to skip) and circle the box which applies to 
you. We cannot use those questions that you leave completely blank. If the answer 
in your case is ‘No’ or ‘I don’t know’ you still need to show this on the paper. If you 
need any help, or have any questions, please ask when you come to the 
examination. Our nurses are there to help you, and one will check through the 
record with you.
Personal history
1. (a) Please circle the appropriate box
(b) Date of birth day
Male I 1 I 
month
(c) How many years have you lived in this town 
or within 10 miles of this town?
Female
year
years
(d) Where were you born? Town/place
County
Country
2. Please circle the box showing your present marital status
1 married 4 widowed
2 cohabiting 5 divorced
3 single 6 separated
(a) What is the highest level of education you have completed?
1 university degree
other professional or technical qualification or diploma after leaving school
3 secondary school
4 primary school
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3. (b) How many years altogether have you gone to school
or studied full-time from the age of 5 years? years
1
4. (a) Please circle the appropriate box about your employment situation,
in a full-time job 
in a part-time job
unemployed, seeking work if unemployed and seeking work,
for how long have you been 
unemployed?
years months
unemployed because sick or disabled 
housewife/homemaker 
wholly retired from employment 
full-time student
(b) Please give full and precise details of your and your husband/wife's 
occupation (if unemployed now, give details of last job).
Your occupation 
Description of your work 
Husband/wife’s occupation 
Description of his/her work
(c) What is your and your partner’s employment status? (If unemployed now, 
give details of last job.)
You Husband/Wife
[ 1 I employee not supervising other employees 
employee supervising other employees 
self-employed not employing others 
self-employed employing others
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5. (a) How do you and your household occupy your accommodation?
as an owner-occupier (including purchase by mortgage)1
by renting, or rent-free, or by lease from a local authority (council or New 
Town) or from a housing association
by renting or rent-free, from a private landlord or in some other way
(b) If you are owner-occupier, is your house one which you previously 
rented from a local authority?
1 yes no
Family history
6. Did your mother or father have heart disease before they were 60 years old?
don’t know1 yes no
7. How many brothers and sisters did you have 
in your family (not counting yourself)? brothers and sisters
8. Did any of your brothers and sisters have heart disease before they were 60 
years old?
0  yes no don’t know
9. How many children have you had (including any who died at birth or in 
childhood)?
children
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Medical history
10. Have you ever been told by a doctor that you have, or have had any of the 
following? Circle Yes or No for each condition.
Yes No
angina
heart attack (coronary thrombosis, myocardial 
infarction)
high blood pressure
stroke
diabetes
high cholesterol
11. Are you now taking any medication for high blood pressure? 
yes1 no
If yes, please write the names of the medicine(s) you are taking:
12. Are you now taking any medication for high cholesterol? 
0  yes no
If yes, please write the name of the medicine you are taking:
13. Are you now taking aspirin regularly?
no If no, go to question 14.1 yes 
If yes, is it for your heart? 
1 yes z  no 3 don't know
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1
If it is for your heart, why did you start taking it? 
the doctor told you to take it 
you decided for yourself 
other reason, please give deta ils ............
14. (a) Are you regularly taking any other medication at present? 
0  yes no
If yes, write the name of the medicine(s) and what you are taking them for (if 
you know). Please include all pills, bottles, tablets, inhalers (puffers), 
injections, etc.
(b) Are you regularly taking any vitamins, minerals or food supplements at 
present?
1 yes no
If yes, give the type of supplement, brand name and how often you take each 
one.
Type Brand (and strength) Frequency
Men miss out the next page and go to question 18
5
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WOMEN ONLY
(men go to question 18 on next page)
15. (a) Are you pregnant now?
□  ye® 2 no
If no, have you ever been pregnant?
no If no, go to question 16.1 yes
(b) How old were you when you had your first pregnancy?
16. (a) Have you ever been on the contraceptive pill?
yes If yes, for how many years?
no If no, go to question 17.
years old
1 years
1
(b) Are you on the contraceptive pill now?
no If no, how long ago did you stop?
months ago
yes
years
1
17. (a) Are you still having periods (menstruating)? 
yes, as usual 
yes, but irregularly
no If no, how old were you when you stopped?
years old
Was this because of a hysterectomy (surgical removal of the womb)? 
T1 yes no
(b) Have you ever taken hormone replacement therapy (HRT)?
1 yes 1 2 no If yes, for how many years? years
If no, go to question 18.
Cl in i ca l  R e s e a r c h  In i t i a t ive  in Hea r t  Fa i lu re
(c) Are you on hormone replacement therapy (HRT) now?
yes 2 no If no, how long ago did you stop taking it?
years months
1
Chest Pain
18. (a) Have you ever had any pain or discomfort in your chest?
If no, go to question 201 yes no
(b) Do you get this pain or discomfort when you walk uphill or hurry? 
0  yes
(c) Do you get it when you walk at an ordinary pace on the level? 
yes1 no
1
(d) When you get any pain or discomfort in your chest, what do you do? 
stop
slow down
continue at the same pace
(e) Does it go away when you stand still?
yes no If no, go to question 18(g)
(f) How soon?
10 minutes or less
I 2 j more than 10 minutes
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(g) Where do you get this pain or discomfort? 
Mark the place(s) with X on the diagram.
19. Have you ever had a severe pain across the front of your chest lasting for half 
an hour or more?
1 yes no
Leg problems
20. (a) Do you get a pain or discomfort in your leg(s) when you walk? 
yes
no If no, go to question 22.
I am unable to walk If unable to walk, go to question 22.
1
21. (a) Does this pain ever begin when you are standing still or sitting? 
yes1 no
(b) Do you get it if you walk uphill or hurry? 
yes1 no
(c) Do you get it when you walk at an ordinary pace on the level? 
yes1 no
(d) What happens to it if you stand still?
Usually continues more than 10 minutes 
Usually disappears in 10 minutes or less
1
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(e) Where do you get this pain or discomfort?
Mark the place(s) with X on the diagram below.
Front Back
Cough
22. (a) Do you usually cough first thing in the morning in the winter? 
yes I '1 no
(b) Do you usually cough during the day, or at night, in the winter?
no1 yes
(c) Do you cough like this on most days for as much as three months each 
year?
1 yes no 8 does not apply
Phlegm
23. (a) Do you usually bring up any phlegm from your chest first thing in the 
morning in the winter?
1 yes no
(b) Do you usually bring up any phlegm from your chest during the day, or at 
night, in the winter?
1 yes no
(c) Do you bring up phlegm like this on most days for as much as three 
months each year?
m yes no 8 does not apply
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Breathlessness
24. (a) Do you get short of breath when hurrying on level ground or walking up a 
slight hill?
1 yes no
(b) Do you get short of breath walking with other people of your own age on 
level ground?
m yes no
(c) Do you have to stop for breath when walking at your own pace on level 
ground?
1 yes no
(d) Do you get short of breath when washing or dressing?
no1 yes
(e) Are you ever wakened from sleep by breathlessness? 
yes1 no
Cigarette smoking
25. (a) Do you smoke cigarettes now? 
yes, regularly
no If no, go to question 26.
occasionally (usually less than one a day)
1
(b) On average, about how many cigarettes do you smoke a day?
cigarettes a day
(c) On average, on how many days a week do you smoke cigarettes?
days a week
(d) How old were you when you began to smoke cigarettes?
years old
10
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1
26. Did you ever smoke cigarettes? 
yes, regularly 
no, never
occasionally (usually less than one a day)
Cigar smoking
27. (a) Have you ever smoked cigars?
|~1 I no If no, go to question 28.
I 2 I used to, but not now If used to, go to question 28.
yes, now smoke occasionally (usually less than one a day) 
yes, now smoke regularly
(b) About how many cigars do you smoke a week? cigars a week
1
Pipe smoking
28. (a) Have you ever smoked a pipe?
no If no, go to question 29.
used to, but not now If used to, go to question 29.
yes, now smoke a pipe occasionally (less than one a day) 
yes, now smoke a pipe regularly
(b) About how many ounces of tobacco do you smoke a week?
ozs a week
11
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Alcoholic drinks
29. (a) Have you ever taken alcoholic drinks?
m yes no
1 yes
(b) Do you take alcoholic drinks at present
seldomno
If no, go to question 31
If no, go to question 30.
(c) Think back carefully over the last seven days. Please write in exactly what 
alcoholic drinks you have consumed on each day during the past week. 
Try to remember where you were and who you were with on each day. 
This may help you remember what you have had to drink.
For each day, write in how much you have drunk:
(i) the number of pints of low-alcohol (or non-alcoholic) beer, lager, etc.
(ii) the number of pints of beer, lager, shandy, cider, stout, etc.
(iii) the number of single glasses of whisky, vodka, gin, rum, etc.
(iv) the number of single glasses of wine, sherry, Martini, port, etc.
Pints of 
low-alcohol 
beer, etc.
Pints of 
beer, etc.
Single glasses 
of spirits
Single glasses 
of wine, etc.
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Sunday
(d) Would you say that last week was fairly typical of what you usually have to 
drink in one week?
1 yes no
(e) If last week was not typical, would you normally drink more or less in a 
wee k?
more 2 less
12
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30. (a) How long ago did you give up alcohol 
(b) Why did you give up alcohol?
because the doctor advised me to
other reasons, please give details
years ago
1
Physical activity
31. Which of the following four activity classes best describes your present activity 
outside of your job? Please consider going to and from work, sporting activity 
and other physical effort during your leisure time, like gardening or dancing, 
(please circle one box only.)
1 No physical activity weekly
Only light physical activity in most weeks
Vigorous physical activity at least 20 minutes once or twice a week 
(Vigorous activity causes shortness of breath, a rapid heart rate and 
sweating)
Vigorous physical activity for at least 20 minutes three or more times a 
week.
THANK YOU for completing this questionnaire. 
Please bring it with you to your appointment.
Office use only
Date of visit 
Pat Init.
Date of birth 
CRI Number 
Checked by
CRI- _1 -
13
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SFQ 01 Please affix 
sticker here
HEALTH STATUS QUESTIONNAIRE
We would be grateful if you could complete this questionnaire and bring it with you when you 
attend the examination. If you have any questions, please ask when you come to the 
examination. Our nurses are there to help you, and one will check through the record with you.
The following questions ask for your views about your health, how you feel and how well you 
are able to do your usual activities. If you are unsure about how to answer any question, please 
give the best answer you can and make any comments in the space available after question 10.
Please circle one:
1. In general, would you say your health is
excellent 
very good 
good 
fair 
poor
2. Compared to one year ago, how would you rate your health in general now:
Much better now than one year ago 
Somewhat better now than one year ago 
About the same
Somewhat worse now than one year ago 
Much worse now than one year ago
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Health and Daily Activities
3. The following questions are about activities you might do during a typical day. Does your 
health limit you in these activities? If so, how much?
Please circle one on each line.
Yes 
limited 
a lot
Yes No, not, 
limited limited 
a little at all
a) Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports
1 2 3
b) Moderate activities, such as moving a table, pushing 
a vacuum cleaner, bowling or playing golf m 2 3
c) Lifting or carrying groceries m 2 3
d) Climbing several flights of stairs m 2 3
e) Climbing one flight of stairs 1 2 3
f) Bending, kneeling or stooping m 2 3
g) Walking more than a mile m 2 3
h) Walking half a mile m ~2 3
i) Walking 100 yards m 2 3
j) Bathing and dressing yourself □ 2 3
4. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of vour phvsical health?
Answer Yes or No to each question.
a) Cut down on the amount of time you spent on work or other 
activities
b) Accomplished less than you would like
c) Were limited in the kind of work or other activities
d) Had difficulty performing the work or other activities (e.g. it took 
extra effort)
Yes No
1 1 2
1 2
1 2
1 2
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5 . During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)?
Answer Yes or No to each question.
Yes No
a) Cut down on the amount of time you spent on work or other 
activities
b) Accomplished less than you would like
c) Didn’t do work or other activities as carefullv as usual
m
6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours or groups:
Please circle one.
1 Not at all
0
Slightly
3 Moderately
4 Quite a bit
5 Extremely
1
7. How much bodily pain have you had during the past 4 weeks? 
None 
Very mild 
Mild
Moderate 
Severe 
Very severe
3
H
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8. During the past 4 weeks, how much did pain interfere with your normal work (including 
work both outside the home and housework)?
1 Not at all 
A little bit 
Moderately 
Quite a bit 
Extremely
Your Feelings
9. These questions are about how you feel and how things have been with you during the 
past month. (For each question, please indicate the one answer that comes closest to the 
way you have been feeling.)
How much time during the past month
a) did you feel full of life?
b) have you been a very nervous 
person?
c) have you felt so down in the dumps 
that nothing could cheer you up?
d) have you felt calm and peaceful?
e) did you have a lot of energy?
f) have you felt downhearted and low?
g) did you feel worn out?
h) have you been a happy person?
i) did you feel tired?
j) has your health limited your social 
activities (like visiting friends or close 
relatives)?
All Most A good
of the of the bit of
timetime the time time
Some A little None 
of the of the of the
time time
4 5” 6
4 5 6
4 5 6
4 5 6
4 5 6
4 5 6
4 5 6
4 1 5 6
4 5 6
4 5 6
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Health in Générai
10. Please choose the answer that best describes how true or false each of the following 
statements is for you.
Please circle one box on each line
a) I seem to get ill more easily than 
other people
b) I am as healthy as anybody I know
c) I expect my health to get worse
d) My health is excellent
Definitely Mostly Not 
true true sure
□
m
m
Mostly Definitely
false false
Thank you very much for your assistance.
Please bring the questionnaire with you to your appointment.
Office use only
Date of visit 
Pat Init.
Date of birth 
CRI Number 
Checked by
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ECHO DATA FORM 1
CRI No.:
Study Date: / / Analysis By:
L.V. VOLUMES AND SIMPSON'S EJECTION FRACTION
1. Echo Quality : 4C | | 2C
4 CHAMBER
2. LVED Vol (ml)
3. LVES Vol (ml)
2 CHAMBER
4. LVED Vol (ml)
5. LVES Vol (ml)
BIPLANE
6. LVED Vol (ml)
7. LVES Vol (ml)
8. LVEF %
8. AOd
MMODE
9. LAs
10. IVSd
11. LVEDD
12. LVPWd
13. IVSs
14. LVESD
15. LVPWs
Unh/ei$l1y of G lasgow
CRI?
ECHO DATA FORM 2
CRI No.: 9 4 - 1 - 0 0
Study Date: / / Analysis By:
UnivofSlly of G lasgow
CRI y
DOPPLER
MEAN
1. MV Peak E 10. MV Quality
2. MV Peak A
3. M V EV TI
4. M V A V TI
5. MV Dec. Time
6. MVPHT
7. AV Peak Vel. 11. AV Quality
8. AVVTI
9. TR Peak Vel. 12. TV Quality
